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Abstract 
 
In the last three decades, the boronic acid notoriety and usefulness changed from almost 
neglected to a highly used class of synthetic reactant. The mild Lewis acidity, together with 
their stability, easy handling and environmental friendly impact attracted the attention of 
the synthetic community towards these peculiar compounds. They found use in classical 
organic chemistry as synthetic reagents as well as in the medicinal chemistry as potent 
inhibitors. The purpose of this work was to explore a relatively new field of application, in 
which the boronic acid functionality acts as a template to promote the assembly of simple 
building blocks into more complex molecules, and explore this strategy as a tool to easily 
synthesize small collections of active compounds. The biological activity of such 
collections was tested against eligible targets (HNE; PHA) in order to select the most 
promising compounds and use them as a new benchmark for a new round of interactive 
optimization aiming to amplify the percentage of success in the discovery of new lead 
compounds. reaction design to mimic the natural architecture using boronic acids as 
tethers for building blocks: 
 Synthesis of the fused tricycle-boronate heterocycles. 
The B ability to act as a tether was used to simply assemble heterocycles through 
covalent bond formation with two oxygen and a dative bond with the N. A highly 
efficient one-pot four component reaction is the protocol exploited to assemble 23 
tricycle boronated heterocycles in yields and diastereoselectivities up to 95% and 97% 
respectively. DFT calculation were performed to clarify the reaction mechanism. 
 Synthesis of fused bicycle-boronate heterocycles and their enzymatic 
evaluation as new human neutrophil elastase (HNE)inhibitors. 
Herein we demonstrate that boron tether strategy may synthetize collection of 
molecules to discover new hit compounds. Through a one pot three components  
 XXII 
 
 
 
reaction 17 new compounds were synthesize in excellent yields up to 98%, high 
diastereoselectivities up to de100%. The compounds were tested as novel enzyme 
inhibitors for HNE and reaching the IC50 up to 1.10 μM. Docking studies were 
performed to enlighten the enzymatic interaction between the molecules and the active 
site of the HNE. . 
Design of phenylalanine hydroxylase (PAH) inhibitors based on fused bicycle-
boronate heterocycles 
The bicycle boronate heterocycles were also tested against the wild type PHA compound 27 
seems able to stabilize the protein affording a new scaffold for further optimization. 
 Synthesis of diazaborines and their enzymatic evaluation as new HNE inhibitors 
Herein we disclose the value of the diazaborines as inhibitor of the HNE. The collection was 
synthetize through optimization of the Dewar’s procedure that enabled the synthesis of the 
diazaborine in yield up to 89%. and IC50 2.5µM potency against HNE. 
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Resumo 
 
No decorrer das últimas 3 décadas, os ácidos borónicos evoluíram de quase curiosidades 
químicas até ao reconhecimento como reagentes de grande utilidade preparativa. A 
acidez de Lewis moderada, acompanhada de uma boa estabilidade, facilidade de 
manuseamento e baixo impacto ambiental, chamaram a atenção da comunidade sintética 
para estes compostos peculiares. Encontraram aplicação em química orgânica clássica 
como reagentes sintéticos, bem como em química medicinal como poderosos inibidores 
enzimáticos. O objecto deste trabalho foi explorar um campo de aplicação emergente, no 
qual o grupo funcional ácido borónico actua como molde para promover a associação de 
blocos constitutivos simples em moléculas mais complexas, e aplicar esta estratégia como 
ferramenta para a síntese de pequenas bibliotecas de compostos activos. A eficácia 
destas bibliotecas foi ensaiada em alvos selecionados (HNE; PHA) por forma a eleger os 
compostos mais promissores, por sua vez utilizados como padrões para um novo ciclo de 
optimização estrutural. Procurou-se assim maximizar a percentagem de sucesso no 
processo de descoberta de novas moléculas promissoras. Ensaiaram-se os seguintes 
conceitos estruturais por forma a mimetizar arquitecturas encontradas em produtos 
naturais: 
 
Síntese de arquiteturas bora-tricíclicas fundidas: 
A capacidade do boro para actuar como elo de ligação foi aproveitada para a construção 
de estruturas heterocíclicas via ligação covalente com dois átomos de oxigénio e uma 
ligação dativa com um átomo de azoto. Através de uma reacção de uma só etapa 
envolvendo quatro componentes, construíram-se 23 espécies tricíclicas boradas em 
rendimentos e diastereoselectividades de até, respectivamente, 95 e 97%. Cálculos de 
DFT permitiram obter informação sobre o mecanismo da reacção. 
 
Síntese de arquiteturas bora-bicíclicas fundidas e respectiva avaliação como 
inibidores da elastase neutrofílica humana (HNE): 
Demonstrou-se que a estratégia de utilizar o boro como elo permite a síntese rápida de 
um conjunto de moléculas, acelerando a descoberta de novas moléculas activas. A 
reacção de três componentes numa só etapa permitiu a síntese de 17 novos compostos 
em excelentes rendimentos de até 98%, e diastereoselectividades de até 100%. O ensaio 
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dos compostos como inibidores enzimáticos da HNE evidenciou IC50’s de até 1,10 µM. 
Efectuaram-se estudos de docking no sentido de elucidar a interacção entre as moléculas 
e o centro activo da HNE. 
 
Desenvolvimento de inibidores da fenilalanina hidroxilase (PAH) baseados na 
arquitetura bora-bicíclica fundida: 
Os referidos bora-bicíclicos foram também ensaiados perante a PAH de tipo selvagem. O 
composto 27 aparenta ser capaz de estabilizar a proteína, servindo de ponto de partida 
para posterior optimização. 
 
Síntese de diazaborinas e respectiva avaliação como novos inibidores da HNE: 
Demonstrou-se o valor de certas diazaborinas como inibidores da HNE. Esta biblioteca foi 
sintetizada por meio da optimização do procedimento de Dewar, tendo-se obtido os 
compostos pretendidos com rendimentos de até 89%, os quais evidenciaram IC50’s de até 
2,5µm contra a HNE.  
 
 1 
 
 
1. General introduction 
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1.1 Overview 
 
Boron is a very curious element, with an uncommon history, starting 
from its primordial creation into the universe, passing through the 
chemists bench, ending inside a living organism playing the pivotal role 
of pharmacophore. The creation process of the boron atom was 
different from most of the heavier elements present the solar system; 
[1,2,] Indeed, while nuclear fusion (two atoms colliding to generate a third new one) is the 
responsible for the genesis of all atoms up to iron and nickel, cosmic ray spallation (alpha 
particles, electron, protons, and heavier nuclei, impacting against an object)[3] is the 
process that is believed to have generated boron, beryllium and lithium elements. Boron is 
one of the members of the 13th group of the periodic table. This group is characterized by 
only three electrons in the valence shell which confers the ability to yield molecules with 
only three-sigma bonds. Boric, boronic and borinic acids are only some possible example 
of the ability of boron to form stable compounds without completing the octet. Such 
molecules possess a planar sp2 geometry around the central atom (B) which bears an 
empty p orbital and, despite the octet rule resulting unsatisfied, these molecules are 
enough stable to be stored and manipulated in ordinary laboratory activities. The empty p 
orbital plays an important role to determine the characteristic chemistry of such molecules. 
Indeed the boron atom, when arranged in the sp2 geometry, is able to receive two extra 
electrons from a donor that allows the boron to achieve the full octet, forming a stable 
complex. The formation of this dative bond also determines a couple of changes in the 
molecule that are noteworthy: a negative charge is formally placed onto the boron and it 
rearranges from sp2 to sp3.   
Boron
n 
10.81 5 
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1.2 Boronic acid compounds as synthetic reagents 
 
Among the boron containing molecules the boronic acids gathered the attention of organic 
chemists for their versatility easy handling. Some examples of reaction in which boronic 
acids found an employment are: aminations, halogenations, allylations or cross-coupling 
reactions. Since this constitutes an immense research field, in this report only some 
examples of the most relevant and useful transformations will be discussed in more 
detailed namely: the Suzuki Miyaura cross coupling reaction, the rhodium-catalyzed 
additions to π-bonds, multicomponent reaction (MCR) and the preparation of tridentate 
boronate-complexes. 
 
Suzuki Miyaura cross coupling reaction 
The Suzuki-Miyaura cross coupling reaction is one of the most famous and useful 
reactions to form C-C bonds and was disclosed in 1979 by Suzuki and Miyaura. It is a Pd 
(0)-catalyzed coupling between boron compounds and organohalides in the presence of a 
base. This reaction affords a new C-C bond formed between the two organo-substituents 
of the starting materials, in many cases with very high yields.[4] (Figure 1) 
 
 
Figure 1- General scheme of Suzuki-Miyaura cross coupling reaction. 
The generally accepted mechanism for this process involves the Pd (0) oxidative addition 
to the halide to give a Pd (II) intermediate, followed by a transmetallation step and the final 
reductive elimination that affords the product and regenerates the catalyst.[4] The 
transmetallation is thought to be facilitated by the base-mediated formation of a tetra 
coordinate boronate anion. (Figure 2) 
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Figure 2- Suzuki-Miyaura cross coupling general mechanism. 
 
Rhodium-catalyzed addition to π systems 
The rhodium-catalyzed addition of boronic acids to electron-deficient olefins and carbonyl 
compounds is another method that exploits boronic acids exquisite reactivity. Such 
carbon-carbon bond formation is a very efficient reaction in terms of yields and selectivity. 
Depending on the ligand used, the rhodium-catalyzed addition of boronic acids may also 
proceed with high levels of asymmetry, this is particularly true for 1,4 additions to 
conjugated ketones. The mechanism features the transmetallation of a phenyl group from 
boron to the hydroxorhodium, giving a phenyl rhodium species. The insertion of the α-ß 
unsaturated carbonyl compound into the phenyl-rhodium generates the oxa-π-allylrhodium 
intermediate which upon hydrolysis affords the conjugate addition product regenerating 
the hydroxorhodium active catalyst.[5] (Figure 3)  
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Figure 3- General mechanism for the Rh-catalyzed additions of boronic acids to 
conjugate ketones. 
Multi-component reactions 
The chemical properties of boron makes the boronic acid a “dynamic functional group”, 
which is able to respond to the “context”, interconverting and rearranging to give the most 
stable molecule or configuration. A clear example of this is the reaction between boronic 
acid and vicinal nucleophiles like diols, to yield boronic esters, a reaction that is reversible 
in aqueous solution and dependent on the pH used.[6] This ability makes the boronic acid 
an ideal partner for multicomponent reactions (MCR), a protocol based on one-pot reaction 
of more than two compounds that afford the product often in high yields. Ideally, the 
molecules involved in a MCR process, are able to afford many different products 
depending on the structural diversity of the reactants used and for that reason are ideal to 
generate libraries of structurally diverse compounds for biological evaluation. 
Generally, MCRs involve a series of reversible and irreversible steps, and can be ranked 
in 3 main categories:  
TYPE1: when only chemical equilibriums are involved in the transformation of the starting 
materials up to the final product.  
TYPE2: when the process involves several reversible reactions and one final irreversible 
step leading to the product formation.  
General introduction  Chapter 1  
 
6 
 
TYPE3: were a sequence of irreversible elementary reactions affords the product.  
For MCR of TYPE1 and 2 the reagents can flow towards the most favorable product, 
which depends on the reaction conditions. Under this light, the success of a MCR depends 
on the efficient interconversion among the reactive intermediates, in other words, the 
careful selection of the reactants and reaction condition are of pivotal importance. For 
MCR of TYPE3, the order of addition dramatically influences the outcome of the reaction, 
since the reaction proceeds through irreversible steps.  
The Petasis MCR (1993) is an effective example of the use of boronic acids in MCR. This 
reaction involves the simultaneous mixing of a primary or secondary amine, an aldehyde 
and a boronic acid, yielding a secondary or tertiary amine and a new C-C bond, under mild 
conditions. The Petasis reaction mechanism [7] involves the iminium or imine formation 
between the amine and the aldehyde and the subsequent reaction of this species with 
boronic acids, via an ATE-complex. The irreversible nucleophilic addition of the alkyl or 
aryl boron substituent yields the product. The fundamental functionality for the process is 
the presence of a hydroxyl group that reacts with the boronic acid generating a more 
nucleophilic tetrahedral boronate species.(Figure 4) 
 
 
Figure 4 - General mechanism for the Petasis MCR. 
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Boronate heterocycles formed with tridentate ligands 
Boronic acids can easily afford stable boronate-complexes when involved in reactions with 
di or tri-dentate ligands. A clear example of this, are the complexes obtained when boronic 
acid reacts with oxygenated or nitrogenated compounds, as for instance N-methyl-
diiminodiacetic acid (MIDA) (Figure 5), affording a range of complexes in which MIDA 
maybe successfully employed as the boron protecting group to mitigate transmetallation in 
the Suzuki-Miyaura reaction,[8]enabling an iterative cross coupling reaction in presence of 
unprotected boronic acid. (Figure 5). More sophisticated complexes were prepared by 
Farfan et al.(Figure 6) This group reported the selective preparation of a boronate 
complex, by reacting the 2-[[(2-hydroxyphenyl)amino]methyl]-phenols with an 
equimolecular amount of boronic acids, salicylaldehyde and 3,5-di-tert-butyl-2-
hydroxybenzaldehyde to afford the bicycle-boronate heterocycle. The resulting tridentate 
complex was obtained in yields ranging from 59% to 91%. [9] (Figure 6) 
 
 
Figure 5 - Tridentate ligand (MIDA) that maybe used as a boron protecting group. 
 
Grimme et al disclosed for the first time, the determination of the absolute configuration at 
a stereogenic boron by CD spectroscopy. In this communication, boronate complexes 
were obtained from 2-amino-1,2,2-triphenylethanol (chosen example) and 2-amino-2,2-
diphenylethanol and were isolated as pure diastereoisomers and/or enantiomers. From the 
crystal structure analyses, the distance between the nitrogen and the boron atom ( .    to 
 .  7  ), clearly indicates the existence of a B-N dative bond. In addition to this, the 
configuration at the boron atom was determined to be R, and more importantly 
epimerization at the boron center was never observed.[10] (Figure 7). 
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Figure 6 - Stable boronate complexes prepared by Farfan et al. 
 
Figure 7 - Stable boronate complex prepared by Grimme et al. 
In the same line, Hutton et al developed a stereoselective asymmetric synthesis of a chiral 
boron complex. Their results demonstrate that the formation of the complexes occurs in a 
highly enantioselective manner by using the Betti base as the chiral o-hydroxybenzylamine 
derivative. By mixing the Betti base, glyoxylic acid, and phenylboronic acid in DMF at 50 
°C for 24 h the boronate complex depicted in Figure 8 was directly obtained in 97% yield. 
According to Hutton the formation of the tridentate ligand must involve three important 
steps: condensation of the amine with the aldehyde to give the corresponding imine, 
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complexation of phenylboronic acid, and isomerization of the aldimine to the 
corresponding ketimine with concomitant loss of the carbon stereocenter.[11] (Figure 8) 
Severin et al reported a new synthetic strategy for the construction of boron-based 
macrocycles and dendrimers. Condensation of aryl- and alkylboronic acids with 3,4-
dihydroxypyridine and a primary amine R-NH2 was shown to give pentameric  macrocycles 
in a highly diastereoselective self-assembly process, in which five boronate esters are 
connected by dative B-N bonds. [12] (Figure 9) 
 
 
Figure 8 - Stable boronate complex prepared by Hutton. 
 
Figure 9 - Boron-based macrocycles prepared by Severin. 
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1.3 Boron-containing natural products 
 
Despite the relative abundance of boron in the earth crust there are very few natural 
products that contain this element. The most well known boron-containing natural products 
are: boromycin, aplasmomycin, tartrolons and borophycin. All this compounds belong to a 
macrolide type family of complex molecules that exhibit a polyhydroxy framework, that act 
as tetradentate ligand for a central boron atom.  
The first compound of this family to be discovered was boromycin[13] (Figure 10), which 
displays antibiotic properties and was isolated from the Streptomyces antibioticus, a 
bacteria found in Ivory coast soil. The macrolide aforementioned, was shown to be active 
mainly against Gram-positive bacteria, plasmodie and babesie protozoa.[14] In 1996 was 
also found to be strongly active against the replication of HIV-1.[15] A similar profile, in 
terms of antibiotic activity is exhibited by the Aplasmocyn natural product (Figure 10), 
isolated from Streptomyces griseus. This compound was shown active against Gram-
positive bacteria and was reported as a potential adjuvant in ruminant animal breeding as 
enhancer of growth through metabolic changes, by increasing the proportion of 
proprionate and butyrate, decreasing at the same time the concentration of methane and 
acetate.[16] 
The tartrolon natural product (Figure 10) is the third of the boron containing natural 
products depicted in Figure 10. This molecule was extracted from Sorangium cellulosum 
and Streptomyces family, and like the two macrolides aforementioned, exhibits a similar 
biological profile like the antibiotic activity against Gram-positive bacteria. In addition to 
this, it also presents a certain larvicide activity on the beet army worm and tobacco bud 
worm.[17,18]  
Finally Borophycin (Figure 10), was isolated from the blue-green alga Nostoc linckia and is 
made of two identical halves with an overall structure reminiscent of other boron-
containingantibiotics.[19] 
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Figure 10 - Boron-containing natural products are: a) boromycin, b) aplasmomycin, 
c) tartrolons, d) borophycin. 
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1.3 Biological activity of boron containing compounds 
 
Compounds containing boron have been investigated in many different fields for the 
peculiar properties of this element in particular they have been extensively explored for 
their unique biological activity profile. The biological uses of boron containing compounds 
is an immense field, therefore, is not the purpose of this work to make a comprehensive 
discussion of all biological uses of boron containing compounds. Nevertheless, in the hope 
to give an idea of the potential of this class of compounds as drugs herein is presented a 
brief description of several examples related with the use of boronic compounds in the 
fight against the major diseases that nowadays affect western societies: cancer, heart and 
coronary artery disease, diabetes, HIV and bacterial infections.  
 
Overview 
 
Generally the biological activity of boron containing compounds can be traced back to 
three basic principles related with boron chemistry: 
 The ready sp2 -sp3 rearrangement, of boron centers 
 The formation of stable anions, centred on boron 
 Boron’s strong affinity for oxygen nucleophiles 
These three distinctive properties afford a solid base to comprehend the basic 
mechanisms that mostly regulate the biological activity of boron compounds. A valid 
example of the influence of the first two factors mentioned above (Figure 11), came from 
the comparison between the biological activities, against the same target, of the boronic 
acid and the carboxylic group as they are classically considered as isosters and both are 
able to receive a lone pair of electrons and as a consequence both groups form a negative 
ion changing their configuration from sp2 to sp3. 
 Nakamura et al [20] in 2006, showed that the cis-stilbene substituted with carboxylic acid 
inhibited the cell growth 10,000 folds less than its boronic acid isoster (Figure 12).This 
observation was related to a higher Lewis acidic character of the boronic acid.[21] 
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Figure 11- Boron sp
2 
-sp
3 
rearrangement. 
 
 
Figure 12 - Comparison between the biologic activity of cis stilbene boronic acid and 
its carboxylic isoster against Mouse melanoma cell line and human lung carcinoma. 
In the same line Kumar et al. while investigating the complex p53/MDM2, synthesized a 
number of boronic-chalcone derivatives (Figure 13).[22]  Murine double minute 2 (MDM2) is 
an oncogenes responsible of the inactivation of the tumor suppressor p53. This group 
speculated that, if the pH is neutral the substitution of the carboxylic acid moiety by a 
boronic acid could result in a stronger salt bridge formation: “due to the electron deficient 
nature (higher performance as Lewis acid) of the boronic acid functionality and the 
electron donating nature of the amino group”. [21] 
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Figure 13 - Boronic-chalcone analogues synthesized to target breast cancer. 
 
The ability of boron to replace a carbonyl group goes beyond the isosteric correspondence 
between boronic acids and carboxylic acids. Indeed the boron of a boronic acid is able to 
substitute efficiently the carbonyl functionality of a β-lactam. Between this two functional 
groups, there is no isosteric identity, for this reason the success of the replacement is most 
likely due to a stronger electrophile character of the boron centre.[21] In this line, Nakamura 
et al synthesized a series of belactosin C analogs, with the β-lactam moiety substituted by 
a boronic acid functionality. The Nakamura’s boronic acid analog of belactosin C displayed 
a significant cell growth inhibition (IC50  ⁄4  .3  M), clearly demonstrating the utility of 
replacing the β-lactam ring by a boronic acid moiety (Figure 14).[23] Latter Shoichet et al 
synthesized a series of boronic acid β-lactamase inhibitors, mimicking the structure of 
cephalotin (Figure 15). They found that the maintenance of the original framework of the 
natural substrate was important to maintain the activity levels; indeed the more similar the 
boron analogue was the greater observed inhibitory activity. [24]  The third factor that 
influences dramatically boron biological activity is the affinity of oxygen towards boron. In 
this field, Adams et al traced back the potent antitumoral activity of bortezomib which is a 
26S proteasome inhibitor, to the formation of a more stable B-O bond then the one formed 
by parent aldehyde functionality. Bortezomib, became the first FDA approved boron 
containing compound (Figure 16).[25] 
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Figure 14 - Belactosin C and boronic acid derivatives developed by Nakamura et al. 
 
Figure 15 - Ki values against AmpC β-lactamase for boronic acid inhibitors developed 
by Shoichet et al. 
.  
Figure 16 - Bortezomib and the corresponding amino acid dipeptid 
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Anticancer activity 
 
Bortezomib® is a 26S proteasome inhibitor which binds to a threonine OH residue through 
a B–O covalent linkage, generating an sp3 hybridized tetrahedral complex. The ubiquitine-
proteasome pathway is an important mechanism for the degradation of abnormal and 
misfolded proteins with an high rate of specificity to target, time and space.[26] Due to the 
importance of this class of proteins play, over homeostasis and regulation, the proteasome 
enzymes are deeply involved in a series of cellular processes such as: cell differentiation, 
cell cycle, antigen processing and hormone metabolism.[27,28] Among the several 
components of the proteasome family, the 26S is the main player, its structure is based on 
three sub units, one 20S responsible to the actual proteolysis , and two regulatory cup  
subunits 19S, which are placed at each end of the 20S subunit. The 19S controls the 
recognition, the misfolding and the transfer of the processed protein into the lumen of the 
20S unit.[29] 
Bortezomib is derived from a series of previously reported dipeptide aldehydes,[30] that 
were non-specific proteasome inhibitors. The substitution of the aldehyde by the boronic 
acid, produces a highly potent and selective inhibitor of the 26S proteasome (Figure 
16).[31] The Bortezomib® not only demonstrated the potential of boron in drug discovery, 
but also proved that the 26S proteasome is a suitable target for the treatment of cancer. 
Despite the success, Bortezomib exhibits important adverse effects while used in the 
treatment of solid tumours; among these, peripheral neuropathy (PN) is perhaps the most 
important. The severe impact of PN is a limiting factor of the administrable dose and 
therefore the efficacy,[32] often leading the patients to leave the therapy. Despite the 
efficacy of Bortezomib, its strong side effects prompt several groups to search for inhibitors 
with higher or comparable efficacy though with a considerable lower toxic profile. 
 The efforts of these investigation have indeed produced a second generation of inhibitors 
as shown in Figure 18.[33] Among these new compounds, MLN9708 was shown to be one 
of the most interesting, since it is a low affinity inhibitor that still shows IC50 values in the 
same range of Bortezomib, which is a high affinity inhibitor. It was suggested that to 
achieve therapeutic efficacy against solid tumor, the pharmacokinetics profile of a 
compound is more relevant than its pharmacodynamics, the fast off-rate of MLN9708 has 
to result in a greater distribution of the drug into the tissues and thereby into the tumor. 
The adverse effects observed for Bortezomib and other proteasome inhibitors are quite 
likely to arise from “on-target” inhibition in “off-target tissues” (which means to hit the 
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proper enzyme in a non-carcinogen tissue), rather than off-target inhibition of non-
proteasomal enzymes. For example neuropathic pain occurs to some degree with each of 
the above inhibitors, has been linked to the accumulation of ubiquitinated proteins in cells 
of the peripheral nervous system.[34]  Bearing in mind, Bachovchin et al in 2011 envisioned 
that would be possible to achieve higher efficacy against solid tumors with a proteasome 
inhibitor with improved inhibitory selectivity for tumor tissues, rather than by developing 
molecules with improved inhibitory potency or specificity for the proteasome.[35] To achieve 
an improved tissue selectivity and decrease the “on-target” inhibition in “off-target tissues”, 
they used a double strategy. They developed a tumor-activated prodrug that could provide 
such tissue specificity, using a tumor-specific protease as trigger whose action releases a 
shorter peptide of boro-leucine from a longer and in active prodrug (Figure 19). This 
shorter boro-leucine peptide is the actual proteasome inhibitor, and is expected to undergo 
a pH-dependent cyclization that could significantly attenuate their inhibitor potency at 
physiological pH, which would help to attenuate systemic effects as excess inhibitor 
diffuses from the tumor site (Figure 17). Such defined and programmed loss of 
pharmacological activity with time is characteristic of the action of agents termed “soft 
drugs”. Typically soft drugs need to be applied directly to the intended site of action (Figure 
19).[36] 
 
Figure 17 - pH-Dependent cyclization that attenuate systemic side effects. 
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Figure 18 - Second generation of inhibitors to the 26S proteasome. 
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Figure 19 - Pro-soft-drug selectivity to avoid “on-target” inhibition in “off-target 
tissues”.  
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Heart disease and coronary artery disease 
 
Heart disease is the number one cause of death in the United States, and hyperlipidemia 
can greatly increase the risk incidence of such traumatic events.[36] In the contest of 
coronary artery disease (CAD), serum concentrations of high density lipoprotein (HDL) 
cholesterol are inversely correlated with the risk for developing CAD. Lipoprotein lipase 
(LPL) is a member of the lipase family, involved in the metabolism of VLDL and 
chylomicrons, promoting the mobilization of fatty acids from the hematic stream to the 
muscles, where it can be used as energy source, or to the adipose tissues, for storage, 
reducing the risk of CAD. There is a positive correlation between HDL-C levels and LPL 
activity.[37] Differently the endothelial lipase (EL), which is a triglyceride lipase, 
preferentially explain its hydrolytic activity towards HDL over other lipoproteins. Moreover, 
HDL is modulated by EL more than by any other lipase.[38] The inhibition of EL over LPL 
would be crucial to achieve the goal of decreasing the risks of CAD, by means of 
increasing the levels of HDL-C. In this context, Bachovchin et al reported the synthesis of 
alkyl, aryl, or acyl-substituted phenylboronic acids that inhibit preferentially EL over LPL. 
They showed that a modification with an alkylic chain at the para-position of a phenyl 
boronic acid, provide such selectivity, achieving the acumen of discrimination with the 
nonyl alkylic chain (Figure 20) An approach to control the levels of lipids into the blood 
could be achieved by transcriptional control of lipogenic and cholesterogenic enzymes, 
since they are involved in the regulation of lipidic metabolism [39]. In 2011 Fajun Yang et all 
synthesized and tested a small library of boron-containing stilbene derivatives (Figure 21), 
this library was further tested for its biological effects as lipogenic inhibitors. In this study 
the mRNA level of fatty acid synthase (FAS) was used as the readout.[40] Treatment of 
HepG2, a line of human hepatoma cells, with the compounds of the library at 30 M 
resulted in a significant decrease of FAS  expression. Also the hepatocytes cell line when 
treated with BF102 resulted in a significant decrease of mRNA levels of both fatty acids 
and cholesterol. 
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Figure 20– IC50 express in µM of the alkyl chain in the para position on the phenyl 
boronic acid tested by Bachovchin et al. 
 
Figure 21 - Boron-containing stilbene derivatives tested as lipogenic inhibitors. 
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Diabetes 
 
Val-boroPro (Figure 22 a), also known as PT-1001 or talabostat and its closely related 
dipeptide boronic acid Ala-boroPro (Figure 22 b), were firstly synthesized as inhibitors of 
dipeptidyl peptidase IV (DPPIV). DPPIV is a member of the prolyl oligopeptidase 
subfamily,[41,42,43] and a valid target for the treatment of type 2 diabetes.[44, 45] 
 
 
Figure 22 - Val-boroPro and Ala-boroPro inhibitors of dipeptidyl peptidase IV. 
 
The mechanism whereby DPPIV decreases the blood levels of insuline, involves the 
degradation of gastrointestinal hormones incretins, which promotes the secretion of 
insuline.[46]  The compound a depicted in Figure 22, was never considered as a clinical 
candidate, for diabetes, due to its toxicity. The other members of the prolyl oligopeptidase 
sub family are reported to be inhibited as potently as DPPIV [41,42,43] and they could be 
involved in the toxic profile of this molecule. The presence of boron in compound a confers 
the interesting characteristic to undergoes cyclization in water according to the pH (Figure 
23). The cyclization reaction is a slow process (T1/2=30’), and at physiological pH the 
equilibrium is shifted towards the cyclic structure,[44,45,47] which in turn makes the molecule 
inactive against its  target.  
Such features were beautifully exploited by Bachovchin et al to mitigate the toxicity of 
these molecules. This group reported the synthesis of a pro-soft-drug (Figure 24)that was 
designed to deactivate in a predictable and controlled manner to prevent unwanted 
systemic effects after exerting their therapeutic action.[48] The author showed that the 
compound depicted in Figure 24, either in vitro and in vivo (Chg-Pro-Val-boroPro), acts as 
a prodrug of a in Figure 22, which is activated and targeted to the same enzyme dipeptidyl 
peptidase IV. DPPIV first activates the pro-soft-drug of a in Figure 22, the compound 
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released is still in the open chain structure which enable it to exert its pharmaceutical 
activity, the molecules which escape from the “target tissue” will be inactivated through the 
cyclization process above discussed (Figure 24). 
This approach enables the molecule to preserve its biological activity against DPPIV but 
decreases the toxics effects, resulting from inhibition of other prolyl oligopeptidases. 
 
 
Figure 23 - pH Dependent cyclization. 
 
Figure 24 - Pro-soft-drug that is activated in situ, yielding the active molecule, which 
will cyclise in a predictable and controlled manner losing its biological activity. 
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Anti HIV viral entry 
 
Balzarini et al in 2007, [49] hypothesized that carbohydrate-binding agent (CBAs), could be 
able to bind the glycan moiety of the Envelope glycoprotein GP120 (gp120) of HIV-1. The 
CBAs could have a double mechanism interfering with the binding between the membrane 
of CD4+ T-lymphocytes and gp120, disabling the mutation process, which guarantees the 
virus escape from the drug activity. Based on this idea Jay et al[50] developed a novel 
microbicide based on the boronic acid ability as CBAs and the protein lectins. This 
approach has the drawback of using expensive components like the protein lectins, 
making it a unsustainable cure for patients of undeveloped countries, which represent the 
most part of worldwide patients. Barbue et al [51] overcame this problem, synthesizing and 
testing a water-soluble polymer, which is polyfunctionalized with benzoboroxol alongside 
with the polymer chain (Figure 25). The polymer was prepared with 25, 50, 75 mol % of 
benzoboroxol, and the latter showed a 11nM activity in reducing HIV viral entry in an in 
vivo test.  
 
 
Figure 25 - Water-soluble polymer based on benzoboroxol. 
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Boron based antibiotics 
 
Bacterial infections have always been one of the main issues of worldwide health care. 
Bacterias and their hosts have influenced the evolution of each other through a process of 
exposition-and-selection, between the pathogen agent which selected the more resistant 
host,whicht in turns with its adapted immune system selected differently virulent 
pathogens, in a never ending dance. The discovery of penicillin and invention of β-lactamic 
antibiotics, have introduced a new efficient way to address this problem. Unfortunately the 
bacteria quickly responded with the synthesis of β-lactamases. Thus the strategies used 
by the pathogen to overcome the use of antibiotics can be resumed in three mechanisms 
[52]:  
 β-Lactamases  
 Low affinity Penicillin Binding Proteins (PBPs) for β-lactams  
 Over expression of resistant PBPs 
The PBPs family, which is the main target for the therapy against the bacterial infections, 
can be divided in three classes.[53,54] Classes A and B, ranked as high-molecular mass 
PBPs which contain two catalytic domains (glycotransfer (GT) and the transpeptidation 
(TP)). Finally, class C is composed by low-molecular mass PBPs, named CPBPs [54,55] 
with a TP activity. The TP domains mostly catalyze the cross-linking of stem peptides via 
an acyl-enzyme intermediate formed by nucleophilic attack of a serine residue. Zervosen 
et al. have shown that boronic acids are potent β-lactamase inhibitors, bearing in mind the 
already reported ability of the boronic acid to form reversible covalent adducts with OH 
groups, which mimic the tetrahedral intermediates in the PBP-catalyzed acylation 
reactions.[52]  
Zervosen group, in 2012 synthesized and studied the potential of a number of 
acylaminomethylboronic acids as inhibitors of PBPs. Several derivatives inhibited PBPs of 
classes A, B and C from penicillin sensitive strains (Figure 26). 
In 2011 Trivedi et al described the preparation of chiral aryl boronate esters of 1,2-o-
isopropylidene-α-D-xylofuranose to screen their activity as a new class of antimicrobial 
agent (Figure 27a).They elected the protected pentose sugar, 1,2-O-isopropylidene-a-D- 
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xylofuranose[56] as a precursor because of its known utility as a key intermediate in the 
synthesis of many drugs among them: anti-HIV agents,[57] nucleosides,[58] antibiotics.[59] 
 
 
Figure 26 - Acylaminomethylboronic acids developed by as inhibitors of PBPs. 
This synthetic approach led them to an efficient and easy way to prepare a wide range of 
boronate esters in a single step. The reaction proceeds in Et2O as solvent at room 
temperature affording the final product in 92% yield for the basic compound a(Figure 
27)used as benchmark. They synthesized several compounds using different boronic 
acids. The evaluation of these compounds revealed that their activity is modulated by 
structural modifications in the aryl group attached to the boron atom. Of all compounds 
tested b and the c depicted in Figure 27 showed an interesting activity as anti-bacterial 
and anti-fungal agents.[56] 
 
 
Figure 27 - Chiral aryl boronate esters of 1,2-o-isopropylidene-a-D-xylofuranose 
developed as new antimicrobical agent. 
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Typically, chemotherapic agents that aim to minimize the adverse sides effects, should 
point to a target that is present in the cells of the pathogen but absent in the cells of the 
host. The bacterial amidotransferase (Glu-AdT), is an essential enzyme to synthesize Glu-
tRNA (Gln), that satisfies this characteristic.[60] Boronate ester were successfully designed 
to inhibit Glu-Adt, through a putative serine trap mechanism. Decicco [61] in his study 
suggested that the presence of a serine hydroxyl functionality is essential for the activity of 
the enzyme Glu-AdT. Thus many serine trap inhibitors were tested against this enzyme. In 
general, a serine trap embodies in its structure an electrophilic center capable of accept in 
a lone pair of electrons from a nucleophile. Ketones with alpha electron withdrawing 
groups (esters, amides, halogen, phosphonates, β-lactams) have been studied as 
inhibitors of the Glu-AdT.[62] 
Decicco et al synthesized Glu-γ-B(O2R) a compound that displayed IC50 values of 1.6M 
and 100nM, respectively, against the glutaminase (GLA into the Figure 28) and the 
transferase (TRA into the Figure 28) activity of Glu-AdT (Figure 28). 
 
 
Figure 28 - Decicco’s Glu-γ-B(O2R) compounds active against the glutaminase and 
transferase activities of Glu-AdT (values in μg/ml). 
The DD-peptidase is the enzyme responsible for the final step of the bacterial cell wall 
synthesis, through the incorporation of the monomers in the already formed structure of 
the peptidoglycan.[63] Pratt et al describe the synthesis of (D-R-aminopimelylamino)-D-1- 
ethylboronic acid (Figure 29) for the R39 DD-peptidase inhibition a low molecular weight 
class of the sub group C penicillin-binding protein. Their study suggested that boronates 
could indeed be a very powerful class of molecules as DD-peptidase inhibitors, as 
mentioned boronate inhibited the peptidase with a Ki value of 32±6 nM. 
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Figure 29 - (D-R-aminopimelylamino)-D-1- ethylboronic acid. 
To understand the possible mechanism of inhibition of D-R-aminopimelylamino)-D-1- 
ethylboronic acid, they performed a crystallography analysis, which suggested that the 
compound could explicit its activity through a transition state fashion mechanism resulting 
in a inhibition of the R39 DD- peptidase as shown in Figure 30. 
 
 
 
Figure 30 - Crystallography analysis of (D-R-aminopimelylamino)-D-1- and R39 DD- 
peptidase. 
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1.4 Boronic acids as templates to promote the 
assemblage of simple building blocks 
 
When considering the structure of a biologically active molecule, it can be ideally divided 
in:  
 Active functionalities: the elements of interaction with the host, 
while performing the biological activity (pharmacophores, 
groups which take part in the interaction with the biological 
target) 
 Inert framework that supplies support to the active functionalities 
appended on it.  
At a first sight, it seems that the biological activity is influenced more pronouncedly by the 
active functionality rather than the inert frame work. Despite the framework lack of direct 
contact with the reactive residues of the protein, it is responsible for the proper geometric 
orientation of the active functionalities. Under this light the biological activity of a molecule 
depends on the “inert” framework as much as the active functionalities. Ideally the active 
functionalities can be pictured as heteroatoms, functional groups of different π-systems, 
while the framework as an all-carbon structure.  
In this context, it is possible to exploit the ability of boron to readily react and establish 
dative bonds with oxygen and nitrogen nucleophiles, to create complex structures that 
may serve as a framework embodying the required geometrical features to maximize the 
pharmacophore enzyme interaction.  
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Synthetic utility of oxygen and nitrogen ligation to boron  
 
The classical synthetic approach, made of multistep synthesis interspaced by various 
separation techniques is a time and resource consuming process. Even more when 
applied to the synthesis of compound libraries, where the magnitude of this “complexity” 
has to be multiplied by the number of the library components.  
The propensity of boron to easily promote the assembly of simple building blocks 
containing oxygen and nitrogen nucleophiles, may contribute to reduce the efforts of 
multistep synthesis of complex molecules. In his context, it is expected that by using 
simple buildings blocks, rationally functionalized with oxygen and nitrogen atoms, it may 
be possible to create structures with the required “active functionalities” and geometry, via 
an assembly reaction promoted by a a boron tether. The implementation of this innovative 
strategy would enable the straightforward generation of discrete molecular surfaces with 
distinct pharmacophore that may be readily tuned for optimal interaction with the biological 
target.  
Based on this idea several approaches have been made to achieve the efficient synthesis 
of small molecules using born tethers. In particular, three of these strategies have been 
well succeeded, and will be discussed in the next few pages: 
 
 Using the B-N bond as a surrogate of the C=C bond. 
 Exploiting the B-O coordination to construct all-carbon 
analogues. 
 Using boronic acids as templates for multi component 
assemblies. 
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Using the B=N bond as a surrogate for the C=C bond 
 
The relationship between the single bond B-N and the double C=C bond is well known 
across many fields of chemistry (organic, inorganic, materials etc.), since the similarity has 
been disclosed, by the seminal work of Dewars et al.[64,65,66,67] 
The analogy triggered the imagination of many scientists, lured by the possibility of 
replacing a difficult task of synthesizing a new bond between two carbon atoms, with a 
much easier strategy, which involves the creation of a link between boron and nitrogen 
atoms. The correlation between the two systems, starts from the position of the boron, 
carbon and nitrogen in the periodic table. The order in which they appear into the second 
period is: B, C, N, in other words boron has one less electron than carbon whereas 
nitrogen has one more electron. Thus, when compared, the B-N and the C=C bonds, 
share the same number of electrons, and in 20% of the cases they also have the same 
numbers of protons and neutrons (natural abundance of B10). Despite these common 
characteristics, these compounds are still not sufficiently similar to consider the B-N as a 
perfect surrogate of the C=C bond. The difference of electronegativity between boron and 
nitrogen is responsible for a sensible polarization of the σ-bond, giving it a considerable 
ionic character, which can alter the global electronic profile of the molecule (ionic against 
the apolar character of the C=C).[68] Moreover the B-N single bond is susceptible to rotate 
around its axis, characteristic that does not afford the structural rigidity idiosyncratic to the 
C=C bond.  
The difference of polarization between B-N and C=C dramatically affects the macroscopic 
property of the molecules or materials in which is present. An example of this difference is 
the case of graphite that is a carbon allotrope, which is black, has a metallic structure and 
high conductivity property, while the B-N analogue of graphite, is white with insulating 
properties.[69] 
A possible solution to increase the homology between molecules and materials featuring 
the two different bond systems, is the presence of an additional dative bond between B-N. 
This dative bond indeed benefits the correspondence between C=C an B-N bond by 
reducing the polarization of the σ bond. In fact, while the direction of the dipole is from 
boron to nitrogen (B-N) in the sigma bond due to the difference of electronegativity, in the 
dative bond, the current is reversed (Figure 31). [70,71,72] In addition to this, the partial π-
interaction determines a geometrical rigidity along the B-N bond.  
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Based on the aforementioned, one must conclude that for a proficient C=C/B-N 
replacement strategy, the components should comprise a nitrogen moiety with an 
available lone pair of electrons and a vacant p-orbital centered in the boron atom. 
 
 
 
Figure 31 - Polarization of the σ and π B-N bonds. 
The molecules with a C=C/B-N isosterism, which satisfy these conditions, can be defined 
as isoelectronic and both are arranged in sp2 hibridization. The only difference between 
the two systems is that in the C=C, bond each carbon contribute in equal manner to the 
bond, while in the B-N π-bond the two electrons are provided by the nitrogen.[73]  
In 2011 Katzenellenbogen et al exploited the possibility of replacingthe C=C bond with the 
B-N bond to synthesize a novel compound active against estrogen receptors (ERs). While 
investigating the design active compounds against this target, they observed that despite 
the structural differences of the molecules tested, they still shared some repetitive 
substructure motifs (active functionalities) which was vital for the biological response.[74] 
They postulated that these “repetitive motifs” were embodied in a core that had essentially 
no contact with the protein. Thus, following on this observation, they proposed that the 
“inert core” could be readily assembled based on the simple condensation of reactants 
exploring the B-N bond. The advantage of this strategy lies in the possibility of producing 
libraries of compounds in a modular fashion. So while the focus of their work, was the 
synthesis of ER active molecules, the climax was achieved through the idea of designing a 
generic and synthetically accessible core, where to attach multiple “active components”. 
The functionality identified as “repetitive active motif” was: a phenol in a homodibenzyl 
motif (Figure 32). 
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Figure 32 - Repetitive homodibenzyl motif ERs. 
In addiction they also found that the C=C double bonds were also present in the core of a 
number of nonsteroidal ER ligands, manly those belonging to the cyclophenil and 
triarylethylene class (respectively structures a and b, in Figure 33).  
 
 
Figure 33 - Cyclophenil and triarylethylene. 
Based on these two observations, Katzenellenbogen et al designed and syntesized a 
series of anilino dimesitylboranes in order to reproduce the structure of the triarylethylene 
ER ligand, replacing the C=C double bond by a B-N bond (Figure 34). These B-N 
analogues showed not only a remarkable stability and affinity for the ERα, but they were 
also much easier to prepare. The synthetic simplicity suggested and biological activity 
uncovered in this study clearly suggested that B-N for C=C substitution could be widely 
used for the preparation of analogues of drug candidates. 
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Figure 34–Anilino dimesiylboranes that replace a double bond C=C with a B-N and 
its ER relative binding affinity. 
Exploiting the B-O coordination to construct a all-carbon analogues 
 
A clear example of this second strategy, was recently disclosed by the work of Woon and 
Schofield that assembled several boronate esters in presence of prolyl hydroxylase 
domain isoform 2 (PHD2), a FeII and 2-oxoglutarate (2OG) oxygenase that regulates the 
human hypoxic response,[75] using the dynamic-combinatorial mass spectrometry (DCMS) 
to detect labile complexes derived from mixtures of boronate formed in situ and the 
enzyme. 
The motif that served as the structural guide for the design of the boronated analogues 
was the 2-(picolinamido)-acetic acid scaffold. Because, based on crystal structures of 
PHD2,[76] was determined that this scaffold chelates with FeII at the active site. Therefore, 
the experiments proceed through the incorporation of a boronic acid moiety, into the 2-
(picolinamido)-acetic acid scaffold as shown in Figure 35. Several diols were let to react 
with the new scaffold, in order to form the cognate boronate esters. 
The diols 2,4-Dihydroxybenzoic acid and cathecol depicted in Figure 35, demonstrated to 
generate the most active compounds against the targeted enzyme. Therefore to validate 
this approach and the potential of this strategy to discover new lead compounds, the 
authors synthesized two stable all-carbons analogues (Figure 35) using the benzofuran- 
and naphthalene-moiety to mimic the structure of the boronate derived from the assembly 
of boronic acid with the diols depicted in the Figure 35. The binding constants of the all 
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carbons analogues were in the same range suggesting that the replacement of the 
boronate with the two rings system was indeed a very effective strategy to discover new 
compounds with biological activity against this strategy. 
 
Figure 35 - 2-(Picolinamido)-boronic acetic acid derivatives and their all carbon 
analogues.  
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Using boronic acids as templates for multi-component assemblies 
 
The ability of boronic acid functionality to act as an internal tether for oxygenated and or 
nitrogenated compounds and their ability to engaged in MCR, makes this versatile  
functionality very useful to create collections of complex compounds with a framework 
designed to correctly present the pharmacophore sat the enzyme active site, and this 
constitutes the realm of this thesis.  
If successful, this approach (which will be named boron tether strategy) affords a direct 
synthesis of complex active molecules via the assemblage of distinct building blocks, that 
may be rationally tuned to improve the uncovered biological activity. In addition to this and 
from a synthetic point of view, this approach, based on a one–pot multicomponent 
reaction, contributes to reduce the long plethora of complex methodologies frequently 
used in a multi-step sequence, which often yield the target compounds in low yields 
determining the need for extensive purification steps (Figure 36).  
 
 
Figure 36– Boron tether strategy Vs classical chemical approach. 
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2. Fused tricyclo-boronate heterocycle 
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2.1 Overview 
 
The chemical modification of natural products is an extensively used procedure in 
medicinal chemistry. Such an approach aims to produce natural-product like compounds 
with an improved biological profile. The pursuit of such goal, often requires the discovery 
of new and complex synthetic routes. Therefore, we envisioned that the boron tether 
strategy could offer the possibility to perform the synthesis of natural-product like 
compounds, overcoming the cost and time demanding problems of classical chemical 
modification of natural compounds and uncover new hit compounds. 
To demonstrate this concept, we looked at Nature seeking for inspiration to select a 
chemical structure combining a certain degree of geometrical complexity and an 
interesting biological profile, which may serve as the base for the design of boronated 
analogues via the assembly of simple building blocks.  
Bearing these requirements in mind, we focused our attention in the family of  spongiane 
diterpenoids that display very interesting structural features and a wide range of biological 
properties, that includes: antifungal, antimicrobial, antiviral, antitumor, antihypertensive, 
anti-inflammatory activity. 
 
2.2 The spongiane diterpenoids 
 
Sponges are classified as sessile animals, which means that they are permanently 
attached to a solid substrate. The impossibility to escape from predator attacks, forced 
them to focus all their defensive strategies on a chemical arsenal mainly composed of a 
wide range of terpenoids. Despite this family of molecules been largely shared by all the 
marine phyla, the spongiane diterpenoids are exclusively present in two families of 
animals: the sponges, which use them as defensive chemical weapons, and the 
nudibranchs. The latter are shell-less mollusks, which feed on sponges, and are able to 
store the spongiane-derived metabolites and even to use them as own self-defense 
strategy.[77] The first compound of this family to be discovered was the isoagatholactone 
(Figure 37), isolated by Minale et al.[78] in 1974 from Spongia officinalis.  
 
Fused tricyclo-boronate heterocycles  Chapter 2  
 
39 
 
 
Figure 37 – Isoagatholactone. 
The terpenic structure of the spongianes is quite heterogeneous and may present very 
important differences among several structures. Gonzàles in a recent review, tried to 
organize the spongiane terpenoids taking as model the general skeleton of 
isoagatholactone highlighted in Figure 37.  
In this review,[78] Gonzàles ranked the nearly 200 compounds (known at the moment of 
writing), keeping in mind the massive number of modifications that can occur on the model 
skeleton (Figure 37), namely the degree of oxidation as well as the rearrangement of the 
6,6,6,5 carbocyclyc system of the model structure aforementioned. According to these 
elements, Gonzàles divided the entire number of compounds in two main subgroups:  
 Compounds having the intact spongiane skeleton   
 Compounds with an incomplete spongiane skeleton 
The molecules belonging to the first subgroup are characterized by a large number of 
different functionalizations, which taken together produce a very high number of variations 
of the intact spongiane skeleton.  
Among the different structural motifs, the oxofuro[2,3-b]furan unit (Figure 38) is an 
intriguing and prevalant highly oxygenated double ring moiety. Schmitz suggested that 
such highly oxygenated bicycle unit could complex cations when interacting with some 
biological target.[77] The mentioned sub-structure is present in the skeletons of the 
aplyroseol-1 a mildly cytotoxic agent in lymphocytic leukemia PS cells, which also 
possesses inhibitor activity against the phospholipase A2 (PLA2), an enzyme involved in 
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inflammatory processes, sharing this activity with aplyroseol-5 and aplyroseol-6.[78] Also 
dendrillol-1 has proved to have cytotoxic activity on tumor cells (Figure 38).[79] 
 
 
 
Figure 38 - Oxofuro[2,3-b]furan unit and some compound having the intact spongiane 
skeleton . 
The oxofuro[2,3-b]furan unit depicted in Figure 38, is also a recurrent motif in some of the 
compounds belonging to the second subgroup described by Gonzàles, where it is even 
more prevalent. The first compound belonging to this family is norrisolide (Figure 39). 
Isolated by Faulkner and Clardy from Chromodoris norrisi [78]. 
 
 
Figure 39 - Norrisolide, molecule that belongs to the second subgroup (compounds 
with an incomplete skeleton), that embodies a oxofuro[2,3-b]furan unit. 
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Other examples are the structures of omriolide A (Figure 40a), isolated from the 
Dictyodendrilla aff. Retiara,[80] which possesses an interesting trioxatricyclodecane ring 
system and chromodorolides A (Figure 40b) and B (Figure 40c), both extracted from 
Chromodoris cavae. Interestingly, compound c showed both cytotoxic and an antimicrobial 
activities.[81][82] 
A classical approach to synthesize the oxofuro[2,3-b]furan unit (Figure 38) was developed  
by Reiser et al, involving a long processes made of seven steps, characterized by the use 
of organometallic reagents and harsh conditions.[83]  
As aforementioned, a main goal of this doctoral project was to develop the synthesis of 
natural-product like compounds via the assembly of building blocks based on the boronic 
acid functionality. As shown in Figure 40, we envisioned that boronate analogues of the 
oxofuro[2,3-b]furan unit, could be prepared substituting the C-C bond between the fused 
cycles by a isoeletronic N-B bond.[98] 
 
 
Figure 40 - Others possible examples of structures that embody the oxofuro[2,3-
b]furan unit.  
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Implementing a boron tether strategy to design the oxofuro[2,3-b]furan 
motif 
 
 
Figure 41– Boron tether stratey to achieve the 5 oxofuro[2,3-b]furan motif. 
To design an assembly reaction that could yield the 5-oxofuro[2,3,b]furan analogue 
depicted in Figure 41, we envisioned that an α-amino acid could complex with the boronic 
acid affording a five member ring featuring the key B-N bond isosteric to the C-C bond 
present in the natural product motif. To append the second ring system, we conceived that 
the candidate building block should comprise an electrophilic center to react with the 
nitrogen, and an α-alcohol to chelate the boron yielding the bicyclo heteroatom analogue 
of the 5-oxofuro[2,3,b]furan unit.  
Based on the aforementioned, apart from the boronic acid, we selected as starting 
components for this assembly reaction, proline as it is a conformational constrained 
nucleophilic amino acid and glycolaldehyde that exhibits an electrophilic aldehyde and OH 
group (Figure 41).  
 
 
2.3Synthesis of 5 oxofuro[2,3-b]furan motif analogue 
 
Bearing in mind the rational design aforementioned, we initiated our study by reacting L-
proline with phenyl boronic acid and glycolaldehyde dimer (Figure 42), using several 
solvents (THF, DCM, H2O, CH3CN), different equivalent ratios, temperatures and reaction 
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times. Very gratifyingly, using methanol as solvent after 1 h of reaction at 60°C and using 
2 equivalents of the amino acid, 1,5 equivalent of the glycolaldehyde dimer afforded the 
heterocycle 1 which structure was determined by X-ray analysis (see below) in 95% yield 
and 94% diastereoselectivity (Figure 43) 
 
 
Figure 42 – Reaction design of the first B-N compound analogue of the  oxofuro[2,3-
b]furan unit.  
The diasteroselectivity of the reaction was determined by comparison of the integration 
values of the signals relatives to the protons derived from the α-carbon of the amino acid 
employed in the reaction. 
 
 
Figure 43 - Synthesis of boronate tricycle-heteroatom architecture using MeOH as solvent. 
 
Very surprisingly, the X-ray crystallography analysis of the crystal obtained for 
heterocycles 1, revealed that what in the NMR spectra of the compound 1 appeared to be 
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a residual impurity coming from the MeOH used as the reaction solvent was instead an 
unexpected functionality of the molecule. Indeed instead of a three-component assembly, 
the tricyclic heterocycle 1 was obtained via a one-pot four-component condensation in 
which methanol entered at the concave face of the lactone-acetal bicyclic system, (Figure 
44). This rather unexpected result increased considerably the homology of the boronate 
complex with the natural-product motif. 
 
 
 
 
Figure 44 - Molecular diagram for molecule 1 of compound 1. Ellipsoids are set at 
50% probability. 
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The mass spectrometry analysis, also confirmed the presence of a peak at 298 m/z, 
corresponding to the heterocycle molecular ion 275 m/z, typically coupled with Na+ (Figure 
46). The unanticipated inclusion of MeOH increased the final product structural similarity 
with the 5-oxofuro[2,3-b]furan unit and occurred either when using MeOH as the solvent or 
as a reagent in THF, though, in this case heterocycle 1 was obtained in a lower yield 
(88%) and diastereoselectivity (82%) as shown in Figure 45.  
 
 
Figure 45 - Synthesis of boronate tricycle-heteroatom architecture using MeOH as 
reagent. 
Recognizing that a higher homology between the target natural product 5-oxofuro[2,3-
b]furan unit and the boron heterocycle could be achieve using other amino acids rather 
than L-proline, we performed the reaction using N-methyl-L-alanine as the nitrogen 
containing component. Disappointingly, this reaction afforded compound 2a but only in 
40% isolated yield and as a complex mixture of diastereoisomers (Figure 47). Similarly, 
using L-proline as the amino acid component, and 1-hydroxyacetone instead of 
glycolaldehyde dimer, also afforded a mixture of compounds 2b and 2c.  
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Figure 46 – ESI-MS of heterocycle 1. 
 
Figure 47 - Reaction with N-methyl-L-alanine instead of proline. 
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Based on these results, clearly the most efficient synthesis of the analogue for the 5-
oxofuro[2,3-b]furan unit  was obtained when using L-proline and glycolaldehyde dimer as 
the assembly partners in MeOH. Therefore, once the most efficient conditions to prepare 
these heterocycles were established, we evaluated the possibility of extending the protocol 
to different alcohols, using the same reaction conditions.  
As showed in Figure 48 several alcohols generated the tricyclic heterocyclic structures in 
good yields and excellent diastereoselectivities, though the reaction was quite sensitive to 
the alcohol steric effect. A clear example of this effect, was the fact that when using EtOH 
as solvent, compound 5 was obtained in 89% yields, while with the bulkier iPrOH, 
heterocycle 6 was isolated in 72% yield and with tBuOH no reaction was observed. 
Despite this, hexanol, butanol, trifluoroethanol, and benzyl alcohols all afforded the 
expected heterocycles in yields ranging from 60% to 78% and diastereoselectivities in 
between 89% and >97%. In addition, unsaturated alcohols such as allyl, phenyl propargyl, 
and propargyl alcohols all yielded the expected products in good yields and excellent 
diastereoselectivities (Figure 48). After confirming the reaction tolerance toward a diverse 
set of alcohols, the assembly reaction was evaluated using different boronic acids. As in 
the case where different alcohols were tested, the boronic acids tested afforded the 
expected heterocycles in good yield and excellent diastereoselectivity, using aryl, 
heteroaryl, and alkyl boronic acids, and diastereoselectivities ranging from 90% to >97% 
(Figure 49).  
Regarding the substitution profile on the aromatic ring, alkyl substituents afforded the 
desired products 12 and 13 in 88% and 75% yield and >97% and 95% de respectively,  
while 2-naphthyl boronic acid yielded the heterocycle 14 in 83% yield and 96% de. The 
reaction was slightly more sensitive toward the electronic profile of the aryl substituent. 
The substitution of the electron-donating para-methoxide in compound 16 by the electron-
withdrawing para-fluoride in compound 17 increased the yield from 57% to 94% 
maintaining the high levels of diastereoselectivity. Finally, the ortho-substitution versus the 
para-substitution had an almost negligible effect in the reaction efficiency as the same 
isolated yield was obtained when using the para- and the ortho-bromo aryl boronic acids 
(Figure 49). Very gratifyingly, despite the possible reaction with proline, the method was 
tolerant to the presence of the ketone functionality as the 4-acetylphenylboronic acid 
afforded product 21 in 65% yield and 95% de. Finally, the 4-cyano-2-methylphenylboronic 
acid and the cyclohexyl boronic acid afforded heterocycles 22 and 23 in 65% yield, 96% 
de and 52% yield, >97% de respectively (Figure 49).  
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Figure 48 - Alcohol scope in the tricyclo-heteroatom architecture reaction. 
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Figure 49 - Boronic acids scope in the tricycle-heteroatom architecture reaction.   
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Mechanistic studies 
 
Once established the synthesis of 5-oxofuro[2,3,b]furan boronated analogues, we initiated 
a study to understand the reaction mechanism. Therefore, we studied the reaction 
mechanism using electrospray ionization mass spectroscopy (ESI-MS) (Figure 50). We 
performed the reaction between L-proline (2 equiv), phenyl boronic acid (1 equiv), 
glycolaldehyde dimer (1.5 equiv), and MeOH (10 equiv) in 2 mL of THF at 60°C. Aliquots 
of the reaction mixture, corresponding to the moment immediately after the addition of all 
reactants and after 10 min at 60°C, were collected and analyzed by ESI-MS.  
As shown in Figure 50, the spectra obtained after the addition of all reactants shows an 
increased concentration of intermediates A and B formed between proline and phenyl 
boronic acid, while analysis of the spectra obtained after 10 min at 60°C revealed the 
formation of a new tricyclic intermediate C. This latter disappears in the spectrum recorded 
after 120 min to afford product 1. Based on these results, the reaction mechanism was 
studied by means of DFT calculations, with the collaboration of prof Luis Veiros at IST, and 
the resulting highlights are shown in Figure 51.  
 
The calculated mechanism starts with a complex of proline and boronic acid (B), and with 
its solvent adduct (A), both detected by ESI-MS data (Figure 51) in the initial aliquot. 
Addition of glycolaldehyde to B results in intermediate C. This step is assisted by OH 
coordination to the B-atom, first, and then by proton transfer from the alcohol to the O-
atom in activating the carbonyl group to the nucleophilic atom from the nitrogen. 
Protonation of C leads to D with the corresponding activation of the B-O bond Then, the 
exchange between the two B-O bonds, from D to E, allows the activation of the C-O bond 
involving the C-atom R to the nitrogen and gives rise to the breaking of that bond and to 
the formation of the iminium ion that occurs in the  
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Figure 50- Mass Spectrum of reaction products at T0, T10 and T120 (Full Scan m/z 60-
600; ESI+; Capillary Potential 3,0kV; Source Potential 40V).
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Figure 51 - Reaction mechanism proposed after DFT calculation. 
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following step, from E to F. Next, from F to G, there is abstraction of one proton by the OH 
group coordinated to boron, with the corresponding breaking of one C-H bond in the side 
chain. In G, there is regeneration of a neutral N-atom and formation of an enol 
(NCH=CHOH) that finally coordinates the boron through its O-atom (in G). From G to H, 
there is a nucleophilic attack from the N-atom to boron with the consequent loss of one 
water molecule. The coordinated enol (H) tautomerizes to the corresponding aldehyde, 
from H to I. The carbonyl group in I is activated by coordination to the B-atom and, thus, 
suffers nucleophilic attack from the solvent (methanol) yielding the final product of the 
reaction. It should be noticed that solvent plays an active and important role in the entire 
reaction path, through its assistance in all proton transfer steps, as expected for a protic 
solvent. Thus, in the calculated mechanism there was explicit consideration of one 
methanol that establishes an H-bond network with the various intermediates. In addition, in 
the section of the mechanism corresponding to enol formation from the iminium ion (F to 
G), a second methanol molecule was used in the calculations. The second solvent 
molecule coordinates the boron, allowing a tetrahedral environment around that atom that 
would other- wise remain trivalent as in F. The coordination of methanol enhances the 
electronic density in the B-atom and increases the basicity of the OH group that abstracts 
the proton from the C-H bond giving rise to the enol in G. In fact, the barrier calculated for 
this step without the B-OMeOH coordination is 6.6 kcal mol-1higher than the one obtained 
considering methanol coordination. This indicates an active participation of the solvent 
along the reaction mechanism, and, in particular, in the enol formation step, the one with 
the highest calculated barrier: 22.9 kcal mol.-1 Another interesting aspect of the reaction is 
the high diastereoselectivity found experimentally, especially taking into consideration the 
existence of four asymmetric centers in the product: the carbon from the proline, the N- 
and the B-atoms, and the acetal C-atom. On the other hand, the configuration observed 
for the N- and the B-atoms can be understood by the geometry of the intermediate B 
(Figure 51). In fact, the conformation of the amine five-membered ring, dictated by the 
configuration of the asymmetric C-atom and by the pyramidal geometry around the 
nitrogen, leaves only one side of the molecule available for the reaction with 
glycolaldehyde and determines the final configuration of both nitrogen and boron. Finally, 
the configuration on the acetal C-atom results from the relative stability of the two epimers. 
The last step is under thermodynamic control with negligible barriers calculated for the 
addition of methanol.  
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2.3.1 Biological evaluation 
 
Once established the synthesis of these analogues of the 5 oxofuro[2,3-b]furan motif they 
were evaluated for their antitumor activity.Therefore, the newly synthesized boron 
heterocycles 7,15,18,20 and 21 were selected to be tested in a cell-based assay against a 
breast adenocarcinoma cell line (MCF-7)(Figure 52). The cells were incubated with the 
boron heterocycles for 24 hours previously to the assessment of the cell viability by a 
tetrazolium compound. This tetrazolium is reduced in metabolicaly active cells and is 
converted into a purple formazan detectable by UV at 570 nm. Based on the results 
obtained, compounds 4, 12, 14 and 15 did not change significantly the cell viability. 
Differently and to our delight, compound 9 exhibited a moderate activity in this assay 
decreasing the cell viability by 60% (Figure 52). Although it is premature to establish any 
structural-activity-relationship, the presence of the n-butyl substituent in the para position 
of the aryl group, appears to be determinant for the activity of this molecule as all other 
compounds tested, featuring different substituent’s at the aryl moiety, displayed no 
relevant activity similarly to what occurred with compound 4 which as a long alkylic chain 
in the acetal moiety. 
 
 
 
Figure 52 - cell-based assay against a breast adenocarcinoma cell line (MCF-7). 
 
Encouraged by the “synthetic accomplishment of our goal" we decided to redirect our 
synthetic efforts towards a new biological target: human neutrophil elastase (HNE). HNE 
inhibitors spread over many different families of compounds with very distinct chemotypes, 
among these, fused cyclic lactones (Figure 53) have been described for the inhibition of 
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HNE with IC50’s ranging from  . 24 to  .  3 μM.
[84] Their bicyclo[3,3,0]octane unit closely 
resembles the structure of the oxofuro[2,3-b]furan unit, whose the boron heteroatom 
analogue was demonstrate to be easily synthesized through the boron tether strategy.  
 
 
Figure 53 - Fused cyclic lactones as HNE inhibitors. 
 
Despite the similarity between the two bicyclo-systems, we realized that the molecules of 
the boronate tricycle-heteroatom library miss the structural recognition requirement to  
properly fit in the active pocket of the HNE, which is widely known to possess extended 
molecular recognition binding sites (S1 is the most important with affinity for small 
hydrophobic groups).[85,86] A confirmation of this hypothesis came from the enzymatic 
assay of compound 3 against the HNE which was unable to induce any appreciable 
inhibition.  
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2.4 Conclusion 
 
In summary we have developed a new one-pot four-component assembly of N-B 
heterocycles with a natural product-like framework similar to the 5-oxofuro[2,3-b]furan unit, 
which is a shared structure of many spongianian diterpenoids with an interesting range of  
biological activity. The reaction displayed a broad scope regarding the alcohol and boronic 
acid components. The N-B heterocycles were obtained in yields up to 95% and excellent 
diastereoselectivities (up to >97%). All of these results indicate that the use of boronic acid 
as a template to promote the assembly of several molecules in a multi component reaction  
(MCR) fashion, is an effective strategy to simply assemble collections of compounds with 
discrete molecular surfaces similar to those found in natural product frameworks. Despite 
this strategy being successful from the synthetic point of view, yielding the fused tricycle 
boronate heterocycles collection, it missed to effectively induce an appreciable biological 
response in the tumor cells. 
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3. Fused bicyclo-boronate heterocycles 
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3.1 Human neutrophil elastase  (HNE) and boron based 
inhibitors 
 
Inflammation is a complex process of the vascular system, which responds to deleterious 
stimuli such as: pathogens, injury and irritants. This mechanism is involved in the 
resolution of infective events and in tissue remodeling after injury occurrences. The human 
neutrophil elastase (HNE)(Figure 54) is one of the enzymes responsible for the destruction 
of the damaged proteins through hydrolysis of elastin that confers elasticity to the 
connective tissue.[85] 
 
 
Figure 54 - The human neutrophil elastase (HNE). 
This enzyme is contained into the azurophilic granules (primary granules) of the 
neutrophils, a phagocyte of the white blood cell system. More specifically, HNE is a serine 
protease that belongs to the chymotrypsin superfamily, constituted by 218 amino acids 
and a total weight of 29–33 kDa. The active site of this enzyme is a typical “catalytic triad” 
(Figure 55) machinery shared over all the large family of the proteases. It is composed by: 
aspartic acid 102, histidine 57 and serine 195.The triad is composed schematically by a 
nucleophile (the side chain –OH of the serine), a base (histidine) and an acid (aspartic 
acid)[87]. The objective of such machinery is to enhance the nucleophilic attitude of serine. 
The mechanism of the catalytic triad (Figure 56) starts with the aspartic acid that polarizes 
the histidine, which deprotonates the serine, making it a better nucleophile. 
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Figure 55- catalytic triad. 
The deprotonated oxygen, from serine, can now easily attack the elected amide. The 
carbonyl of the amide changes the conformation from trigonal planar to tetrahedral. This 
new intermediate is stabilized by hydrogen bonding from Gly193 and a NH from the 
backbone of the Ser195, such region is commonly called the oxyanion hole. Histidine 57 
assists the collapse of the tetrahedral intermediate to sp2 acyl group, by proton donation to 
the amine leaving group. The enzyme activity is re-established through hydrolysis of the 
acyl-enzyme.[87] 
 
 
Figure 56 - Mechanism of the serine proteases. 
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The natural endogenous inhibitors of the HNE, are α -proteinase inhibitor (α -PI, α1-
antitrypsin), secretory leukocyte protease inhibitor (SLPI) and elafin (ESI or SKALP).[88,89] 
They play the important role of protecting the health and functionality of the tissues from 
the destructive effects of extracellular HNE. An imbalance between the enzyme and its 
endogenous inhibitor could lead to an aberrant photolytic activity responsible for severe 
diseases such as: chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, 
cystic fibrosis.[85] Nowadays, and just in Japan, Sivelestat is the only drug approved as 
HNE inhibitor. Since the lack of responses for such severe and urgent problems, organic 
chemists synthesized a number of inhibitor whose action could be ranked in three main 
categories according to their mode of action:  
1. Transition state analogues  
2. Acylating agents 
3. Mechanism like inhibitors 
 
Regardless of how an HNE inhibitor is classified, the initial steps of the inhibition 
mechanism always begin in a similar manner:  
 Nucleophilic attack of the serine 195 OH  
 Creation of the tetrahedral Inhibitor-enzyme complex 
The evolution of this sp3 intermediate is what makes the difference among the three 
different mechanisms.  
 
Transition state analogues 
An inhibitor is classified as a transition state agent, when the inhibitor-enzyme complex is 
stable enough to occupy the active pocket as long as an appreciable inhibition is 
produced. Among several drugs exploiting this mechanism ONO 6818 represents one of 
the most noteworthy examples. This molecule has shown to be active against: chronic 
obstructive pulmonary disease (COPD), acute lung injury (ALI) and acute respiratory 
distress syndrome (ARDS). With a Ki value of 12.16 nM, the aforementioned inhibitor was 
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active through oral administration (ED501.4 mg/kg). The crystal structure of the inhibitor-
enzyme complex, suggests that the molecule acts as a transition state agent, with Ser 195 
attacking the amidic carbonyl to generate a tetrahedral intermediate with a negative 
oxygen stabilized by the oxyanion hole (Figure 57). [85, 92] This promising molecule arrived 
to phase II clinical trials, To be discontinued when the an abnormal elevation in liver 
functions was revealed in the patients under the treatment with ONO 6818.[93] 
 
 
Figure 57 - schematic interaction between ono-6818 and PPE investigated through X-
ray analysis. 
Acylating agents 
These compounds interact with the enzyme via the generation of a tetrahedral complex 
between the inhibitor and the enzyme. Differently from a transition state agent this 
complex is not stable and the enzymatic machinery continues its natural action catalyzing 
the release of the amine through proton donation of the hystidine 57, producing the 
acylated enzyme, which is a natural intermediate in the normal action of the HNE, which 
evolves a free enzyme through hydrolysis of the acyl group. What differentiates an 
acylitang agent from a natural substrate is the ability to produce an acyl-enzyme 
intermediate resistant to hydrolysis, disabling the enzyme form returning into its active 
form.  
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Figure 58 - ONO 5046. 
ONO 5046 (Figure 58) is the most important HNE inhibitor, the only one to reach the 
commercialization (Japan only) and is an acylating agent. It is used for the treatment of 
ALI and ARDS. It has an IC50 of  ,  44 μM. The acylated enzyme was identified after 10 
min of incubation with ONO 5046 by using LCESI-MS.[94,95] 
 
Figure 59 - ONO-5046 inhibition mechanism. 
Mechanism based inhibitors 
This class of compounds embodies in their structure a masked electrophilic functionality. 
The formation of the acyl intermediate triggers the unmasking of the hidden electrophilic 
moiety that can be attacked by a second nucleophile, which commonly is His 57. These 
inhibitors share the initial steps of the interaction with the enzyme, with the acyl-enzyme 
inhibitors. Indeed the first intermediate formed is an acyl enzyme that quickly evolves into 
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an electrophore. When such electrophore is attacked by a nucleophilebelonging to the 
enzyme the mechanism is classified as “double hit mechanism”.  
An example of this is provided by the chloromethyl ketone that after activation is able to 
irreversibly alkylate the histidine residue of serine proteases (Figure 60). 
This kind of activity it also called double hit mechanism since the presence of two 
nucleophilic attacks, the first from serine and the second from histidine.[96] 
 
 
Figure 60 - Chloromethyl ketone double hit mechanism.  
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3.2 Synthesis and evaluation of fused byciclo-boronate 
heterocycles 
 
Inspired by the proven inhibitory activity of the cyclic lactones against HNE,[97] we 
envisionedthat the Boron tether strategy could be exploited to create a series of boronated 
structures with similar architectures to the lactones, with a double fused ring system, in 
which electrophilic centers are incorporated in order to act as pharmacophore. 
We figured that the lactone mimics could be readily assembled by combining a chelating 
aldehyde, a boronic acid and an amino acid.[98,99] These constructs could be simply tuned 
to promote a selective enzyme inhibition via formation of an acyl-enzyme complex as 
shown in Figure 61. Importantly, the boron construct depicted in Figure 61 can provide two 
major structural requirements for enzyme inhibition:  
 A substitution pattern appropriate for molecular recognition   
 An increased reactivity of the 5-membered ring towards the 
catalytic serine.  
 
Figure 61 - bicycle-heteroatom architecture design. 
As aforementioned, the topology of HNE active site comprises extended molecular 
recognition binding sites, of which the S1 is the primary specificity binding pocket with 
affinity for small hydrophobic groups.[86,87]Therefore as shown in Figure 61 a careful 
selection of the components may permit an optimal interaction with HNE active site. 
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Based on this, we selected amino acids with hydrophobic side chains like L-alanine, L-
leucine and L- phenyl as partners, together with phenyl boronic acid and salicylaldehyde to 
generate the fused lactone mimic (Figure 62). Given the solubility issues related with the 
use of amino acids, the three components were combined in one-pot in water end reacted 
over 20 h at 90°C. As shown in Figure 62, this simple approach afforded the expected 
compounds in yield up to 76%. This protocol evidenced another advantage as the 
products precipitated from the aqueous phase and for that reason were simply collected 
by filtration in good to excellent yields and diastereoselectivities.[99] Once prepared, 
compounds 24-26 were readily evaluated against HNE using a fluorometric assay in which 
HNE activity is monitory using the fluorogenic substrate MeO-Suc-Ala-Ala-Pro-Val-AMC.  
Compounds 24 and 25, were shown almost inactive (Figure 62). Very differently and to our 
delight, compound 26 synthesized with L-phenylalanine, displayed a very promising IC50 of 
2 .27μM. Foreseen a possible in situ hydrolysis of the complex into the assembly 
partners, the individual components phenyl boronic acid and salicylaldehyde were also 
evaluated against HNE and displayed no activity. These results clearly demonstrated that 
the recorded activity for compound 26 is indeed due to the heterocycle structure and not 
the individual components. Motivated by the identification of compound 26 as a HNE 
inhibitor, we embarked on a hit optimization program empowered by the chemical 
versatility offered by this synthetic strategy synthesizing the small collection of boronated 
compounds depicted in the Figure 64. A very satisfactory level of diasteroselectivity, 
measured by 1H NMR, was achieved in all the reactions reported in 64. The X-ray 
crystallographic study data, and DFT calculations rendered a deeper insight over the 
structural characteristics of these molecules. Suitable crystals for X-ray analysis were 
obtained for heterocycles 26, 28, 29 (Figure 63). The first data evidenced by the 
crystallographic analysis was the importance of the stereo constrains of the boron-
heterocycles architecture. Indeed despite the different boronic acids used to prepare 26, 
28 and 29 they all display similar N–B dative bond distances ( . 77(2)   (26),  . 74(3)   
(28) and  .  9(4)   (29)). The DFT calculation of the optimized geometry of compounds 
26, 28, 29 and were also in good agreement with the experimental X-ray data, the 
deviation of the N-B distances values in all three cases, was within 0.001Å. The similarity 
of the N-B bonds was also extended to the bond strength, confirmed by the Wiberg 
indices,[101]of 0.61, and the electronic distribution calculated for all the B-atoms of the three 
structures, with an atomic charge (NPA)[102-109,] 1.02. 
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Figure 62 - Bicycle-heteroatom architecture with L-alanine, L-leucine, L-
phenilalanine. 
 
Figure 63 - Molecular diagrams  of the complexes 26, 28 and 29 (from left to right) 
obtained by x-ray diffraction . 
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3.2.1 Inhibitor profile of fused bicyclo-boronate heterocycles 
 
Regarding the biological activity as shown in figure 64, heterocycles 27-29 which were 
successfully prepared in 83%, 31% and 80% yields respectively and excellent 
diastereoselectivities (100%), using para substituted aromatic boronic acids, L- 
phenylalanine and salicylaldehyde, were readily tested against HNE. These compounds 
though, revealed no significant improvement in the inhibition profile of HNE, when 
compared with the inhibition obtained with compound 26. Of this series the best result was 
obtained with compound 29 (IC50 = 16.06 μM) featuring a para fluorinated aromatic ring of 
the boronic acid component. 
Based on this, the modification was extended to the aromatic moiety of the aldehyde. The 
inclusion of a methyl group only slightly improved the activity of compound 30  
(IC50 = 15.39μM), while a methoxy function at the same position had a much more 
pronounced effect and reduced the IC50 up to 9.3μM. Therefore, compound 31 was 
selected as the starting point for another round of optimization in which functionally diverse 
boronic acids were explored as components of the assembly. Disappointingly compounds 
32-33 displayed a poor inhibitory activity when compared with compound 31. Very 
differently, the introduction of a bromine atom either in the para or ortho positions of the 
boronic acid aromatic moiety, greatly improved the potency up to 2μM. The same trend 
was observed in compounds 37 (IC50 = 2μM) and 38 which feature a chlorinated aromatic 
boronic acid ortho and para substituted and displayed an IC50 of  .9 μM. Based on all 
modifications operated in this scaffold the methoxy substituent introduced in the aldehyde 
aromatic moiety was shown instrumental for potency. For this reason, compound 39 was 
prepared with 4-diethylamino-salicylaldehyde with the objective of improving the effect 
previously observed. Therefore, L-phenylalanine, 4-diethylamino-salicylaldehyde and 2,4-
dichlorophenyl boronic acid were reacted in ethanol for 20 h at 70°C to yield 39 in 89 % 
yield and 98 % de. Very gratifyingly, the operated modification resulted in the improvement 
of the activity against HNE and 39, with an IC50 = 1.1μM, becames the most efficient 
inhibitor prepared in this work. After this, we addressed the selectivity of 39 in the 
presence of other proteases like porcine pancreatic elastase (PPE), proteinase 3 (PR3) 
and Cathepsin G. As shown in Figure 48, compound 39 displayed a good selectivity 
towards HNE as at   μM concentration only displayed an IC50 of  2μM against cathepsin 
G and was inactive towards PPE and PR3. Finally, the inhibitory activity of compound 39 
towards HNE was also determined using the progress curve method (chapter 5 
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experimental). Significantly, a time-dependent inhibitory profile was observed and the 
corresponding pseudo first-order rate constant values, kobs, varied linearly with the 
concentration of 39, yielding a second-order rate constant of inactivation, kinact/Ki, of 
1.2×102 M-1 s-1. This value compares well with those reported to other potent HNE 
inhibitors.[87] Overall, these results suggest that 39 inhibits HNE irreversibly, and contrasts 
sharply with compound 26, for which reversible inhibition kinetics were observed.  
 
 
Figure 64 - Bicycle-heteroatom architecture library. 
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3.2.2 Mechanicistic studies 
 
Once demonstrated the potential of this methodology to prepare new HNE inhibitors, we 
initiated a study to unravel their mechanism of action.  Considering the general structure of 
this family of compounds we envisioned that the nucleophilic attack of the Ser195 hydroxyl 
oxygen atom to the lactone moiety would be the most likely mechanism of action. To 
confirm this assumption, we synthesized compound 41 in which the lactone mimic is 
absent and for which is expected no activity. The synthesis of this compound is based on 
two steps, the first affords the N-(2-hydroxybenzilidene)-2-amino-2-benzyl-ethanol (Figure 
65b), by reaction of 2-amino-2-benzyl-ethanol and salicylaldehyde in ethanol and in the 
presence of molecular sieves. The second step is a condensation reaction in toluene that 
affords the boron heterocycles 41. Very gratifyingly and as envisioned, the evaluation of 
compound 41 against HNE revealed the loss of activity when compared with the reference 
compound 26. Encouraged by this result, we synthesized compound 40, aiming to 
demonstrate that the lactone was indeed the reactive centre and not the imine moiety. The 
reaction proceeded through two steps, the first affords the N-(2-hydroxybenzil)-α-amino 
acid (Figure 65a), the in situ reduced product of the condensation between salicylaldehyde 
and the amino acid. The second step afforded the saturated boron heterocycle 40. With 
compound 40 at hand it was evaluated against HNE. Surprisingly compound 40 was also 
shown inactive. Puzzled by these results, we considered that the saturation of the imine 
bond would significantly alter the electrophilicity of the lactone carbon, disfavoring by this 
way, the nucleophilic addition to this position. Nevertheless, the 11B NMR of 26, 40 and 41 
did not expose any substantial differences between these molecules neither the atomic 
charges (NPA) calculated for 26, 40 and 41 by means of DFT calculations,[110] 
corroborated this assumption (Figure 65). 
Based on these results, we performed the evaluation of the stability of 39 in the presence 
of sodium methoxide, a strategy often used to mimic the action of the serine hydroxyl 
group at the active centre of the enzyme.[111] 
The reaction was performed in methanol at room temperature and followed by mass 
spectrometry. Surprisingly, the product (ESI+ m/z = 386.10) formed in this transformation, 
indicates that two molecules of methoxide reacted with 39 (Figure 66a) and that the 
boronic acid component was released in the process (Figure 66). Interestingly, no product 
corresponding to the addition of just one molecule of methoxide to 39 was detected in the 
reaction mixture. This unexpected result indicated that the mechanism of action would 
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probably involve the addition to both the imine and the lactone moieties. Therefore, the 
mechanism of the reaction of O-nucleophilic attack on the heterocycles tested as HNE 
inhibitors was studied by means of DFT calculations in collaboration with professor Luis 
Veiros at IST (Figure 67). The system used was compound 26 as substrate and methanol 
as nucleophile, for computational convenience. The energy profile obtained is represented 
in (Figure 67). 
 
Figure 65 - biological evaluation, NPA atomic charges in parenthesis. 
The mechanism starts with substrate 26 plus two molecules of methanol, represented by A 
in Figure 67. In the first step there is a nucleophilic attack of one methanol molecule on the 
imine C-atom, while at the same time the other MeOH molecule assists in the proton 
transfer from the OH bond in the nucleophile to the oxygen of the carbonyl group of the 
lactone. In the corresponding transition state, TSAB, formation of the new C–O bond is 
almost accomplished, as shown by a distance of 1.58 Å, while the proton transfer is 
underway with the four relevant O– H bond lengths ranging from 1.07 and 1.40 Å. 
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Figure 66 - Reaction of 39 with NaOMe in methanol followed by mass spectrometry. 
Then, there is proton transfer from the oxygen, in B, to the nitrogen, in C, where there is a 
formally positive N-atom and the lactone C=O group is regenerated. Interestingly, this N-
protonation step produces a significant stabilization of the intermediate, C being more 
stable than B by 21 kcal/mol. A third molecule of methanol is added to model, from C to D, 
as it will be required to assist the second nucleophilic attack. This attack occurs in the 
following step, from D to E, and the extra MeOH molecule assists in the protonation of the 
O in the carbonyl group of the lactone, while, at the same time, there is formation of the 
new C–O bond between the oxygen atom of methanol and the carbonyl C-atom. In the 
transition state, TSDE, formation of the new C–O bond is well advanced as indicated by a 
distance of 1.65 Å, while the process of proton transfer, from the methanol OH bond to the 
carbonyl O-atom, is half way through, as shown by the relevant O–H distances ( .  – .32 
 ). 
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Figure 67 - The reaction of O-nucleophilic attack on the heterocycles tested as HNE 
inhibitors, studied by DFT calculations. 
 
From E to F there is a rearrangement in the H-bonds between the intermediate and the 
neighbor MeOH molecule. Finally, in the last step there is proton transfer from the carbonyl 
O-atom to the oxygen connected to the boron atom, It is important to notice that the 
barriers calculated for the mechanism represented in Figure 67are rather high, presenting 
values of 24 and 30 kcal/mol for the two steps corresponding to nucleophilic attack. This is 
due to the use of methanol has nucleophile in the model employed in the calculations, a 
much poorer nucleophile than methoxide, the nucleophile used in the experiment 
described above. Nevertheless, the barriers obtained indicate a feasible reaction, 
especially taking into account an expected large excess of methanol if this species is used 
as solvent in the reaction medium. In addition, the similarity between the values calculated 
for the two energy barriers justify the existence of two consecutive methanol additions and, 
thus, the fact that the reaction cannot be stopped after the first attack, on the imine C-
atom. Since there are two O-nucleophilic attacks in the reaction described above it is 
important to study the sequence of those attacks in order to gain insight into the 
mechanism of HNE inhibition. In other words, what occurs first, addition of the nucleophile 
to the carbonyl C-atom or attack on the imine C-atom? In order to answer this question the 
alternative path was explored by means of DFT calculations, i.e., a mechanism were the 
first step corresponds to methanol nucleophilic attack on the C=O of the lactone (Figure 
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68), while the entire path is presented as ESI (Figure 67). Corresponding hydrolysis of this 
bond and the opening of the former lactone ring. In the transition state, TSFG, scission of 
the C–O bond is  ust starting, with a distance ( . 9  ) that is only  . 9   longer than the 
corresponding one in intermediate F. Once again, assistance of the adjacent MeOH 
molecule is crucial to the H-transfer process that occurs along that step and the relevant 
O–H distances, indicate that, in fact, such process is underway in TSFG ( .  – .39 ). 
 
Figure 68 - Energy profile (kcal/mol) calculated for nucleophilic attack of methanol on 
C=O group. 
The O-nucleophilic attack of methanol on the lactone C=O group of substrate 3 occurs 
similarly to the equivalent steps in the first mechanism addressed. Thus, there is methanol 
assisted proton transfer, from the incoming methanol molecule to the O-atom in the 
carbonyl group of the substrate, simultaneously to the formation of the new C–O between 
substrate and nucleophile. Formation of that bond is well advanced in the transition state, 
TSHI, with a C–O distance of  .7   . Also, the process of H- transfer is evident in TSHI 
with the four relevant O–H distances between  . 3 and  .29  . Most interestingly, the 
energy barrier calculated for this step is 3 kcal/mol higher than the one obtained for the 
attack on the imine C-atom, as first step of the reaction mechanism (TSAB Figure 67). This 
indicates the imine as the more favorable location on the substrate for the first O-
nucleophilic attack, being a rather surprising result, taking into account the atomic charges 
calculated for 41(Figure 65), that show the carbonyl C-atom as more electrophilic than the  
imine one. However, the LUMO of the substrate (Figure 69) has a significant participation 
on the imine C=N bond, representing a π* interaction between those two atoms and 
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presenting 51% of the electron density of that orbital. The results above indicate that 
reaction is under orbital control, rather than being ruled by charge (Figure 69). 
 
Figure 69 - Representation of the LUMO of the compound 26. 
Aiming to explain the observed biological activity of the various heterocycles (Figure 64) 
and to get insight into their mechanisms of action at the molecular level, we also 
performed in silico molecular docking studies in the active site of HNE, using GOLD 5.1 
software.[112] The coordinates of the enzyme structure were obtained from Protein Data 
Bank selecting the structure with accession code 1HNE (X-ray coordinates at 1.84 Å 
resolution, previously validated for docking procedures). Modelling the interaction of 
compounds 24, 26, 38 and 39 in HNE active site (Figure 70A, B, C and D, respectively), 
the most striking feature evidenced by the docking of all 4 compounds, is their distinct 
recognition by the enzyme’s primary specificity binding pocket (S ). As shown in Figure 
70A, the inactive compound 24 does not occupy S1, contrasting with the moderately active 
compound 26 (IC50 of 2 μM), prepared with L-phenyl alanine, which sits the benzyl side 
chain well within the S1 pocket (Figure 70B). Interestingly, in this optimized conformation, 
the imine and lactone possible reactive sites are still quite distant from any HNE 
nucleophile. Regarding the most stable conformations obtained for the most potent 
inhibitors 38 and 39, inspection of Figure 70 C and D indicates that the L-phenyl alanine 
side chain is no longer occupying the S1 pocket, being replaced by the 4-methoxy or the 
4-diethyl amino substituent of the aldehyde aromatic moiety. Interestingly, this 
arrangement visibly favours the proximity of the imine reactive site to the Ser 9  (4.2  
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(38)  4.   (39)) and His 7 (2.   (38)  2.9  (39)).To validate this model and confirm the 
importance of the aldehyde aromatic substituent for the recognition and potency (Figure 
71), compound 42 was prepared from glycine, 4-methoxy- salicylaldehyde and 2,4-
dichlorophenylboronic acid in THF. Very gratifyingly, compound 42 that lacks the benzyl 
group displayed a 3. 7μM IC50 which is comparable with the activity exhibited by 
compound 38 prepared from L-phenyl alanine. 
 
 
Figure 70 - Modelling the interaction of compounds 24, 26, 36, 39 in HNE active site 
(respectively A, B, C, D). 
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Figure 71 - The biological evaluation of compound 43 shows the importance of the 
aldehydic substituent for the recognition of the molecule in the active site of the HNE. 
Regarding the mechanism of inhibition, the lack of activity of compounds 40 and 41 
indicates that the reaction of the imine and lactone ring opening are both key events in the 
inhibitory process. Although it is uncertain the exact sequence of events of the 
mechanism, we envision that Ser195 hydroxyl group firstly adds to the nearby imine 
carbon centre to form an amino ketal (Figure 72 A), in line with the accepted first step of 
serine proteases mode of action,[113] and with the mechanism of methanol addition to 26, 
obtained by DFT calculations (see above). The O-nucleophilic attack on the imine 
neutralizes the nitrogen atom and generates a negatively charged intermediate, which 
may be readily protonated in the N-atom by the near His57, reestablishing the N-B ylide. 
This parallels the intermediate step in the mechanism of Figure 67, from B to C in which 
there is a gain of 2  kcal/mol. Subsequently, the proximity of the His 7 to the amino ketal 
carbon centre (2.9 ) may assist in the dissociation of the hydroxyl group of Ser195 (Figure 
72B), liberating this fragment for the following lactone ring opening that promotes the 
release of the boronic acid moiety as suggested by the reaction of 39 with sodium 
methoxide (Figure 72C). In agreement with this proposal, the minimized structure 
generated from the reaction of 39 with His57 and Ser195 in the HNE pocket (performed 
with MOE 2011.10 software27) shows the maintenance of the 4-diethyl amino substituent 
of the aldehyde aromatic moiety well fitted in to the S1 pocket as shown 
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Figure 72 - Proposed mechanism of inhibition of the compound 39 against HNE. 
Based on this proposal, we perform the LC-ESI-MS analysis of the reaction between 
inhibitor 39 and HNE (Figure 73). Very gratifyingly, we observed that 39 is completely 
consumed in the presence of HNE, at the same time that, compound a in the Figure 73 is 
formed in the reaction mixture (Figure 73). The in situ formation of a(Figure 73) is a 
particularly important observation as it is in good agreement with the aforementioned 
mechanism, in which imine a (Figure 73) maybe generated via hydrolysis of the 
intermediate depicted in Figure 72 A. Nevertheless, these results should be taken 
cautiously as the appearance of a (Figure 73) as a result of a spontaneous reaction of 
phenylalanine and salicylaldehyde formed via alternative pathways cannot be ruled out.  
Once established the usefulness of this compounds to inhibit this important biological 
target, we addressed the toxicity of the leading compound 39 as well as the individual 
building blocks (Figure 74). The referred compounds were assayed against colon adeno-
carcinoma cells (CaCo-2) and did not show any significant toxicity. 
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Figure 73 - LC-ESI-MS analysis of the reaction between inhibitor 39 and HNE. 
 
 
 
Figure 74 – Toxicity test over CaCo-2 cell line, with 100 µM concentration.  
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3.3 Conclusion 
This study demonstrates that a boron promoted one-pot assembly reaction can be used to 
design novel bioactive scaffolds. This strategy was applied to the discovery of new HNE 
inhibitors generated from components like salicylaldehyde, aryl boronic acids and amino 
acids. The versatility of this assembly strategy allowed the synthesis of new HNE inhibitors 
in excellent yields, high diastereoselectivities and IC50 up to  . μM (compound 39). The 
combination of synthetic, biochemical, analytic and theoretical studies, allowed us to 
conclude that the boron tether can provide the structural requirements necessary for 
enzyme inhibition. Moreover, we were able to identify the 4-methoxy or the 4-diethyl amino 
substituent of the salicylaldehyde as the most important recognition moiety in the 
molecule, and the imine alkylation, lactone ring opening and release of the boronic acid as 
key events in the mechanism of inhibition. 
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4. Evaluation of fused bicycle-boronate 
heterocycles against the phenylalanine 
hydroxylase (PAH)
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4.1 Overview 
 
In the course of our studies, in which we explored the activities of fused bicyclo-boronated 
heterocycles against the HNE. A molecule found in the literature with some degree of 
structural analogy with bicyclo-boronate heterocycle architecture gathered our attention. 
This molecule is the 3-amino-2-benzyl-7-nitro-4-(2-quinolyl)-1,2-dihydroisoquinolin-1-one 
(Figure 75) and was reported to be a promising structure for the treatment of the 
phenylketonuria (PKU). [114] 
 
 
 
Figure 75 - Analogy between 3-amino-2-benzyl-7-nitro-4-(2-quinolyl)-1,2-
dihydroisoquinolin-1-oneof and fused bicycle boronate heterocycle obtained with 
phenylalanine. 
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4.1.1 Phenylketonuria (PKU) 
 
PKU is a metabolic genetic disorder characterized by high levels of phenylalanine, in all 
body tissues.[115]In most cases, PKU is related with dysfunctional activity of phenyl alanine 
hydroxylase (PAH) exhibiting conformational defects imposed by mutations in the PAH 
gene.[114,115.116,117]In humans the number of mutations responsible for a mistaken 
transcription of PAH gene is very large, nowadays they were numbered as over 500. A 
substantial part of these genetic modifications are classified as missense mutations,[116,118] 
which lead during the translation of the mRNA to include a wrong amino acid in the 
primary structure of the PAH. The final result is a muted and misfolded PAH protein with 
an decreased turnover in vivo. To understand the impact of PKU over our society, it is 
enough to quote the annual rate of incidence of this disease in the USA 1:16,000[120]. PKU 
is the most frequent of the amino acid metabolism inborn errors and, if untreated, leads to 
the disturbance of brain neurotransmitters levels that develops progressively into mental 
retardation, brain damage, epilepsy among other incapacitating neurological 
disorders.[115]PAH belongs to the family of aromatic amino acid hydroxylases and 
catalyses the oxidation of Phe to tyrosine (Tyr), which is the first step of the catabolic 
degradation of Phe.Consequently, a defective activity of PAH leads to Phe accumulation 
up to toxic levels, forcing PKU patients to stringently hold on to a Phe diet free, which often 
results on malnutrition and neurologic problems. For these, alternative strategies to control 
PKU are now beginning to emerge such as the diet supplementation with 
tetrahydrobiopterin (BH4), which is a PAH natural cofactor that is able to act as a 
pharmacological chaperon stabilizing the mutated protein. In the 2008 Pey et al [114]. 
reported the possibility to use the 3-amino-2-benzyl-7-nitro-4-(2-quinolyl)-1,2-
dihydroisoquinolin-1-one (Figure 75) as pharmacological chaperones of the PAH, in order 
to increase the correct folding of mutant form of the protein. Their study analyzed in deep 
the effect of the molecule in the Figure 75, in which disclosed the stabilizing effect on PAH 
enzyme kinetics; on the stability and folding of WT and mutant proteins. They found that 
the 3-amino-2-benzyl-7-nitro-4-(2-quinolyl)-1,2-dihydroisoquinolin-1-one: 
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 Enhances the thermal stability of PAH without showing PAH 
inhibition activity. 
 That it stabilizes the functional conformation of PAH either in the 
recombinant and mutants PAH.  
 PAH liver levels activity of mouse, increased after a 12-day oral 
administration.  
They concluded their report writing: 
“The fact that compound III (3-amino-2-benzyl-7-nitro-4-(2-quinolyl)-1,2-dihydroisoquinolin-
1-one depicted in the Picture 59) does not display significant inhibitory effect indicates that 
the compound might be modified in order to increase its affinity for PAH. This would 
enhance its potency as pharmacological chaperone, therefore allowing potentially larger 
correction of the phenotype while still using relatively low concentrations.” 
Lured by the structural analogy between such promising structure and the bicyclo-
heteroatom architecture library, and by the fact that, PAH, apart from BH4, is also activated 
by Phe, which is embodied in the bicyclo-structures, we decided to test our compounds as 
chaperones of PAH in the attempt to investigate the possibility of an employment of these 
compounds in the treatment pf the PKU. 
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4.1.2 Evaluation of bicycle-boronate heterocycles collection for 
phenylalanine hydroxylase (PAH) inhibition 
 
Apart from BH4, the regulation of mammalian PAH is also operated via the cAPM-
dependent protein kinase mediated phosphorylation at the Ser 16 and by the substrate 
Phe. PAH is activated several fold by pre-incubation with Phe. The mechanism for this 
activation is not yet comprehended and there is no agreement on whether it is caused by 
Phe binding to an allosteric site, in the regulatory domain, or to the active site. Regardless 
of its mode of action, activation by Phe is the most important mechanism for PAH 
regulation, and for this reason, Phe represents a very attractive structural starting point to 
develop new modulators of PAH. Based on this and on the fact that the bicycle boronate 
heterocycles incorporate the Phe in its structure, we tested this family of compounds 
against the PAH. We started our studies by evaluation of compounds 24-26 against PAH. 
The activity was measured with 100 µM L-Phe and 100 µM of each compound in 1% 
DMSO. Samples were preincubated with L-Phe and compound (substrate activated), not 
preincubated (non-activated), or preincubated with compound only (compound activated), 
respectively black white and dotted bars in the following figures, for 5 minutes at 25 ºC 
prior to the addition of BH4 to start the activity measurements. The reaction final 
concentrations were: 100 mM Na-Hepes, pH 7, 0.1 mg/ml catalase, 100 µM Fe2+, 5 mM 
ascorbic acid, 0.5 mM HCl, 100 µM L-Phe, 100 µM compound (in 1% DMSO), 75 µM BH4 
and 5 µg (0.45 µM subunit) hPAH WT tetramer. The values were normalized by subtracted 
the background L-Tyr contribution from each compound (assay without substrate). 
 As shown in Figure 76, the iminoboronate 26 was able to modulate the activity of PAH. 
This compound clearly competed with the substrate Phe and, more importantly, exhibited 
the ability to activate PAH in the absence of Phe. Very differently, the iminoboronates 25 
and 24, prepared with L-leucine and L-alanine respectively, didn’t show an activator 
profile. Taken these results together with the fact that the individual components, 
salicylaldehyde and phenyl boronic acid, were unable to activate the enzyme (Figure 76), 
they clearly suggest that the observed activity, is due to the incorporation of Phe into the 
structure of heterocycle 26. Therefore we extended the study to other boron heterocycles 
as shown in Figure 77, compounds 27 featuring a methyl at the boronic acid aromatic para 
position demonstrated a similar substrate competitive profile as observed for 26, though 
with no activation.Very differently, compound 29 prepared with 4-fluorophenylboronic acid, 
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markedly activated PAH, on the other way, the introduction of a methoxide substituent in 
28 resulted in a clear inhibition of PAH. 
 
 
Figure 76 - Specific activity (nmol Tyr mg
-1
 mon
-1
). 
Further we evaluated the substitution at the aromatic ring of the aldehyde (Figure 78). 
Compound 30 is a variation of 26 with a methyl at the para position of the aldehyde 
moiety, such functionalization decreased the activation profile of the molecule. In the 
compound 31 the inclusion of a methoxide at the same position lead to an improved ability 
to activated the enzyme when comparing with 26. This molecule was consider as new lead 
compound and as new benchmark in the functionalization process, for a second round of 
evaluation. Compounds 32, 33, 34, 35, 36 and 37 were tested (Figure 78,). Unfortunately, 
compounds 33 and 37 displayed only a very modest activation profile, whereas 35 and 32 
only moderately compete with the substrate for the access to the enzyme active site. More 
interestingly the isomer of compound 35 bearing a bromo orto substituted boronic acid 
aromatic moiety (compound 36) only moderately competed with the substrate at the same 
time that was able to activate the enzyme towards the hydroxylation of Phe alanine. As 
shown is the combination of para-methoxy-salicylaldehyde with different aromatic and 
vinylicboronic acids didn’t improved the activation previously observed with compound 31. 
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Figure 77 - comparation among the specific activity of compounds 27, 29, 28(nmol Tyr 
mg
-1
 min
-1
). 
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Figure 78 - Comparison among the specific activity of compounds 30, 31, 32, 33, 34, 
35, 37 (nmol Tyr mg
-1
 min
1
).  
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4.1.3 Conclusion 
 
The profile of the molecules tested against the wild type of PHA showed a clear ability to 
modulate the biological activity of PHA despite this study still stand in a preliminary phase 
they shows that fused bicycle boronate heterocycles are an interesting scaffold able to 
interact with PHA and they may be considered as a benchmark for next round of 
optimization process. 
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5. Diazoborine as inhibitor of HNE  
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5.1 Overview 
 
The diazoborine is a well-known class of chemical compounds structurally characterized 
by an etheroatomic ring that embodies boron and two nitrogens. Until today these 
heterocycles have been described as antibacterial, limited to the gram-negative 
population. Two characteristics of this compounds attracted our attention: the general 
architecture of the diazaborines and the speculation proposed by Baldock in 1998 
according to which the boron of diazoborine undergoes a sp2-sp3 transformation while 
interacting with an –OH functionality of its biological target.[121] Intrigued by these two 
considerations we wonder if the diazaborine could be employed as a HNE inhibitors.  
Beyond the putative activity against HNE, this family of compounds is also eligible to be 
prepared via a simple assembly reaction in line with our boron tether strategy. In 1963 
Dewar and Dougherty reported the possibility to obtain the (1,2,3) diazaborine through an 
easy one-pot reaction between a formylboronic acid and hydrazine (Figure 79) in ethanol, 
followed by product precipitation in water. A more carefully analysis of this synthesis reveal 
even more analogies between the reactions discussed in the previous chapters and the 
one disclosed by Dewar and Dougherty. To synthesize either the tricyclo and the bicyclo-
boronated heterocycle architectures three important components are required: an 
aldehyde, a boronic acid and a compound with reactive nitrogenated and oxygenated 
functionalities, which work as connectors. In the reaction for the synthesis of the 
diazaborine this pattern is partially maintained, the boronic acid and the aldehyde are 
fused in one molecule. Based on this we envisioned that this methodology and scaffold 
could be used to test against HNE. 
 
 
Figure 79 Reaction components of Dewar’s protocol. 
Regarding the structure of diazaborines, it is possible to highlight the characteristic 
heteroatom ring that is often fused with a second ring system (Figure 80a), and the nature 
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of such ring system may vary (benzene, naphthalene, thiophene, furan, pyrrole).[121] The 
positions of the heteroatoms in the ring system is not set, and it can have several variants  
(Figure 80). 
 
 
Figure 80 - examples of the variable arrangement of the heteroatoms in the 
diazoborines. 
The systematic name for such molecules indicates the position of each etheroatom in the 
cycle, (1,3,2) diazaborine for the structure a, (2,4,1) diazaborine for the structure b[122]and 
(1,2,3) diazaborine for the c. ,[121] 
Regarding the biological activity of these compounds, they are reported to be selectively 
active against gram-negative bacteria,[121]which suggests the biological target of these 
molecules to be related with the cell wall. Turnowsky et al. [123] identified and proved that 
the cellular target of the diazaborine is NAD(P)H-dependent enoyl acyl carrier protein 
reductase (ENR), an enzyme responsible for the last step of fatty acid synthase. The 
diazaborine inhibition of the ENR requires the presence of the NADP+ that is a pivotal 
element either in the binding of the diazaborine and in the inhibitory mechanism in 
itself.[124] Baldock et al. reported a x-ray crystallographic analysis of the enzyme incubated 
with the cofactor and the diazaborine, showing that they form a bisubstrate due to a 
covalent bond between the boron and the 2’ OH of the nicotinamide ribose a 
rearrangement of the boron from trigonal planar to tetrahedral geometry.[121]  
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Figure 81 - X-ray crystallographic analysis of the enzyme, the cofactor and the 
diazaborine. 
To support their data, Baldock et al, suggested an analogy between the mechanisms that 
leads to the tetrahedral borate in the diazaborine/NADP+ disubstrate and the boronic 
acid/serine proteases. As far as our knowledge goes the diazaborine have been 
exclusively employed as antimicrobic for the treatment of the tubercolosis. Despite the 
analogy suggested by Baldock and co-workers, this class of compounds has not been 
tested as serine proteases inhibitor, even though the correspondence between the 
boronate formed by diazaborine/NADP+ and boronic acid inhibotrs/serine proteases is 
real: B-O covalent bond formation, tetrahedral rearrangement of the boron, formal negative 
charge formally placed onto the boron. 
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5.1.1 Synthesis of a diazaborine library and its enzymatic evaluation 
against HNE 
 
Bearing in mind the considerations discussed above, we started our study by synthesizing 
molecules 43, 44, 45, 46 depicted in the Figure 82. The products were prepared by 
combining different boronated aldehyde (2-Formylphenylboronic acid; 3-fluoro-2-
formylphenylboronic acid; 2-formyl-3-thiopheneboronic acid) with hydrazine hydrate 64%. 
The reaction was performed following Dewar’s procedure and using methanol as solvent, 
the product was simply precipitated from the reaction mixture with cold water, a simple 
filtration afforded the product, in good yield, [125] that required no extra purification steps. 
With these products in hands we readily tested them against HNE.  
 
 
Figure 82 Activity of compounds 43-46 against HNE. 
As shown in Figure 82 compounds 43, 44 and 46 did not show any inhibitory activity 
against the enzyme, but compound 45, even if in small magnitude, shown some inhibition 
of HNE. Encouraged by this result we wonder if the modulation of the inhibitory activity 
could be achieved by functionalization of the N bonded to B with a phenyl group. We also 
questioned whether the relative position of the sulphur in the diazaborine could also 
improve the biological activity. Motivated by these questions, we synthesized molecules 47 
and 48 shown in Figure 83, using either the 2/3-formyl-2/3-thiopheneboronic acid; 
hydrazine and phenyl hydrazine. 
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Figure 83 Activity of compounds 47, 48 against HNE. 
 
The enzymatic evaluation of the products illustrated in the Figure 83, revealed a dramatic 
increase of the inhibitory activity of the diazaborines prepared with phenyl hydrazine. 
However, despite this interesting result, the interpretation of the relation between the 
inhibitory activity and the structures of the diazaborine 45, 46, 47, 48 remained 
controversial. Indeed comparing the molecule 45 and 46 it appears that the position of the 
sulphur has a very deep effect on the ability of the molecule to inhibit the HNE, differently 
compounds 47 and 48 show almost the same activity against the enzyme. A partial 
explanation could come from the observation that the inhibitory activity is affected by the 
phenyl group and the sulphur position in the aromatic ring in a divergent sense. 
Nevertheless the importance of the phenyl appear to be more decisive for the activity. At 
this point, we considered how other substituents at the nitrogen could alter the biological 
activity of the diazaborine. Therefore we prepared compounds 49 and 50 (Figure 84), 
though the presence of a electron withdrawing group sulphone did not improve the 
previous observed activity. 
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Figure 84 - Activity of compounds 49-50 against HNE. 
Once established that the phenyl was indeed pivotal for the activity, we wonder if the 
phenyl functionality could also improve the biological profile of molecules 43 and 44 
similarly to what happened with the compounds 47 and 48.  
Therefore we synthesized diazaborines 51, 52 and 53 (Figure 85) and tested them against 
HNE, unfortunately in this case, the phenyl group did not enhance the biological activity of 
these new molecules. 
 
 
Figure 85 - Activity of compounds 51-53 against HNE. 
Taken these results in consideration we move on and synthesize two new diazaborines 
(Figure 86) combining 2-acetyl phenylboronic acid and phenyl hydrazine (54, 55). Once 
prepared these compounds were tested in an assay against HNE. Very gratifyingly this 
evaluation rendered an activity of 2.  μM for compound 54, which until now is the most 
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potent compound of the library. Interestingly compound 55 featuring no substitution at the 
nitrogen had no activity outlining, once again, the importance of this function. The 
comparison among the structures and the inhibition induced in the HNE by molecules 43, 
52, 54, 55 suggest that to have inhibitory activity against the enzyme a phenyl and a 
methyl group are required respectively at the positions 2 and 4 of the heterocycle. To 
better understand the contribution of the methyl and phenyl groups over the activity of 
these diazaborine, we evaluated molecules 43, 52, 54, 55 in a preliminary docking study.  
 
 
Figure 86 - Effect on the inhibitorial activity of the methyl as substituent in 
compounds 43 and 52. 
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Docking studies 
 
In order to understand how the diazaborines interact with reactive site of HNE we 
performed in silico molecular docking studies of the diazaborine 52, 54 and 55 (Figure 86), 
using GOLD 5.1 software.[112]  
The coordinates of the enzyme structure were obtained from Protein Data Bank selecting 
the structure with accession code 1HNE (X-ray coordinates at 1.84 Å resolution, previously 
validated for docking procedures). Once again the S1 binding pocket plays a pivotal role 
for the recognition of the molecules into the active site. The diazaborine 55 does not have 
any specific interaction with the S1 (Fig 87 a), which in turn is in good accordance with the 
lack of inhibitory activity of this compound. Differently both compounds 52 and 54 (Figure 
87 b, c) place their phenyl substituent into the S1 region, but according the enzymatic 
assays only the compound 52 displayed a reasonable activity. 
 
 
Figure 87 – Docking of compounds 52, 54, 55, cyclic form . 
interestingly, despite compounds 52 and 54 siting their N-phenyl substituent inside the S1 
binding pocket, the distances between the boron and the oxygen of the Ser 195, which is 
the nucleophile responsible for the biological activity of the enzyme, is too large to predict 
an efficient covalent interaction between the two atoms. Surprisingly, despite the distances 
could be considered almost equal (3.81Å for compound 52, 3.85 Å for compound 54), is 
the inactive compound 52 to set in closer proximity the boron closer to the oxygen of ser 
195. 
Puzzled by the discordance between docking studies and experimental evidences, we 
envisioned the possibility of the diazaborine to actually act as a prodrug. As shown in 
figure 88 diazaboorines could exist in equilibrium with is open form and it is this latter that 
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could be the responsible of the enzymatic activity. This concept was already disclosed by 
Bachovchin as already mentioned in the first chapter.  
 
 
Figure 88 -  Comparison between the Bachovchin soft-drug cyclizatoin which decrease 
the activity of the molecule and diazaborine pro-drug chain opening responsible of the 
putative activity of these compounds.   
Bachovchin exploited this cyclization as a time dependent mechanism to decrease the 
side effect of the boropeptide.  
Despite such speculation needs deeper investigation, a positive feedback seems to come 
from the docking studies of the open forms of the molecules 43, 52, 54, 55. The first 
notable feature is that the moiety of the diazaborines responsible of the molecular 
recognition to the S1-binding pocket (Figure 89) is now the aromatic ring bonded to the 
boron and no longer the phenyl group, which now is available for a π-π interaction with 
the Hys 57 . Despite the molecule 43 and 55 were able to interact with the pocket S1 
(Figure 89 a, b) they miss any π-π interaction with the Hys 57, data that eventually 
explain the lack of inhibitory activity. In addition molecules 52 and 54 possess either an 
aromatic moiety to fit in the S1 pocket and a phenyl group that may interact through π-π 
interaction with the hys 57 (Figure 89 c, d) but only 54 is active. 
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Figure 89 - Docking of compounds 43, 52, 54, 55, in opened form. 
 
A more carefully inspection of the Figure 89, reveals that the serine 195 is present at the 
entrance of the S1 pocket and that, if may efficiently bind to the boron atoms of the two 
structures. This shows that both structures are able to place their pharmacophores in close 
proximity with the serine 195 not explaining the dramatic difference in the inhibitor activity 
between the two diazaborines. Instead the diazophenyl side chains of the molecules 52 
and 54, present a different arrangement, more evident in Figure 90, specifically the 
molecule 54 shows an orientation of the N-phenyl substituent that favors a stronger π-π 
interaction with the Hys 57. Despite this data is in accordance with the enzymatic assay, 
the difference between the π-π interactions between the N-phenyl group of the two 
molecules is sufficiently large to justify a difference in the biological activity of 2.  μM for 
diazaborina 54 and >    μM for diazaborine 52. A possible explanation may be the steric 
hindrance provided by the methyl group which block the entrance of the S1 pocket 
protecting the boronate complex (diazaborine-enzyme) from hydrolysis enough to produce 
a sensible enzymatic inhibition. As already mentioned in “What characterizes an acylating 
agent from a natural substrate is the ability to produce an acyl-enzyme intermediate 
resistant to the hydrolysis, disabling the enzyme to return into its active form”. Among all 
diazaborines tested so far, compound 54 is not the only one to incorporate a 4-methyl 
group. The diazaborine 55 also embodies this functionality but still miss any biological 
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response. The difference of activity between molecules 54 and 55 (respectively 2.  μM 
and >   μM) maybe sit in the double presence of the N-phenyl and the 4-methyl groups, 
which together afford an effective protection from the hydrolysis (Figure 91). The Figure 91 
a is the optimized structure of the compound 55 in to the active site of HNE, the methyl 
group and the diazo moiety seems also to close the entrance of the S1 pocket. Differently 
from the docking model, in the reality, the protein and the molecule are dynamic entities 
and a certain degree of rotation, along the bond Ar---C(CH3)NN2H that allows alternative 
conformations with reduced steric hindrance, should be taken in count. In compound 54 
the π-π interaction between the N-phenyl group and the his 57 may prevent or limit 
possible rotations along the Ar---C(CH3)NN2Ph bond, conferring a certain degree of 
structural rigidity, which in turn, enhance the protective hindrance from hydrolysis , 
provided by the 4-methyl group. 
 
 
Figure 90 – Overlapped structures of compounds 52 and 54.  
 
Figure 91 – Comparison  between molecules 54 and 55. 
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5.2 Conclusion 
 
Despite the exploitation of diazaborine as new inhibitor of HNE is still in a preliminary 
phase we shown that this class of compounds can offer, under the synthetic point of view, 
an easily accessible scaffold able to modulate the HNE activity. Nevertheless further 
experiments are required either to enlighten the pharmacokynetic and pharmacodynamic 
of this family of molecules and also to continue exploring the functionalization process that 
can improve the activity of diazaborines as inhibitor of HNE.  
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In conclusion, with the synthesis of the tricycle heteroatoms, the bicycle heteroatoms and 
the diazaborine collections, we demonstrate the efficiency of the Boron tether strategy as 
alternative route to discovery new hit compounds and evolve the optimization toward lead 
compounds. The Boronate tether strategy fall inside the groove already tracked by the 
combinatorial chemistry, representing a specific section of this relatively new branch of 
chemistry. The boron tether strategy rapresent an intriguing tool a disposal of the 
chemists, in which the main strong points of this alternative synthetic approach are: a more 
logical employment of the resources, through a high atom economy, exploiting in many 
cases of environmental friendly solvents, such as water and ethanol, and a more economic 
approach made of easy purification procedures. The boron tether strategy represent one 
of the many branches of chemistry, which with the aforementioned characteristics try to 
better respond to the nowadays resource waste and ecological needs.     
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7.1 General Remarks 
 
Tetrahydrofuran (THF) was distilled over calcium hydride/benzophenone immediately prior 
to use and ethyl acetate was distilled over potassium carbonate. All reactions were 
performed in oven-dried glassware under argon. Methanol and ethanol as reaction 
solvents were used as distilled. All the other superior alcohols used were analytical grade. 
The aldehydes, boronic acids and L-proline were purchased from Aldrich and used without 
further purification. Flash chromatography was carried out on silica gel 60 M Merck 
(Ref.107734). Reaction mixtures were analyzed by TLC using F254 from Merck (Ref. 
105554, silica gel 60), and visualization of TLC spots was effected using UV and 
phosphomolybdic acid solution. Proton nuclear magnetic resonance spectra (1H NMR) 
were recorded on Bruker AMX 400 spectrophotometer with CDCl3 as solvent. Chemical 
shifts for  H NMR spectra are reported as δ in units of parts per million (ppm) downfield 
from SiMe4 (δ  . ) and relative to the signal of chloroform (δ 7.2 , singlet). Multiplicities 
are given as: s (singlet), d (doublet), t (triplet), q (quartet), dd (double of doublet), td (triplet 
of doublets) or m (multiplets). The number of protons (n) for a given resonance is indicated 
by nH. Coupling constants are reported as a J value in Hertz. Carbon nuclear magnetic 
resonance spectra ( 3C NMR) are reported as δ in units of parts per million (ppm) 
downfield from SiMe4 (δ  . ) and relative to the signal of chloroform (δ 77.  , triplet).  The 
diastereomeric excess was determined based on the 1H integration of the acetal moiety 
proton. Infrared spectra (IR) spectra were recorded with FTIR spectrometer as thinly 
dispersed films.  
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7.2 Preparation and characterization of boronate 
heterocycles 
 
General Procedure for Preparation of fused tricycle boronate 
heterocycles collection using alcohol as a solvent 
 
A round bottom flask equipped with a magnetic stirrer was charged with proline (2.0 eq), 
glycolaldehyde dimer (1.5eq), boronic acid (0,206 mmol) and the corresponding alcohol 
(2.0 ml). This suspension was stirred at 60 °C for 1 h. The reaction mixture was 
concentrated under reduced pressure to 1 ml. The obtained residue was purified through 
silica flash chromatography eluted with gradient AcOEt/Hexane (3.5:1.5);(4:1). 
 
General Procedure for Preparation of fused tricycle boronate 
heterocycles collection using alcohol as a reactant 
 
A round bottom flask equipped with a magnetic stirrer was charged with proline (2.0 eq), 
glycolaldehyde dimer (1.5eq), boronic acid (0,206 mmol), the corresponding alcohol (10 
eq) and THF (2.0 ml). This suspension was stirred at 60 °C for 1 h. The reaction mixture 
was concentrated under reduced pressure to 1 ml. The obtained residue was purified 
through silica flash chromatography eluted with gradient AcOEt/Hexane (3.5:1.5);(4:1). 
 
General Procedure for Preparation of fused bicycle boronate 
heterocycles collection using alcohol as a reactant 
 
A round bottom flask equipped with a magnetic stirrer was charged with amino acid (2.0 
equiv.), aldehyde (1.5 equiv.) and distilled water (2.0 mL). This suspension was stirred at 
90ºC for 1 h after which the boronic acid (0.41 mmol) was added, the mixture was then 
stirred at 90ºC for 20 h. The reaction mixture, which appears as a biphasic composition of 
precipitate and a supernatant liquid, was filtered and the solid retained in the filter was 
then washed with water followed by hexane. The desired compound was recovered with 
dichloromethane, which was subsequently removed under reduced pressure. 
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General Procedure for Preparation of 1 hydroxy 2,3,1 
benzodiazaborine collection 
 
A round bottom flask equipped with a magnetic stirrer was charged with the boronic acid 
(1.0 equiv.), hydrazine (1.0 equiv.) and the methanol (2.0 ml). This suspension was stirred 
at RT, 18h in the procedure A, 72h in the procedure B. After the appropriate amount of 
time, the reaction was quenched with 6ml of a mixture of water and ice, in order to 
promote the precipitation of the product, stirred for few minutes, and stored overnight into 
the refrigerator to complete the precipitation process. The mixture of surnatant and 
precipitate was filtered, the solid onto the filter washed with few ml of fresh water, followed 
by few ml of hexane. The product was recovered from the filter through dissolution with 
DCM, the residuals of water were eliminated by sodium sulfate anhydrous. The resulted 
dry solution free of the drying agent sodium sulfate was evaporated through the rotavapor, 
the residual traces of solvent were removed by high vacuum pomp. 
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Compounds Characterization 
 
Compound 1 
 
 
 
Isolated yield = 95% de = 94% (flash chromatography eluent AcOEt\Hexane)  
[α]D
20°= + 5.35 (c 2, CHCl3)
 
IR (film): νmax (cm
-1): 3053, 2976, 2926, 2362, 2328, 1747, 1732, 1651, 1633 1456, 1435. 
1H NMR (400 MHz, CDCl3, 25 °C, TMS): δ =1,37-1.48 (m, 1H, NCHCH2CH2), 1.55-1.62 
(m, 1H, NCHCH2CH2),2.11-2,22 (m, 1H, NCH2CH2CH2), 2.29-2,33 (m, 1H, NCH2CH2CH2), 
2.64 (dt, J = 11.4, 6.0 Hz,1H, NCHCH2CH2CH2), 2.96 (dd, J = 10.1, 6.5 Hz, 1H, 
NCHCH2CH2CH2), 3.15 (dd, J = 11.8, 3.7 Hz, 1H, NBOCHCH2), 3.27 (d, J = 11.8 Hz, 1H, 
NBOCHCH2), 3.32 (s, 3H, CHOCH3), 4.17 (d, J = 8.7 Hz, 1H, NCH2CH2CH2CH), 5.22 (d,  
J = 3.6 Hz, 1H, NBOCH), 7.21-7.29 (m, 3H, C6H5), 7.46-7.49 (m, 2H, C6H5). 
13C NMR (100 MHz, CDCl3, 2  °C): δ = 23.95(NCHCH2CH2), 29.88(NCH2CH2CH2), 
54.09(BOCHOCH3), 59.83 (NCHCH2CH2CH2), 65.76 (NBOCHCH2), 72.46 
(NCH2CH2CH2CH), 99.76 (NBOCH), 127.73, 128.72, 132.79 (C6H5), 174,25(C=O). 
11B NMR(300 MHz, CDCl3, 25°C): δ = 12.83 
HMRS (ESI):m/z calculated [M+Na]+ = 298.122363, found [M+Na] + = 298.120816. 
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Compound 1 prepared in THF experiment 
 
Isolated yield = 88% de= 88%(flash chromatography eluent AcOEt\Hexane)  
1H NMR (400 MHz, CDCl3, 25 °C, TMS): δ =1,35-1.48 (m, 1H, NCHCH2CH2), 1.55-1.62 
(m, 1H, NCHCH2CH2),2.11-2,25 (m, 1H, NCH2CH2CH2), 2.31 (dd, J = 12.9, 6.6 Hz, 1H, 
NCH2CH2CH2), 2.61-2.68 (m, 1H, NCHCH2CH2CH2), 2.94-2.98 (m, 1H, NCHCH2CH2CH2), 
3.15 (dd, J = 11.8, 3.7 Hz, 1H, NBOCHCH2), 3.27 (d, J = 11.8 Hz, 1H, NBOCHCH2), 3.32 
(s, 3H, CHOCH3), 4.17 (d, J = 8.7 Hz, 1H, NCH2CH2CH2CH), 5.22 (d, J = 3.6 Hz, 1H, 
NBOCH), 7.24-7.26 (m, 3H, C6H5), 7.46-7.49 (m, 2H, C6H5).  
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Compound 2 a 
 
 
 
Isolated yield = 40% (flash chromatography eluent AcOEt\Hexane)  
[α]D
20°= +2 (c 1.8, CHCl3) 
IR (film):ν  max = 3053, 2985, 2918, 2835, 2684, 2304, 1747, 1600, 1651, 1458, 1421cm-1 
1H NMR (400 MHz, CDCl3, 25 °C, TMS):δ =  1.49 (d, J = 7.1 Hz, 3H, NCHCH3),2.54 (s, 
3H, NCH3), 2.97 (d, J = 12.5 Hz, 1H, NCH2), 3.24-3.34 (m, 1H, NCH2), 3.54-3.59 (m, 1H, 
NCH), 3.59 (s, 3H, CHOCH3), 5.27 (d, J = 4.9 Hz, 1H, NBOCH), 7.33-7.38 (m, 3H, C6H5), 
7.54-7.57 (m, 2H, C6H5). 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 8.85(NCHCH3), 44.81 (CHOCH3), 54.80 (NCH3), 
59.23 (NCH2), 65.61 (NCH), 100.36 (NBOCH), 127.76, 128.77,132.83 (C6H5), 170.86 
(C=O). 
11B NMR (300 MHz, CDCl3, 25°C): δ = 11.68 
HMRS (ESI):m/z calculated [M+Na]+ =286.122345, found [M+Na] + = 286.121857 
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Compound 2 b, 2 c 
 
 
 
Isolated yield = 50% as mixture of two position isomers (flash chromatography eluent 
AcOEt\Hexane)  
IR (film): ν  max = 3053, 2976, 2926, 2362, 2328, 1747, 1732, 1651, 1633 1456, 1435 cm- 
Compound 2b 
 13C NMR (100 MHz, CDCl3, 2  °C): δ = 17.97 (NCHCH3), 23.28 (NCHCH2CH2), 30.47 
(NCH2CH2CH2), 54.17 (BOCHOCH3), 57.19 (NCHCH2CH2CH2), 66.46 (NCH2CH2CH2CH), 
72.35 (NBOCHCH), 101.07 (NBOCH), 127.68, 127.75, 127.80, 127.90, 128.66, 128.68, 
128.69, 129.01, 132.72, 138.82, 132.85, 135.06 (C6H5, peaks of the two position isomers ), 
174.33, 174.36 (C=O, peaks of the two position isomers).
 
Compound 2c 
13C NMR (100 MHz, CDCl3, 2  °C): δ = 20.77 (NCCH3), 23.74 (NCHCH2CH2), 29.98 
(NCH2CH2CH2), 48.28 (NCOCH3), 59.92 (NCHCH2CH2CH2), 63.90 (NCH2CH2CH2CH), 
72.35 (NBOCH2), 103.05 (NC), 127.68, 127.75, 127.80, 127.90, 128.66, 128.68, 128.69, 
129.01, 132.72, 138.82, 132.85, 135.06 (C6H5, peaks of the two position isomers ), 174.33, 
174.36 (C=O, peaks of the two position isomers). 
 HMRS (ESI):m/z calculated [M+Na]+ = 312.138030, found [M+Na] + = 312.137595 
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Compound 3 
 
 
 
Isolated yield = 89% de = 93% (flash chromatography eluent AcOEt\Hexane) 
IR (film):νmax (cm
-1): 3053, 2958, 2924, 2304, 1743, 1734, 1598, 1458. 
[α]D
20°= +4.1 (c 1.2, CHCl3) 
1H NMR (400 MHz, CDCl3, 25 °C, TMS): δ = 1.21 (t, J = 7.1 Hz, 3H, BOCHOCH2CH3), 
1.46-1.59 (m, 1H, NCHCH2CH2), 1,66-1,72 (m, 1H, NCHCH2CH2), 2.18-2.32 (m, 1H, 
NCH2CH2CH2), 2.43 (dd, J = 13.1, 6.6 Hz, 1H, NCH2CH2CH2), 2.69-2.80 (m, 1H, 
NCHCH2CH2CH2), 3.08 (dd, J = 10.4,6.3 Hz, 1H, NCHCH2CH2CH2), 3.26 (dd, J = 11.6, 3.7 
Hz, 1H, NBOCHCH2), 3.36 (d, J = 11.6 Hz, 1H, NBOCHCH2), 3.43-3.54 (m, 1H, 
BOCHOCH2), 3.92 (dq, J = 9.4, 7.1 Hz, 1H, BOCHOCH2), 4.32 (dd, J = 10.3, 1.5 Hz, 1H, 
NCH2CH2CH2CH), 5.43 (d, J = 3.6 Hz, 1H, NBOCH), 7.32-7.38 (m, 3H, C6H5), 7.58 (dd, J 
= 6.4, 2.9 Hz, 2H, C6H5). 
13C NMR (100 MHz, CDCl3, 25 °C): 14.97 (BOCHOCH2CH3), 23.95 (NCHCH2CH2), 29.91 
(NCH2CH2CH2), 59.84 (NCHCH2CH2CH2), 62.19 (BOCHOCH2), 65.88 (NBOCHCH2), 
72.52 (NCH2CH2CH2CH), 98.34 (NBOCH), 127.73, 128.70, 132.80 (C6H5), 174.28 (C=O). 
11B NMR (300 MHz, CDCl3, 25°C): δ = 13.96 
HMRS (ESI):m/z calculated [M+Na]+ = 312.138030, found [M+Na] + = 312.136847. 
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Compound 4 
 
 
 
Isolated yield = 72% de = 85% (flash chromatography eluent AcOEt\Hexane) 
IR (film):νmax (cm
-1): 3053, 2974, 2927, 2360, 2330, 1743, 1598, 1458, 1435. 
[α]D
20°= + 3.12 (c 1.6, CHCl3) 
1H NMR (400 MHz, CDCl3, 25 °C, TMS):δ = 1.07 (d, J = 6.1 Hz, 3H, BOCHOCH(CH3)2), 
1.12 (d, J = 6.3 Hz, 3H, BOCHOCH(CH3)2), 1.37-1.49 (m, 1H, NCHCH2CH2), 1.60 (dt, J = 
12.1, 6.0 Hz, 1H, NCHCH2CH2), 2.17-2.21 (m, 1H, NCH2CH2CH2), 2.36 (dd, J = 13.1, 6.4 
Hz, 1H, NCH2CH2CH2), 2.58-2.70 (m, 1H, NCHCH2CH2CH2), 3.00 (dd, J = 10.5, 6.2 Hz, 
1H, NCHCH2CH2CH2), 3.17 (dd, J = 11.6, 3.7 Hz, 1H, NBOCHCH2), 3.24 (d, J = 11.6 Hz, 
1H, NBOCHCH2), 4.06 (dt, J = 12.3, 6.2 Hz, 1H, BOCHOCH), 4.26 (dd, J = 10.3, 1.5 Hz, 
1H, NCH2CH2CH2CH), 5.46 (d, J = 3.6 Hz, 1H, NBOCH), 7.25-7.26 (m, 3H, C6H5), 7.48 
(dt, J = 6.9, 3.3 Hz, 2H, C6H5). 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 20.72, 23,21 (BOCHOCH(CH3)2), 23,96 
(NCHCH2CH2), 29.75 (NCH2CH2CH2), 59.94 (NCHCH2CH2CH2), 66.02 (NBOCHCH2), 
67.73 (BOCHOCH), 72.74 (NCH2CH2CH2CH), 96.10 (NBOCH), 127.73, 128.67, 132.81 
(C6H5), 174.43 (C=O). 
11B NMR (300 MHz, CDCl3, 25°C): δ = 12.95 
HMRS (ESI):m/z calculated [M+Na]+ = 326.153698, found [M+Na] + = 326.152009. 
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Compound 5 
 
 
 
Isolated yield = 69% de= 92% (flash chromatography eluent AcOEt\Hexane) 
IR (film):νmax (cm
-1): 3051, 2954, 2931, 2358, 2341, 1747, 1687, 1458, 1435. 
[α]D
20°= + 6.5 (c 0.2, CHCl3) 
1H NMR (400 MHz, CDCl3, 25 °C, TMS): δ = 0.75-0.85 (m, 3H, BOCHO(CH2)5CH3), 1.18-
1.54 (m, 8H, BOCHOCH2(CH2)4CH3), 1.57-1.63 (m, 2H, NCHCH2CH2), 2,11-2,22 (m, 1H, 
NCH2CH2CH2) 2.33-2,38 (m, 1H, NCH2CH2CH2), 2.61-2,69 (m, 1H, NCHCH2CH2CH2) 2.99 
(dd, J = 10.5, 6.1 Hz, 1H, NCHCH2CH2CH2), 3.17 (dd, J = 11.7, 3.8 Hz, 1H, NBOCHCH2) 
3.26-3.36 (s, 2H, NBOCHCH2, BOCHOCH2, overlapped), 3.75-3.80 (m, 1H, BOCHOCH2), 
4.23 (dd, J = 10.2, 1.5 Hz, 1H, NCH2CH2CH2CH), 5.33 (d, J = 3.7 Hz, 1H, NBOCH), 7.16-
7.33 (m, 3H, C6H5), 7.48-7.50 (m, 2H, C6H5). 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 14.09 (BOCHO(CH2)5CH3), 22.61 
(BOCHO(CH2)4CH2CH3), 23.98 (NCHCH2CH2), 25.84 (BOCHO(CH2)3CH2CH2CH3), 29.31 
(BOCHO(CH2)2CH2(CH2)2CH3), 29.90 (NCH2CH2CH2),  31.64 
(BOCHOCH2CH2(CH2)3CH3), 59.86 (NCHCH2CH2CH2), 65.88 (NBOCHCH2), 67.05 
(BOCHOCH2(CH2)4CH3), 72.49 (NCH2CH2CH2CH), 98.63 (NBOCH), 127.72, 128.67, 
132.79 (C6H5), 174.08 (C=O). 
HMRS (ESI):m/z calculated [M+Na]+ = 368.200699, found [M+Na] + = 368.200393. 
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Compound 6 
 
 
 
Isolated yield = 60% de = 96% (flash chromatography eluent AcOEt\Hexane)  
IR (film):νmax (cm
-1): 3051, 2958, 2931, 2360, 2341,1747, 1687, 1458, 1435. 
[α]D
20°= + 2 (c 0.2, CHCl3) 
1H NMR (400 MHz, CDCl3, 25 °C, TMS): δ = 0.83 (t, J = 7.4 Hz, 3H, BOCHO(CH2)3CH3), 
1.26 (dq, J = 14.8, 7.4 Hz, 2H, BOCHO(CH2)2CH2CH3), 1.34-1.53 (m, 3H, 
BOCHOCH2CH2CH2CH3, NCHCH2CH2 overlapped) 1.56-1.62 (m, 1H, NCHCH2CH2), 
2,10-2,22 (m, 1H, NCH2CH2CH2) 2.34 (dd, J = 13.1, 6.5 Hz, 1H, NCH2CH2CH2), 2.64 (td, J 
= 12.2, 10.8, 5.5 Hz, 1H, NCHCH2CH2CH2), 2.97 (dd, J = 10.5, 6.3 Hz, 1H, 
NCHCH2CH2CH2), 3.15 (dd, J = 11.7, 3.8 Hz, 1H, NBOCHCH2), 3.26 (d, J = 11.7 Hz, 1H, 
NBOCHCH2), 3.32 (dt, J = 9.6, 6.7 Hz, 1H, BOCHOCH2), 3.77 (dt, J = 9.4, 6.7 Hz, 1H, 
BOCHOCH2), 4.22 (dd, J = 10.3, 1.6 Hz, 1H, NCH2CH2CH2CH), 5.32 (d, J = 3.7 Hz, 1H, 
NBOCH),7.24-7.27 (m, 3H, C6H5) 7.46-7.49 (m, 2H, C6H5). 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 13.90 (BOCHO(CH2)3CH3), 19.35 
(BOCHO(CH2)2CH2CH3), 23.97 (NCHCH2CH2), 29.87 (NCH2CH2CH2), 31.49 
(BOCHOCH2CH2CH2CH3), 59.84 (NCHCH2CH2CH2), 65.85 (NBOCHCH2), 66.74 
(BOCHOCH2), 72.47 (NCH2CH2CH2CH),  98.70 (NBOCH), 127.71, 128.67, 132.78 (C6H5), 
174.10 (C=O). 
HMRS (ESI):m/z calculated [M+Na]+ = 340.169365, found [M+Na] + = 340.168926. 
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Compound 7 
 
 
 
Isolated yield = 78% de= 89% (flash chromatography eluent AcOEt\Hexane)  
IR (film):νmax (cm
-1): 3053, 2958, 2926, 2370, 2330, 2310,1743, 1629, 1598  1452, 1435. 
[α]D
20°= + 7.5 (c 2.2, CHCl3) 
1H NMR (400 MHz, CDCl3, 25 °C, TMS): δ = 1.33-1.46 (m, 1H, NCHCH2CH2), 1.52-1.59 
(m, 1H, NCHCH2CH2), 2.05-2.15 (m, 1H, NCH2CH2CH2), 2.29 (dd, J = 12.8, 6.1 Hz, 1H, 
NCH2CH2CH2), 2.57-2.64 (m, 1H, NCHCH2CH2CH2), 2.87-3.03 (m, 1H, NCHCH2CH2CH2), 
3.12 (d, J = 11.7 Hz, 1H, NBOCHCH2), 3.26 (d, J = 11.8 Hz, 1H, NBOCHCH2), 4.21 (d, J = 
10.2 Hz, 1H, NCH2CH2CH2CH), 4.36 (d, J = 11.3 Hz, 1H, BOCHOCH2), 4.77 (d, J = 11.3 
Hz, 1H, BOCHOCH2), 5.38 (s, 1H, NBOCH), 7.26 (s, 8H, C6H5), 7.48 (s, 2H, C6H5). 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 22.92 (NCHCH2CH2), 28.82 (NCH2CH2CH2), 58.71 
(NCHCH2CH2CH2), 64.66 (NBOCHCH2), 67.42 (BOCHOCH2), 71.28 (NCH2CH2CH2CH), 
97.08 (NBOCH), 126.73, 126.82, 127.43, 127.47, 127.66, 127.73, 131.77 (C6H5), 173.11 
(C=O). 
11B NMR (300 MHz, CDCl3, 25°C): δ = 13.14 
HMRS (ESI):m/z calculated [M+Na]+ = 374.153766, found [M+Na] + = 374.152043. 
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Compound 8 
 
 
 
Isolated yield = 88% de > 97% (flash chromatography eluent AcOEt\Hexane) 
IR (film): νmax (cm
-1): 3051, 2958, 2929, 2358, 2322, 1747, 1732, 1645, 1598, 1452, 1435. 
[α]D
20°= +3.9 (c 2.8, CHCl3) 
1H NMR (400 MHz, CDCl3, 25 °C, TMS): δ = 1.45-1.54 (m, 1H, NCHCH2CH2), 1.63-1.69 
(m, 1H, NCHCH2CH2), 2,19-2.30 (m, 1H, NCH2CH2CH2), 2.36-2.41 (m, 1H, 
NCH2CH2CH2), 2.69-2.76 (m, 1H, NCHCH2CH2CH2), 3.03 (dd, J = 10.0, 6.0 Hz, 1H, 
NCHCH2CH2CH2), 3.24 (dd, J = 11.8, 3.8 Hz, 1H, NBOCHCH2), 3.38 (d, J = 11.8 Hz, 1H, 
NBOCHCH2), 3.99 (dd, J = 12.6, 6.5 Hz, 1H, BOCHOCH2), 4.18-4.38 (m, 1H, 
BOCHOCH2), 4.18-4.38 (m, 1H, NCH2CH2CH2CH), 5.17 (d, J = 10.3 Hz, 1H, 
BOCHOCH2CHCH2), 5.27 (d, J = 17.2 Hz, 1H, BOCHOCH2CHCH2), 5.44 (d, J = 3.6 Hz, 
1H, NBOCH), 5.85-5.96 (m, 1H, BOCHOCH2CH), 7.32-7.33 (m, 3H, C6H5), 7.53-7.56 (m, 
2H, C6H5). 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 23.95 (NCHCH2CH2), 29.88 (NCH2CH2CH2), 59.86 
(NCHCH2CH2CH2), 65.73 (NBOCHCH2), 67.25 (BOCHOCH3), 72.51 (NCH2CH2CH2CH), 
97.99 (NBOCH), 117.44 (BOCHOCH2CHCH2), 127.73, 128.62, 132.81 (C6H5), 133.91 
(BOCHOCHCH2), 174.15 (C=O). 
11B NMR (300 MHz, CDCl3, 25°C): δ = 12.98 
HMRS (ESI):m/z calculated [M+Na]+ = 324.138048, found [M+Na] + = 320.136345. 
  
Experimetnal  Chapter  7 
 
121 
 
Compound 9 
 
 
 
Isolated yield = 72% de= 97% (flash chromatography eluent AcOEt\Hexane)  
IR (film):ν  max = 3053, 2960, 2924, 2852, 23492, 2304, 1734,  1472, 1340, 1398 cm-1. 
[α]D
20°= + 4.1 (c 2.4, CHCl3) 
1H NMR (400 MHz, CDCl3, 25 °C, TMS) δ = 1.48-1.60 (m, 1H, NCHCH2CH2), 1.67-1.74 
(m, 1H, NCHCH2CH2), 2.22-2.32 (m, 1H, NCH2CH2CH2), 2.42-2.50 (m, 2H, NCH2CH2CH2, 
OCH2CCH), 2.73-2.80 (m, 1H, NCHCH2CH2CH2), 3.11 (dd, J = 10.5, 6.3 Hz, 1H, 
NCHCH2CH2CH2), 3.33 (dd, J = 11.9, 3.8 Hz, 1H, NBOCHCH2), 3.43 (d, J = 11.9 Hz, 1H, 
NBOCHCH2), 4.24-4.32 (m, 1H, NCH2CH2CH2CH), 4.33 (d, J = 2.4 Hz, 1H, CHOCH2), 
4.39 (d, J = 2.3 Hz, 1H, CHOCH2), 5.69 (d, J = 3.7 Hz, 1H, NBOCH), 7.34-7.37 (m, 3H, 
C6H5), 7.56-7.60 (m, 2H, C6H5). 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 23.98 (NCHCH2CH2), 29.68 (NCH2CH2CH2), 29.68 
(OCH2CCH), 53.07 (OCHOCH2), 60.02 (NCHCH2CH2CH2), 65.61 (NBOCHCH2), 72.50 
(NCH2CH2CH2CH), 74.69 (OCH2CCH), 78.93(OCH2CCH), 96.77 (NBOCH), 127.77, 
128.82, 132.77 (C6H5), 173.82 (C=O)  
11B NMR (300 MHz, CDCl3, 25°C): δ = 13.14 
HMRS (ESI):m/z calculated [M+Na]+ =322.122398, found [M+Na] + = 322.120800 
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Compound 10 
 
 
 
Isolated yield = 73% de= 92% (flash chromatography eluent AcOEt\Hexane)  
IR (film):ν  max = 3444, 2960, 2347, 1747, 1637, 1633 1458, 1435 cm-1. 
[α]D
20°= +2 (c 1.8, CHCl3) 
1H NMR (400 MHz, CDCl3, 25 °C, TMS) δ = 1.44-1.59 (m, 1H, NCHCH2CH2), 1.68-1.75 
(m, 1H, NCHCH2CH2), 2.22-2.36 (m, 1H, NCH2CH2CH2), 2.41-2.47 (m, 1H, 
NCH2CH2CH2), 2.77(td, J = 12.3, 10.8, 5.5 Hz, 1H, NCHCH2CH2CH2), 3.10 (dd, J = 10.5, 
6.3 Hz, 1H, NCHCH2CH2CH2), 3.31 (dd, J = 12.2, 3.7 Hz, 1H, NBOCHCH2), 3.50 (d, J = 
12.2 Hz, 1H, NBOCHCH2), 3.97-4.10 (m, 2H, CHOCH2), 4.30 (dd, J = 10.2, 1.7 Hz, 1H, 
NCH2CH2CH2CH), 5.57 (d, J = 3.6 Hz, 1H, NBOCH), 7.35-7.40 (m, 3H, C6H5), 7.53-7.56 
(m, 2H, C6H5). 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 23.86 (NCHCH2CH2), 30.12 (NCH2CH2CH2), 58.52 
(OCHCF3), 60.18 (NCHCH2CH2CH2) 63.09 (q, J = 34,7 OCHCF3), 65.38 (NBOCHCH2), 
72.79 (NCH2CH2CH2CH), 99.14 (NBOCH), 127.80, 128.90, 132.86(C6H5), 173.48 (C=O). 
11B NMR (300 MHz, CDCl3, 25°C): δ = 13.13 
HMRS (ESI):m/z calculated [M+Na]+ = 366.10976, found [M+Na] + = 366.10933. 
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Compound 11 
 
 
 
Isolated yield = 54% de= 95% (flash chromatography eluent AcOEt\Hexane)  
IR (film):ν  max = 3053, 2985, 2958, 2926, 2854, 2684, 2411, 2304, 1747, 1598, 1489, 
1456, 1442, 1421, 1352 1358cm-1. 
[α]D
20°= + 4.3 (c 1, CHCl3) 
1H NMR (400 MHz, CDCl3, 25 °C, TMS) δ = 147-1.58 (m, 1H, NCHCH2CH2), 1.62-1.77 (m, 
1H, NCHCH2CH2), 2.21-2.31 (m, 1H, NCH2CH2CH2), 2.40-2.46 (m, 1H, NCH2CH2CH2), 
2.70-2.79 (m, 1H, NCHCH2CH2CH2), 3.06-3.11 (m, 1H, NCHCH2CH2CH2), 3.31 (dd, J = 
12.0, 3.7 Hz, 1H, NBOCHCH2), 3.44 (d, J = 11.9 Hz, 1H, NBOCHCH2), 4.32 (d, J = 9.0 Hz, 
1H, NCH2CH2CH2CH), 4.53 (d, J = 16.1 Hz, 1H, BOCHOCH2), 4.62 (d, J = 16.0 Hz, 1H, 
BOCHOCH2), 5.75 (d, J = 3.6 Hz, 1H, NBOCH), 7.26-7.41 (m, 6H, C6H5), 7.43-7.54 (m, 
2H, C6H5), 1.57-160 (m, 2H, C6H5)  
13C NMR (100 MHz, CDCl3, 25 °C): δ = 23.98 (NCHCH2CH2), 29.93 (NCH2CH2CH2), 53.85 
(BOCHOCH2), 59.99 (NCHCH2CH2CH2), 65.62 (NBOCHCH2), 72.50 (NCH2CH2CH2CH), 
84.33 (CCC6H5), 86.36 (CCC6H5), 96.83 (NBOCH), 122.51,127.78 ,128.56, 131.68,132.91 
(C6H5), 174.02 (C=O). 
11B NMR (300 MHz, CDCl3, 25°C): δ = 11.97 
HMRS (ESI):m/z calculated [M+Na]+ =398.158800, found [M+Na] + = 398.152946 
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Compound 12 
 
 
 
Isolated yield = 88% de>97% (flash chromatography eluent AcOEt\Hexane)  
IR (film):νmax (cm
-1): 2956, 2922, 1735, 1608, 1456. 
[α]D
20°= + 7.5 (c 1, CHCl3) 
1H NMR (400 MHz, CDCl3, 25 °C, TMS): δ = 1.57 (td, J = 19.3, 12.8, 6.4 Hz, 1H, 
NCHCH2CH2), 1.64-1.76 (m, 1H, NCHCH2CH2), 2.18-2.33 (m, 1H, NCH2CH2CH2), 2.36 (s, 
3H, C6H4CH3), 2.45 (dd, J = 13.2, 6.6 Hz, 1H, NCH2CH2CH2), 2.67-2.81 (m, 1H, 
NCHCH2CH2CH2), 3.12 (dd, J = 10.4, 6.3 Hz, 1H, NCHCH2CH2CH2), 3.26 (dd, J = 11.7, 
3.7 Hz, 1H, NBOCHCH2), 3.36 (d, J = 11.7 Hz, 1H, NBOCHCH2), 3.43 (s, 3H, 
BOCHOCH3), 4.28 (dd, J = 10.4, 1.8 Hz, 1H, NCH2CH2CH2CH), 5.34 (d, J = 3.6 Hz, 1H, 
NBOCH), 7.17 (d, J = 7.5 Hz, 2H, C6H4), 7.48 (d, J = 7.8 Hz, 2H, C6H4). 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 21.43 (NCHCH2CH2), 23,99 (NCH2CH2CH2), 29,95 
(C6H4CH3), 54,09 (BOCHOCH3), 59.89 (NCHCH2CH2CH2), 65.77 (NBOCHCH2), 72.42 
(NCH2CH2CH2CH), 99.63 (NBOCH),128.54 ,132.81, 138.35 (C6H4), 174.03 (C=O). 
11B NMR (300 MHz, CDCl3, 25°C): δ = 12.97 
HMRS (ESI):m/z calculated [M+Na]+ = 312.138030, found [M+Na] + = 312.136382. 
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Compound 13 
 
 
 
Isolated yield = 75% de = 95% (flash chromatography eluent AcOEt\Hexane)  
IR (film):νmax (cm
-1): 3053, 2956, 2929, 2684, 2304, 1743, 1734, 1598, 1458. 
[α]D
20°= +3 (c 0.2, CHCl3) 
1H NMR (400 MHz, CDCl3, 25 °C, TMS): δ = 0.84 (t, J = 7.3 Hz, 3H, C6H4(CH2)3CH3), 
1.19-1.64 1,38-1.64 (m 6H, NCHCH2CH2, C6H4(CH2)2CH2, C6H4CH2CH2 overlapped), 
2.11–2.21 (m, 1H, NCH2CH2CH2), 2.25-2.38 (m, 1H, NCH2CH2CH2), 2.44-2.57 (m, 2H, 
C6H4 CH2), 2.60-2,67(m, 1H, NCHCH2CH2CH2), 2,97-3.01 (m, 1H, NCHCH2CH2CH2), 3.13 
(dd, J = 11.8, 3.4 Hz, 1H, NBOCHCH2), 3.25 (d, J = 11.8 Hz, 1H, NBOCHCH2), 3.31 (s, 
3H, NBOCHOCH3), 4.16 (d, J = 10.2 Hz, 1H, NCH2CH2CH2CH), 5.21 (d, J = 2.8 Hz, 1H, 
NBOCH), 7.07 (d, J = 7.7 Hz, 2H, C6H4), 7.37 (d, J = 7.6 Hz, 2H, C6H4).Relevant peaks 
from minor diastereoisomer: 6.66-6.68; 6.91-6.93. 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 13.93 (C6H4(CH2)3CH3), 22,28 (C6H4(CH2)2CH2), 
23.97 (NCHCH2CH2), 29.89 (NCH2CH2CH2), 33.60 (C6H4CH2CH2), 35.60 (C6H4CH2), 
54.04 (BOCHOCH3), 59.83 (NCHCH2CH2CH2), 65.69 (NBOCHCH2), 72.42 
(NCH2CH2CH2CH), 99.72 (NBOCH), 127.87 132.77 143.93 (C6H4), 174.30 
(C=O).Relevant peaks from minor diastereoisomer 115, 129. 
11B NMR (300 MHz, CDCl3, 25°C): δ = 12.0 
HMRS (ESI):m/z calculated [M+Na]+ = 354.185032, found [M+Na] + = 354.182812. 
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Compound 14 
 
 
 
Isolated yield = 83% de = 91% (flash chromatography eluent AcOEt\Hexane) 
IR (film):νmax (cm
-1): 3051, 2956, 2927, 2308, 1745, 1627, 1595, 1456, 1344. 
[α]D
20°= + 3.3 (c 0.6, CHCl3) 
1H NMR (400 MHz, CDCl3, 25 °C, TMS): δ = 1.42-1.67 (m, 2H, NCHCH2CH2), 2.19-2.29 
(m, 1H, NCH2CH2CH2), 2.43 (dd, J = 13.1 Hz, 1H, NCH2CH2CH2), 2.68 (td, J = 11,5 Hz, 
1H, NCHCH2CH2CH2) 3.03 (d, J = 12.0 Hz, 1H, NCHCH2CH2CH2), 3.29 (dd, J = 11.8 Hz, 
1H, NBOCHCH2), 3.37 (d, J = 11.8 Hz, 1H, NBOCHCH2), 3.44 (s, 3H, BOCHOCH3),4.30 
(d, J = 10.1 Hz, 1H, NCH2CH2CH2CH), 5.37 (d, J = 3.4 Hz, 1H, NBOCH), 7.43-7.53 (m, 
2H, C10H7), 7.64 (d, J = 8.2 Hz, 1H, C10H7) 7.77-7.90 (m, 3H, C10H7) 8.10 (s, 1H, C10H7). 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 24.02 (NCHCH2CH2), 29.1 (NCH2CH2CH2), 54.18 
(BOCHOCH3), 59.88 (NCHCH2CH2CH2), 65.85 (NBOCHCH2), 71.57 (NCH2CH2CH2CH), 
98.87 (NBOCH), 125.57, 126.02, 127.07, 127.61, 128.31, 129.82, 132.04, 133.08, 133.83 
(C10H7), 174.20 (C=O). 
11B NMR (300 MHz, CDCl3, 25°C): δ = 13.71 
HMRS (ESI):m/z calculated [M+Na]+ = 348.138082, found [M+Na] + = 348.136111. 
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Compound15 
 
 
 
Isolated yield = 71% de= 91% (flash chromatography eluent AcOEt\Hexane) 
IR (film): νmax (cm
-1): 3055, 2958, 2926, 2362, 1741, 1637, 1629, 1508, 1456. 
[α]D
20°= +2.15 (c 1.9, CHCl3) 
1H NMR (400 MHz, CDCl3, 25 °C, TMS):δ = 1.41-1.53 (m, 1H, NCHCH2CH2), 1.63-1.69 
(m,1H, NCHCH2CH2), 2.13-2.25 (m, 1H, NCH2CH2CH2), 2.33 (dd, J = 13.1, 6.5 Hz, 1H, 
NCH2CH2CH2), 2.65-2.73 (m, 1H, NCHCH2CH2CH2), 3.03-3.08 (m, 1H, NCHCH2CH2CH2), 
3.17 (dd, J = 11.8, 3.7 Hz, 1H, NBOCHCH2), 3.28 (d, J = 11.8 Hz, 1H, NBOCHCH2), 3.31 
(s, 3H, BOCHOCH3), 4.19-4.13 (m, 1H, NCH2CH2CH2CH), 5.18 (d, J = 3.5 Hz, 1H, 
NBOCH), 7.10 (d, J = 4.8 Hz, 1H, thiophenyl), 7.26 (dd, J = 4.5, 2.8 Hz, 1H, thiophenyl), 
7.42 (d, J = 2.5 Hz, 1H, thiophenyl). 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 24.12 (NCHCH2CH2), 29.68 (NCH2CH2CH2), 54.10 
(BOCHOCH3), 59.94 (NCHCH2CH2CH2), 65.62 (NBOCHCH2), 72.42 (NCH2CH2CH2CH), 
99.54 (NBOCH), 125.60 130.70 131.28 (thiophenyl), 173.95 (C=O).Relevant peaks from 
minor diastereoisomer: 23.08, 24.76, 29.43, 30.03, 68.26, 128,85. 
11B NMR (300 MHz, CDCl3, 25°C): δ = 11.79 
HMRS (ESI):m/z calculated [M+Na]+ = 304.078754, found [M+Na] + = 304.077574. 
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Compound 16 
 
 
 
Isolated yield = 57% de = 97% (flash chromatography eluent AcOEt\Hexane) 
IR (film): νmax (cm
-1): 3053, 2974, 2927, 2360, 2343, 1743, 1450, 1435, 1340. 
[α]D
20°= + 6.12 (c 0.8, CHCl3) 
1H NMR (400 MHz, CDCl3, 25 °C, TMS): δ = 1.38-1.49 (m, 1H, NCHCH2CH2), 1.58-1.64 
(m, 1H, NCHCH2CH2), 2.12-2.22 (m, 1H, NCH2CH2CH2), 2.33 (dd, J = 13.1, 6.5 Hz, 1H, 
NCH2CH2CH2), 2.61-2.70 (m, 1H, NCHCH2CH2CH2), 3.01 (dd, J = 10.2, 6.4 Hz, 1H, 
NCHCH2CH2CH2), 3.15 (dd, J = 11.7, 3.7 Hz, 1H, NBOCHCH2), 3.26 (d, J = 11.7 Hz, 1H, 
NBOCHCH2), 3.31 (s, 3H, BOCHOCH3), 3.74 (s, 3H, C6H4 OCH3), 4.18 (d, J = 10.1 Hz, 
1H, NCH2CH2CH2CH), 5.22 (d, J = 3.7 Hz, 1H, NBOCH), 6.81 (d, J = 8.3 Hz, 2H, C6H4), 
7.41 (d, J = 8.2 Hz, 2H, C6H4). 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 23.93 (NCHCH2CH2), 29.95 (NCH2CH2CH2), 54.04 
(BOCHOCH3), 54.96 (C6H4OCH3), 59.83 (NCHCH2CH2CH2), 65.68 (NBOCHCH2), 72.38 
(NCH2CH2CH2CH), 99.62 (NBOCH), 113.29, 134.16, 160.20 (C6H4), 174.17 (C=O). 
11B NMR (300 MHz, CDCl3, 25°C): δ = 13.06 
HMRS (ESI):m/z calculated [M+Na]+ = 328.132945, found [M+Na] + = 328.131426. 
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Compound 17 
 
 
 
Isolated yield = 94% de= 96% (flash chromatography eluent AcOEt\Hexane) 
IR (film):νmax (cm
-1): 3003, 2964, 2916, 2351, 2320, 1745, 1598, 1504, 1454. 
[α]D
20°= + 6.5 (c 0.9, CHCl3) 
1H NMR (400 MHz, CDCl3, 25 °C, TMS):δ = 1.32-1.44 (m, 1H, NCHCH2CH2), 1.54-1.65 
(m, 1H, NCHCH2CH2), 2.13-2.24 (m, 1H, NCH2CH2CH2), 2.28-2.33 (m, 1H, 
NCH2CH2CH2), 2.60-2.75 (m, 1H, NCHCH2CH2CH2), 2.85-2.99 (m, 1H, NCHCH2CH2CH2), 
3.15 (dd, J = 11.8, 3.5 Hz, 1H, NBOCHCH2), 3.27-3.31 (m, 4H, NBOCHCH2, BOCHOCH3 
overlapped), 4.18 (d, J = 10.2 Hz, 1H, NCH2CH2CH2CH), 5.21 (d, J = 3.1 Hz, 1H, 
NBOCH), 6.94 (t, J = 8.8 Hz, 2H, C6H4), 7.45 (t, J = 7.2 Hz, 2H, C6H4). 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 23.91 (NCHCH2CH2), 29.85 (NCH2CH2CH2), 54.10 
(BOCHOCH3), 59.78 (NCHCH2CH2CH2), 65.71 (NBOCHCH2), 72.41 (NCH2CH2CH2CH), 
99.71 (NBOCH), 114.55, 134.67, 162.39, 163.59, 164.82 (C6H4), 174.03 (C=O). 
11B NMR (300 MHz, CDCl3, 25°C): δ =12.45 
HMRS (ESI):m/z calculated [M+Na]+ = 316.112941, found [M+Na] + = 316.111601. 
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Compound 18 
 
 
 
Isolated yield = 78% de = 90% (flash chromatography eluent AcOEt\Hexane) 
IR (film):νmax (cm
-1): 3051, 2956, 2926, 2362, 2322, 1743, 1602, 1581, 1458. 
[α]D
20°= + 0.4 (c 1, CHCl3) 
1H NMR (400 MHz, CDCl3, 25 °C, TMS): δ = 1.33-1.46 (m, 1H, NCHCH2CH2), 1,61-1,67 
(m, 1H, NCHCH2CH2), 2.13-2.24 (m, 1H, NCH2CH2CH2), 2.31-2.36 (m, 1H, 
NCH2CH2CH2), 2.64-2.72 (m, 1H, NCHCH2CH2CH2), 2.93-2.97 (m, 1H, NCHCH2CH2CH2), 
3.15 (dd, J = 11.8, 3.6 Hz, 1H, NBOCHCH2) 3.29 (d, J = 11.8 Hz, 1H, NBOCHCH2), 3.32 
(s, 3H, BOCHOCH3), 4.19 (d, J = 10.3 Hz, 1H, NCH2CH2CH2CH), 5.22 (d, J = 3.5 Hz, 1H, 
NBOCH), 7.30-7.47 (m, 4H, C6H4). 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 23.99 (NCHCH2CH2), 29.88 (NCH2CH2CH2), 54.19 
(BOCHOCH3), 59.87 (NCHCH2CH2CH2), 65.81 (NBOCHCH2), 72.51 (NCH2CH2CH2CH), 
99.73 (NBOCH), 123.45, 130.91, 134.57 (C6H4), 173.91 (C=O). 
HMRS (ESI):m/z calculated [M+Na]+ = 376.032876, found [M+Na] + = 376.031248. 
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Compound 19 
 
 
 
Isolated yield = 78% de> 97%  (flash chromatography eluent AcOEt\Hexane) 
IR (film):ν  max = 3051, 2956, 2926, 2362, 2322, 1743, 1602, 1581, 1458. 
[α]D
20°= + 11 (c 1, CHCl3) 
1H NMR(400 MHz, CDCl3, 25 °C, TMS): δ = 1.29-1.38 (m, 1H, NCHCH2CH2), 1.65-1.70 
(m, 1H, NCHCH2CH2), 2.15-2.31 (m, 2H, NCH2CH2CH2), 2.87 (td, J = 11.5, 5.4 Hz, 1H, 
NCHCH2CH2CH2), 3.32 (s, 3H, BOCHOCH3), 3.34 (s, 1H, NBOCHCH2), 3.38-3.42 (m, 1H, 
NCHCH2CH2CH2), 3.82 (dd, J = 11.5, 3.3 Hz, 1H, NBOCHCH2), 4.09-4.21 (m, 1H, 
NCH2CH2CH2CH), 5.25 (d, J = 3.3 Hz, 1H, NBOCH), 7.11 (t, J = 7.5 Hz, 1H, C6H4), 7.20 (t, 
J = 7.3 Hz, 1H, C6H4), 7.48 (d, J = 7.9 Hz, 1H, C6H4), 7.63 (d, J = 7.4 Hz, 1H, C6H4). 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 24.46 (NCHCH2CH2), 29.73 (NCH2CH2CH2), 54.00 
(BOCHOCH3), 59.59 (NCHCH2CH2CH2),66.79 (NBOCHCH2), 73.73 (NCH2CH2CH2CH), 
100.32 (NBOCH), 126.72, 129.11, 130.64, 133.58, 136.52 (C6H4), 173.45 (C=O). 
11B NMR (300 MHz, CDCl3, 25°C): δ = 12.33 
HMRS (ESI):m/z calculated [M+Na]+ = 376.032876, found [M+Na] + = 376.030680. 
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Compound 20 
 
 
 
Isolated yield = 70% de> 99% (flash chromatography eluent AcOEt\Hexane)  
IR (film):ν  max = 3053, 2985, 2960, 2927, 2304, 1749, 1732, 1579, 1421, 1346 cm-1. 
[α]D
20°= + 10.27 (c 1.4, CHCl3) 
1H NMR (400 MHz, CDCl3, 25 °C, TMS) δ = 1.34-1.42 (m, 1H, NCHCH2CH2), 1.72-1.86 
(m, 1H, NCHCH2CH2), 2.23-2.43 (m, 2H, NCH2CH2CH2), 2.97 (td, J = 11.5, 5.4 Hz, 1H, 
NCHCH2CH2CH2), 3.38-3.45 (m, 5H, NCHCH2CH2CH2, NBOCHCH2 ,CHOCH3 overlapped 
peaks), ), 3.74 (dd, J = 11.5, 3.7 Hz, 1H, NBOCHCH2), 4.28 (dd, J = 9.9, 2.7 Hz, 1H, 
NCH2CH2CH2CH), 5.31 (s, 1H, NBOCH), 7.17-7-30 (m, 1H, C6H3), 7.37 (d, J = 1.5 Hz, 1H, 
C6H3), 7.66 (d, J = 8.1 Hz, 1 H, C6H3). 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 24.53 (NCHCH2CH2), 29.76(NCH2CH2CH2), 54.00 
(BOCHOCH3), 59.56 (NCHCH2CH2CH2), 66.42 (NBOCHCH2), 73.61 (NCH2CH2CH2CH2), 
100.15 (NBOCH), 126.53, 129.71, 135.56, 136.90, 139.61 (C6H3), 173.18 (C=O) 
11B NMR (300 MHz, CDCl3, 25°C): δ = 12.07 
HMRS (ESI):m/z calculated [M+K]+ = 382.01835, found [M+K] + = 382.01812 
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Compound 21 
 
 
 
Isolated yield = 65% de= 95% (flash chromatography eluent AcOEt\Hexane)  
IR (film):ν  max = 3053, 2976, 2926, 2362, 2328, 1747, 1732, 1651, 1633 1456, 1435 cm-
1[α]D
20°= + 2.43 (c 2.3, CHCl3) 
1H NMR (400 MHz, CDCl3, 25 °C, TMS) δ = 1.39-1.60 (m, 1H, NCHCH2CH2), 1.67-1.77 
(m, 1H, NCHCH2CH2),2.28 ( m, 1H, NCH2CH2CH2), 2.38-2.50 (m, 1H, NCH2CH2CH2), 
2.61 (s, 3H, C6H4COCH3), 2.72-2.85 (m, 1H, NCHCH2CH2CH2), 2.96-3.07 (m, 1H, 
NCHCH2CH2CH2), 3.29 (dd, J = 11.8, 3.5 Hz, 1H, NBOCHCH2), 3.36-3.45 (m, 4H, 
NBOCHCH2, CHOCH3,overlapped peaks,4.30 (d, J = 10.2 Hz, 1H, NCH2CH2CH2CH), 5.34 
(d, J = 1.8 Hz, 1H, NBOCH), 7.68(d, J = 7.0 Hz, 2H C6H4), 7.90-7.94 (m, 2H, C6H4). 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 24.01 (NCHCH2CH2), 26.73 (C6H4COCH3), 29.85 
(NCH2CH2CH2), 54.19 (BOCHOCH3), 59.85 (NCHCH2CH2CH2), 65.91 (NBOCHCH2), 
72.56 (NCH2CH2CH2CH), 99.83 (NBOCH), 127.46 (C6H4), 133.04 (C6H4), 137.33 (C6H4), 
173.79 (CHC=O), 198.76 (C6H4CO). 
HMRS (ESI):m/z calculated [M+Na]+ =339.13631, found [M+Na] + = 339.13623 
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Compound 22 
 
 
 
Isolated yield = 65% de= 96% (flash chromatography eluent AcOEt\Hexane)  
IR (film):ν  max = 3053, 2976, 2926, 2362, 2328, 1747, 1732, 1651, 1633 1456, 1435 cm-1 
[α]D
20°= + 8.9 (c 1, CHCl3) 
1H NMR (400 MHz, CDCl3, 25 °C, TMS) δ = 1.34-1.45 (m, 1H, NCHCH2CH2), 1.73-1.80 
(m, 1H, NCHCH2CH2), 2.27-2.42 (m, 2H, NCH2CH2CH2), 2.51 (s, 3H, C6H3CH3), 2.87-2.94 
(m, 1H, NCHCH2CH2CH2), 3.04-3.08 (m, 1H, NCHCH2CH2CH2), 3.34-3.54 (m, 5H, 
NBOCHCH2, CHOCH3, overlapped signals), 4.27 (dd, J = 10.1, 2.7 Hz, 1H, 
NCH2CH2CH2CH), 5.34 (d, J = 3.3 Hz, 1H, NBOCH), 7.39-7.46 (m, 2H, C6H3), 7.71 (d, J = 
7.6 Hz, 1H, C6H3). 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 22.46 (C6H3CH3), 24.40 (NCHCH2CH2), 29.72 
(NCH2CH2CH2), 54.11 (BOCHOCH3), 59.63 (NCHCH2CH2CH2), 66.62 (NBOCHCH2), 
73.41 (NCH2CH2CH2CH), 99.88 (NBOCH), 112.31 (C6H3), 119.26 (C6H3CN), 128.45, 
133.68, 135.04(C6H3), 173.18(C=O) 
11B NMR (300 MHz, CDCl3, 25°C): δ = 12.82 
HMRS (ESI):m/z calculated [M+K]+ =353.10723, found [M+K] + = 353.10700 
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Compound 23 
 
 
 
Isolated yield = 52% de> 99% (flash chromatography eluent AcOEt\Hexane)  
IR (film):ν  max = 3053, 2985, 2960, 2927, 2304, 1749, 1579, 1421cm-1. 
[α]D
20°= +2 (c 1, CHCl3) 
1H NMR (400 MHz, CDCl3, 25 °C, TMS) δ = 1.08-1.40 (m, 6H, C6H11), 1.52 (d, J = 11.1 
Hz, 1H, C6H11), 1.64-1.80 (m, 3H, C6H11), 1.80-1.95 (m, 2H, C6H11, NCHCH2CH2, 
overlapped peaks), 2.00-2.07 (m, 1H, NCHCH2CH2), 2.19-2.32 (m, 1H, NCH2CH2CH2), 
2.32-2.44 (m, 1H, NCH2CH2CH2), 2.98 (td, J = 11.0, 5.8 Hz,1H, NCHCH2CH2CH2), 3.08 
(dd, J = 11.5, 4.0 Hz, 1H, NBOCHCH2), 3.28 (d, J = 11.5 Hz, 1H, NBOCHCH2), 3.35 (s, 
3H, CHOCH3) 3.66-3.78 (m, 1H, NCHCH2CH2CH2),4.33 (dd, J = 9.8, 2.9 Hz, 1H, 
NCH2CH2CH2CH), 5.11 (d, J = 3.9 Hz, 1H, NBOCH). 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 25.14 (NCHCH2CH2), 27.05, 27.66, 27.17, 28.62, 
28.99 (C6H11), 29.32 (NCH2CH2CH2), 54.02 (BOCHOCH3), 58.36 (NCHCH2CH2CH2), 
66.28 (NBOCHCH2), 73.01 (NCH2CH2CH2CH), 99.11 (NBOCH), 173.54 (C=O) 
11B NMR (300 MHz, CDCl3, 25°C): δ = 12.50 
HMRS (ESI):m/z calculated [M+Na]+ =304.16931, found [M+Na] + = 304.16911 
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Compound 24 
 
 
 
Isolated yield = 52 % de100%, after 20 h at 90 ºC (0.142 g). 
1H NMR (400 MHz, CDCl3, 25ºC, TMS):  1.73 (d, 3H, J = 6.8 Hz, -CHCH3), 4.62 (qd, 
1H,J = 6.7, 2.3 Hz, -CHCH3), 6.93 –7.08 (m, 1H, Ar), 7.16 (d, 1H, J = 8.4 Hz, Ar), 7.20 – 
7.33  (m, 3H, Ar), 7.40 (dd, 2H,J = 7.5, 1.7 Hz, Ar), 7.45 (dd, 1H,J = 7.8, 1.6 Hz, Ar), 7.55–  
7.71 (m, 1H, Ar), 8.17 (d, 1H, J = 2.2 Hz, Ar)  
13C-RMN (100MHz, CDCl3, 25ºC, TMS):  12.98 (-CHCH3), 58.59 (-NCHCH3-), 117.30, 
120.22, 120.35, 125.83, 127.83, 128.48, 130.74, 131.60, 139.07 (Ar), 156.61 (Ar, 
quaternary), 159.79 (ArCHN-), 170.66 (-CHCOO-).  
11B NMR (300 MHz, CDCl3, 25°C): δ = 6.99 
ESI+: 318, 302, 280, 122. 
HMRS (EI): m/z calc. [M+] = 279.1067, found [M+] = 279.1066. 
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Compound 25 
 
 
 
Isolated yield = 50 %de 100%,after 20 h at 90 ºC (0.142 g).  
1H NMR (400 MHz, CDCl3, 25ºC, TMS):  1.05 (dd, 6H, J = 12.9, 6.4 Hz, -
CHCH2CH(CH3)2), 1.77–1.96 (m, 1H, -CHCH2CH(CH3)2), 2.03–  2.27 (m, 2H, -
NCHCH2CH(CH3)2), 4.53 (td, 1H, J = 5.7, 2.3 Hz, -NCHCH2CH(CH3)2),6.96 – 7.07 (m, 1H, 
Ar), 7.16 (d, 1H,J = 8.4 Hz, Ar), 7.21 - 7.35 (m, 4H, Ar), 7.39 (dd, 2H, J = 7.5, 1.8 Hz, Ar), 
7.44 (dd, 1H, J = 7.8, 1.6 Hz,Ar), 7.62 (td, 1H, J = 8.7, 7.4, 1.7 Hz, Ar); 
13C-RMN (100MHz, CDCl3, 25ºC, TMS):  22.50(-CHCH2(CH3)2), 22.93 (-CHCH2(CH3)2), 
25.16 (-NCHCH2CH-), 37.16 (-NCHCH2-), 60.64 (-NCHCH2 -), 117.49, 120.21, 120.27, 
125.98, 127.83, 128.43, 130.89, 131.65 (Ar), 139.02 (-NCHAr-), 156.70, 159.70 (Ar, 
quaternary), 170.79 (-CHCOO-).  
11B NMR (300 MHz, CDCl3, 2 °C): δ =  .73 
ESI+: 360, 344, 322, 274, 236 
HMRS (EI): m/z calc.[M+] = 321.1536, found [M+] = 321.1534 
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Compound 26 
 
 
 
Isolated yield = 86% de 91%, after 20 h at 90ºC (0.125 g). 
1H NMR (400 MHz, CDCl3, 25ºC, TMS): δ 2.71 (t, 1H, J= 13.2, –CHCH2Ph), 3.41 (dd, 1H, 
J=3.6, 14.0, –CHCH2Ph), 4.34 (dd, 1H, J= 3.6, 12.4, –NCHCH2Ph), 6.87–6.95 (m, 3H, Ar), 
7.02–7.05 (m, 1H, Ar), 7.11– 7.16 (m, 2H, Ar), 7.27–7.34 (m, 6H, Ar), 7.43–7.55 (m, 3H, 
Ar);  
13C-NMR (100 MHz, CDCl3, 25ºC, TMS):  37.73 (–CHCH2Ph), 66.92 (–NCHCOCH2–), 
117.57, 120.19, 120.32, 127.79, 127.90, 128.58, 129.16, 129.21, 130.55, 131.45, 135.11, 
139.04 (Ar), 159.95 (-NCHAr-), 160.43(Ar, quaternary), 170.22 (–CHCOO–). 
11B NMR (300 MHz, CDCl3, 25°C): δ = 6.71 
ESI+: 394, 378, 356, 270, 248. 
HMRS (EI): m/z calc. [M+H+] = 356.1458, found [M+H+] = 356.1466 
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Compound 27 
 
 
 
Isolated yield = 83 % yield, de 100%, after 20 h at 90 ºC (0.126 g). 
1H NMR (400 MHz, CDCl3, 25ºC, TMS):  2.34 (s, 3H, -ArCH3), 2.73 (t, 1H, J= 12.0, -
CHCH2Ph), 3.42 (dd, 1H, J= 4.0, 14.0, -CHCH2Ph), 4.35 (dd, 1H, J= 4.0, 12.0, -
NCHCH2Ph), 6.91 (t, 1H, J= 8.0, Ar), 6.99-7.04 (m, 3H, Ar), 7.12-7.16 (m, 4H, Ar), 7.28-
7.38 (m, 5H, Ar), 7.50-7.56 (m, 1H, Ar);  
13C-RMN (100MHz, CDCl3, 25ºC, TMS):  21.44 (-ArCH3), 37.78 (-CHCH2Ph), 66.90 (-
NCHCH2Ph-), 117.62, 120.14, 120.32, 127.80, 128.67, 129.16, 129.28, 130.61, 131.46, 
135.21, 138.19, 138.94 (Ar), 159.94 (Ar, quaternary), 160.35 (ArCHN-), 170.35 (-CHCOO-). 
11B NMR (300 MHz, CDCl3, 2 °C): δ =  .97 
ESI+: 392, 370, 300, 188. 
HMRS (EI): m/z calc. [M+H+] = 370.1614, found [M+H+] = 370.1620. 
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Compound 28 
 
 
 
Isolated yield =31 % de 97%, after 20 h at 90 ºC (0.048 g)  
1H NMR (400 MHz, CDCl3, 25ºC, TMS):  2.72 (t, J= 13.0, 1H, -CHCH2Ph), 3.42 (dd, 
1H,J= 3.2, 13.6, -CHCH2Ph), 3.81 (s, 3H, -ArOCH3), 4.34 (dd, 1H,J= 3.2, 12.4, -
NCHCOCH2-), 6.80-7.35 (m, 14H, Ar); 
13C-RMN (100MHz, CDCl3, 25ºC, TMS):  37.87 (-CHCH2Ph), 55.04 (-ArOCH3), 66.82 (-
NCHCOCH2-), 113.42, 117.55, 120.15, 120.27, 127.80, 129.16, 129.28, 131.48, 131.96, 
135.14, 138,92 (Ar), 159.94(ArCHN-), 159.98, 160.22 (Ar, quaternary), 170.42 (-CHCOO-). 
11B NMR (300 MHz, CDCl3, 2 °C): δ =  .9  
ESI+: 408, 386, 288, 270.  
HMRS (EI): m/z calc. [M+H+] = 386.1564, found [M+H+] = 386.1556.  
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Compound 29 
 
 
 
Isolated yield = 80 % de 100%, after 20 h at 90 ºC (0.122 g).  
1H NMR (400 MHz, CDCl3, 25ºC, TMS):  2.68 (t, J= 13.2,, 1H -CHCH2Ph), 3.45 (dd, 
1H,J= 3.4, 13.8, -CHCH2Ph), 4.36 (dd, 1H,J= 3.2, 12.4, -NCHCH2Ph-), 6.80-7.71 (m, 14H, 
Ar); 
13C-RMN (100MHz, CDCl3, 25ºC, TMS):  37.79 (-CHCH2Ph), 66.87 (-NCHCH2-), 114.74, 
114.94, 117.47, 120.32, 120.38, 127.91, 129.16, 129.24, 131.53, 132.34, 132.41, 134.97, 
139.23 (Ar), 159.84 (Ar, quaternary), 160.56 (Ar, quaternary), 170.13 (-HCOO). 
11B NMR (300 MHz, CDCl3, 25°C): δ = 6.50 
ESI+: 412, 374, 270. 
HMRS (EI): m/z calc. [M+H+] = 374.1364, found [M+H+] = 374.1367 
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Compound 30 
 
 
 
Isolated yield = 63 % de. 100% , after 20 h at 90 ºC  (0.095 g).  
1H NMR (400 MHz, CDCl3, 25ºC, TMS):  2.35 (s, 3H, -ArCH3), 2.70 (t, 1H, J= 12.0, -
CHCH2Ph), 3.41 (dd, 1H, J= 2.0, 14.0, -CHCH2Ph), 4.34 (dd, 1H, J= 4.0, 12.0, -
CHCH2Ph), 6.73 (d, 1H, J= 8.0Hz, Ar), 6.85 (s, 1H, Ar), 6.97-7.03 (m, 3H, Ar), 7.12 (s, 1H, 
AR), 7.28-7.38 (m, 6H, Ar), 7.45-7.47 (m, 2H, Ar).  
13C-RMN (100MHz, CDCl3, 25ºC, TMS):  22.50 (-ArCH3), 37.75(-CHCH2Ph), 66.75 (-
NCHCOCH2-), 115.41, 120.38, 121.74, 127.74, 127.88, 128.48, 129.14, 129.24, 130.58, 
131.23, 135.28 (Ar), 151.41 (Ar, quaternary), 159.95 (Ar, quaternary), 159.99 (ArCHN-), 
170.58 (-CHCOO-).  
11B NMR (300 MHz, CDCl3, 2 °C): δ =  .94. 
ESI+: 408, 392, 370, 284. 
HMRS (EI): m/z calc. [M+H+] = 370.1614, found [M+H+] = 370.1615.  
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Compound 31 
 
 
 
Isolated yield = 88 % yield, de 100%, after 20 h at 90 ºC  (0.133 g). 
1H NMR (400 MHz, CDCl3, 25ºC, TMS):  2.69 (t, 1H, J= 13.0, -CHCH2Ph), 3.39 (dd, 1H, 
J= 3.6, 14.0, -CHCH2Ph), 3.84 (s, 3H, -ArOCH3), 4.31 (dd, 1H, J= 3.2, 12.4, -NCHCH2Ph-), 
6.45-6.50 (m, 2H, Ar), 6.97-7.09 (m, 4H, Ar), 7.28-7.48 (m, 6H, Ar), 7.49-7.50 (m, 2H, Ar); 
13C-RMN (100MHz, CDCl3, 25ºC, TMS):  37.78 (-CHCH2Ph), 55.87 (-ArOCH3), 66.54 (-
NCHCOCH2-), 102.62, 110.12, 111.47, 127.65, 127.88, 128.42, 129.10, 129.24, 130.57, 
132.88, 135.47 (Ar), 158.98 (ArCHN-), 162.65 (Ar, quaternary), 168.80 (Ar, quaternary), 
170.91 (-CHCOO-). 
11B NMR (300 MHz, CDCl3, 25°C): δ = 7.62 
ESI+: 424, 408, 386, 300. 
HMRS (EI): m/z calc. [M+H+] = 386.1564, found [M+H+] = 386.1571.  
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Compound 32 
 
 
 
Isolated yield = 66 % de 77%, after 20 h at 90 ºC  (0.111 g). 
1H NMR (400 MHz, CDCl3, 25ºC, TMS): 3.08 – 3.18 (m, 1H, -NCHCH2Ph-), 3.55 (dt, 
1H,J= 8.6, 4.3 Hz, -CHCH2Ph), 3.85 (s, 3H, -OCH3), 4.34 (dd, 1H, J= 11.9, 3.7 Hz, -
CHCH2Ph), 7.46 – 6.71 (m, 16H, Ar). 
13C-RMN (100MHz, CDCl3, 25ºC, TMS):  38.8 (-CHCH2Ph), 56.2 (-OCH3), 66.0 (-
NCHCOCH2-), 103.0, 110.3, 112.0, 126.8, 127.8, 128.1, 128.7, 129.5, 129.7, 133.2, 135.7, 
138.9, 158.6 (Ar, quaternary), 162.8 (Ar, quaternary), 168.9 (Ar, quaternary), 171.4 (-
CHCOO-). 
11B NMR (300 MHz, CDCl3, 2 °C): δ =  .3 . 
ESI+: 300, 188, 166, 120. 
HMRS (EI): m/z calc.  [M+] = 411.1642, found [M+] = 411.1638. 
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Compound 33 
 
 
 
Isolated yield = 78 %de 100%, after 20 h at 90 ºC  (0.125 g). 
1H NMR (400 MHz, CDCl3, 25ºC, TMS):  2.73 (t, 1H, J= 13.0, -CHCH2Ph), 3.44 (dd, 1H. 
J=  3.6, 14.0, -CHCH2Ph), 3.85 (s, 3H, -ArOCH3). 4.31 (dd, 1H, J= 3.4, 12.2, -NCHCH2Ph-
), 6.47-6.52 (m, 2H, Ar), 6.95-7.04 (m, 5H, Ar), 7.28-7.40 (m, 5H, Ar). 
13C-RMN (100MHz, CDCl3, 25ºC, TMS):  38.22 (-CHCH2Ph), 55.89 (-ArOCH3), 66.02 (-
NCHCOCH2-), 102.72, 110.19, 111.50, 125.71, 127.70, 127.75, 129.11, 129.34, 129.80, 
132.82, 135.32 (Ar), 158.24 (ArCHN-), 162.34 (Ar, quaternary), 168.70 (Ar, quaternary), 
171.05 (-CHCOO-).  
11B NMR (300 MHz, CDCl3, 25°C): δ = 5.70 
ESI+: 430, 392, 338, 300. 
HMRS (EI): m/z calc. [M+H+] = 392.1128, found [M+H+] = 392.1138. 
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Compound 34 
 
 
 
Isolated yield = 50 %de 91% , after 20 h at 90 ºC  (0.08 g). 
1H NMR (400 MHz, CDCl3, 25ºC, TMS):  2.54 (dd, 1H,J = 14.1, 12.3 Hz, -NCHCH2Ph), 
3.23 (dd, 1H,J = 14.2, 3.0 Hz, -CHCH2Ph), 3.83 (s, 3H, -OCH3), 4.32 (dd, 1H,J = 12.2, 3.1 
Hz, -CHCH2Ph), 6.39 – 6.46 (m, 2H, Ar ), 6.99 (d, 1H, J = 8.7 Hz, Ar), 7.03 – 7.17 (m, 2H, 
Ar), 7.07-7.39(m, 5H, Ar), 7.61 (dd, 1H, J = 7.9, 0.9 Hz, Ar), 7.68 (dd, 1H,J = 7.5, 1.7 Hz, 
Ar). 
13C-RMN (100MHz, CDCl3, 25ºC, TMS):  37.82 (-CHCH2Ph), 55.89 (-OCH3), 66.49 (-
NCHCOCH2-), 102.60, 110.27, 114.76, 127.73, 127.63, 129.15, 129.5, 132.34, 132.25,  
132.89, 135.32, 158.99 (Ar), 162.57 (-CHCOO-). 
11B NMR (300 MHz, CDCl3, 25°C): δ = 6.48 
ESI+: 442, 426, 360, 300. 
HMRS (EI): m/z calcd. [M+H+] = 404.1464, found [M+H+] 404.1455. 
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Compound 35 
 
 
 
Isolated yield = 66 %, de 88% , after 20 h at 90 ºC (0.12 g). 
1H NMR (400 MHz, CDCl3, 25ºC, TMS):  2.59–2.69 (m, 1H, -NCHCH2Ph-), 3.40 (dd, 1H, 
J= 13.8, 3.2 Hz, -NCHCH2Ph), 3.84 (s, 3H, -OCH3), 4.34 (dd, 1H, J= 12.3, 3.3 Hz, -
NCHCH2Ph), 6.17-6.51 (m, 2H, Ar), 6.92-7.07 (m, 3H, Ar), 7.19–7.50 (m, 7H, Ar). 
13C-RMN (100MHz, CDCl3, 25ºC, TMS):  38.1 (-CHCH2Ph), 56.2 (-OCH3), 66.8 (-
NCHCH2Ph-), 103.0, 110.7, 111.7, 123.1, 129.5, 131.3, 132.7, 133.3, 135.6, 159.5 (Ar), 
162.8 (Ar, quaternary), 169.4 (Ar, quaternary), 169.3 (-CHCOO-). 
11B NMR (300 MHz, CDCl3, 25°C): δ =6.48 
ESI+: 502, 486, 464,152. 
HMRS (EI): m/z calcd.  [M+] = 463.0590, found  [M+] 463.0583. 
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Compound 36 
 
 
 
Isolated yield = 50 % de 77%, after 20 h at 90 ºC (0.09 g). 
1H NMR (400 MHz, CDCl3, 25ºC, TMS):  2.54 (dd, 1H, J = 14.1, 12.4 Hz, -NCHCH2Ph-), 
3.24 (dd, 1H, J = 14.1, 2.9 Hz, -CHCH2Ph), 3.84 (s, 3H, -OCH3), 4.30 (dd, 1H, J= 12.3, 3.3 
Hz, -CHCH2Ph), 6.43-6.46 (m, 2H, Ar), 7.07 – 7.30 (m, 3H, Ar), 7.28-7.40(m, 5H, Ar), 7.61 
(dd, 1H, J = 7.9, 1.0 Hz, Ar), 7.70 (dd,1H, J = 7.5, 1.7 Hz, Ar) ; 13C-RMN (100MHz, CDCl3, 
25ºC, TMS):  37.26 (-CHCH2Ph), 55.9 (-OCH3), 68.38 (-NCHCOCH2-), 101.78, 110.33, 
112.6, 126.8, 127.8, 129.0, 129.3, 129.86, 133.0, 134.2, 133.5, 135.6, 161.7, 169.41 (Ar, 
quaternary), 162.8 (Ar, quaternary), 169.7 (Ar, quaternary), 170.4 (-CHCOO-). 
11B NMR (300 MHz, CDCl3, 2 °C): δ = .29 
ESI+: 502, 486, 464, 256.  
HMRS (EI): m/z calcd.  [M+] = 463.0591, found  [M+] 463.0580. 
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Compound 37 
 
 
 
Isolated yield = 84%, de 96%, after 20 h at 90 ºC (144 mg). 
1H NMR (4   MHz,CDCl3, 2 ºC, TMS): δ 2. 2 (t,  H,J= 13.2 Hz, -NCHCOCH2-), 3.38 (d, 
1H,J= 13.9 Hz, -CHCH2Ph-), 3.82(s, 3H, -OCH3), 4.28 (d, 1H,J= 11.7 Hz, -CHCH2Ph-), 
6.36 – 7.45 (m, 14H, Ar). 
13C NMR (100 MHz, CDCl3) δ38.1 (-CHCH2Ph-), 56.2 (-OCH3), 66.8 (-NCHCH2Ph-), 
102.9, 110.7, 111.7, 128.1, 128.4, 129.5, 132.3, 133.3, 134.6, 135.6 (Ar), 159.5 (Ar, 
quaternary), 162.8 (Ar, quaternary), 169.3 (Ar, quaternary), 171.0 (-CHCO) 
11B NMR (300 MHz, CDCl3, 25°C): δ = 6.48 
ESI+: 442, 322, 300, 166. 
HMRS (EI): m/z calcd.  [M+] = 419.1096, found  [M+] 419.1106. 
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Compound 38 
 
 
 
Isolated yield = 98 % de 68%, after 20 h at 90 ºC (183 mg). 
1H NMR (4   MHz,CDCl3, 2 ºC, TMS): δ 2.47 (dd,  H, J = 14.0, 12.4 Hz, -NCHCH2Ph-), 
3.23 (dd, 1H,J= 14.1, 3.0 Hz, -NCHCH2Ph-), 3.83 (d, 3H,J= 9.5 Hz, -OCH3), 4.25 (dd, 
1H,J= 12.2, 3.1 Hz, -CHCH2Ph-),6.27–6.41  (m, 2H, Ar), 6.91 – 7.07  (m, 4H, Ar), 7.14 – 
7.34  (m, 6H, Ar). 
13C NMR (    MHz, CDCl3) δ 37.  (-CHCH2Ph-), 56.2 (-OCH3), 68.5 (-NCHCH2Ph-), 
102.0, 110.7, 112.1, 126.8, 127.9, 128.5, 129.4, 129.5, 129.7, 129.8, 133.2, 135.0, 
135.1,135.4, 135.7, 139.7 (Ar), 161.8 (Ar, quaternary), 162.3 (Ar, quaternary), 162.6 (Ar, 
quaternary), 169.8 (-CHCOO). 
11B NMR (300 MHz, CDCl3, 25°C): δ =  .3  
ESI+: 492, 454, 300. 
HMRS (EI): m/z calcd.  [M+H+] = 454.0779, found  [M+H+] 454.0763. 
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Compound 39 
 
 
 
A round bottom flask equipped with a magnetic stirrer was charged with amino acid (2.0 
equiv.), aldehyde (1.5 equiv.) and distilled ethanol (2.0 mL). This suspension was stirred at 
90ºC for 1 h after which the boronic acid (0.41 mmol) was added, the mixture was then 
stirred at 75ºC for 20 h. The reaction mixture, which appears as a biphasic composition of 
precipitate and a supernatant liquid, was filtered and the solid retained in the filter, was 
then washed with water followed by hexane. The desired compound was recovered with 
dichloromethane, which was subsequently removed under reduced pressure. 
 
 
Isolated yield = 89 %, de 98%, after 20 h at 75 ºC  (0.08 g). 
1H NMR (400 MHz, CDCl3, 25ºC, TMS):  1.11 (t, 6H, J = 6.8 Hz, –N(CH2CH3)2, 2.37 (t, 
1H,J = 13.0 Hz, -CHCH2Ph), 3.10 (d, 1H,J = 13.6 Hz, -CHCH2Ph), 3.18 – 3.45 (m, 4H, –
N(CH2CH3)2),  4.10 (d, 1H,J = 10.3 Hz, -CHCH2Ph), 5.98 (s, 1H, Ar), 6.12 (d, 1H,J = 8.4 
Hz, Ar ), 6.84 (d, 1H,J = 8.6 Hz, Ar), 6.96 (s, 1H, Ar), 7.03 (d, J = 7.0 Hz, 2H, Ar), 7.42 – 
7.08 (m, 6H, Ar). 
13C-RMN (100MHz, CDCl3, 25ºC, TMS):  45.08 (–N(CH2CH3), 67.72 (-CHCH2Ph), 98.12 
(-NCHCOCH2-), 105.97, 108.34, 126.30, 127.33, 128.27, 128.94, 129.24, 133.50, 134.26, 
134.70, 135.09, 136.18, 139.46, 156.56, 158.90, 161.43, (Ar), 171.47 (-CHCOO).  
11B NMR (300 MHz, CDCl3, 25°C): δ = 5.96 
ESI+: 517, 495, 341. 
HMRS (EI): m/z calcd. [M+] = 494.1335, found [M+] = 494.1330. 
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Compound 40 
 
 
 
A round bottom flask equipped with a magnetic stirrer was charged with amino acid (0,82 
mmol), Cl2SO (1equiv.), distilled methanol (3.0 mL) after which the suspension was stirred 
at reflux for 12 h. Then the volatiles were removed under reduced pressure and the 
remaining solid was solubilized with a mixture of methanol and THF (3.0 mL, 1:1), the 
aldehyde was then added (1eqiv) and the reaction was stirring for 6 h at reflux to yield the 
schiff base. Subsequently, NaBH4 (3 equiv.) was slowly added at 0ºC to the reaction 
mixture which was then allowed to react at this temperature for 1 h after which the reaction 
was quenched with HCl (3 equiv.). The reaction mixture volatiles were then evaporated 
under reduced pressure. The residue was then solubilized with NaOH (1,5ml 3 M) and the 
mixture stirred for 2 h at rt, after which HCl was added until PH 7 was obtained. The 
mixture than was evaporated by reduced pressure. The product was solubilized with 
CH2Cl2, the insoluble material was discarded. The product was dried by reduced pressure. 
Further 0,41mmol of this compounds were solubilized by 1/1 mixture of ethanol and 
benzene (2mL) and reacted with phenyl boronic acid (1equiv.) in presence of  
NaHCO3(1,5equiv.) for 12h at reflux. 
Isolated yield =  48%,de 100%. 
1H NMR (400 MHz, CDCl3, 25"C, TMS):  3.13-3.25 (m, 2H,–CHCH2Ph), 3.37 (d, 1H, J = 13.5 Hz, –
NHCH2C6H4–), 3.77 (d, 1H, J = 7.4 Hz,–NCHCH2–), 4.15 (d, J = 11.9 Hz, 1H –NHCH2C6H4–), 4.63 
(s, 1H -NH-), 7.38 – 6.80 (m, 14H, Ar), 
13C-NMR (100 MHz, CDCl3, 25ºC, TMS):  34.53 (–CHCH2Ph), 47.03 (–NHCH2C6H4), 60.36(-
NHCHCH2-)117.07, 119.93, 120.78, 127.94, 128.38, 128.73, 129.21, 129.29, 131.34, 133.47 (Ar), 
155.77 (Ar, quaternary), 171.67 (–CHCOO–).  
11B NMR (300 MHz, CDCl3, 25°C): δ = 6.33. 
ESI+: 358, 294, 272. 
HMRS (EI): m/z calcd.  [M+] 357.1536, found  [M+] = 357.1541 .  
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Compound 41 
 
 
 
A round bottom flask equipped with a magnetic stirrer and molecular sieves, was charged 
with amino alcohol (0.41 mmol), aldehyde (1.0equiv.) and distilled ethanol (2.0 mL). This 
suspension was stirred at reflux for 1 h, after which the solvent was evaporated under 
educed pressure. Toluene (2 mL) and boronic acid (1.0 equiv.) was then added and the 
mixture was stirred at reflux for 24 h. The mixture reaction that appears as yellow clear 
solution was filtered at room temperature through a silica column and the expected 
compound was precipitated from this mixture by low temperature. 
 
Isolated yield = 20 % (0.133 g). 
1H NMR (400 MHz, CDCl3, 25ºC, TMS): 2.77 – 3.04 (m, 2H, J= 13.0, -CHCH2Ph), 4.09 
(d, 2H,J = 8.9 Hz, -NCHCH2O-, -NCHCH2O-), 4.34 (dd, 1H,J = 9.7, 6.8 Hz, -NCHCH2O-), 
6.83 (t, 1H,J = 7.4 Hz, -Ar), 6.99 (dd, 3H,J = 11.7, 8.1 Hz, Ar), 7.14 (d, 1H,J = 7.7 Hz, Ar), 
7.22 – 7.38 (m, 7H, Ar), 7.45 – 7.53 (m, 3H, Ar). 
13C-RMN (100MHz, CDCl3, 25ºC, TMS):  39.84 (-CHCH2Ph), 66.15 (-NCHCH2-), 67.87 (-
NCHCH2-), 117.62, 118.94, 120.34, 127.15, 127.46, 127.51, 128.84, 129.22, 130.80, 
131.00, 136.67, 137.64, 159.03, 160.39 (Ar). 
11B NMR (300 MHz, CDCl3, 25°C): δ = 6.47 
ESI+: 380, 364, 342, 256.  
HMRS (EI): m/z calcd.  [M+] = 341.1587, found  [M+] = 341.1544  
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Compound 42 
 
 
 
Isolated yield = 17 %  
1H NMR (400 MHz, CDCl3, 25ºC, TMS): , 3.80 (s, 3H, -OCH3), 4.14 (d, 1H, J = 16.9 Hz, -
NCH2-), 4.48 (d, 1H, J = 16.9 Hz, NCH2-), 6.41 – 6.56 (m, 1H, Ar), 7.09 (d, J= 8.0 Hz, 1H, 
Ar), 7.21 (d, J= 11.6 Hz, 4H, Ar), 7.41 (d, J = 8.1 Hz, 1H, Ar);  
13C-RMN (100MHz, CDCl3, 25ºC, TMS):   54.28 (-NCH-), 56.00 (-OCH3), 102.18, 110.68, 
126.21, 129.29, 132.99, 135.10 (Ar), 138.58, 159.95, 161.92 (Ar, quaternary), 169.39 (-
CHCOO-). 
11B NMR (300 MHz, CDCl3, 25°C): δ =  
ESI+: [Mþ1H] , found 364.15 [Mþ1H] . 
HMRS (EI): m/z calcd [Mþ1H] 363.0236, found [Mþ1H]. 
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Compound 43 procedure A 
 
 
 
Isolated yield = 90% 
1H NMR (400 MHz, DMSO, 25 °C, TMS): δ =2.48 (s, 3H, HOBNHNCHCH3C6H4), 7.52–
7.64 (m, 1H)7.73–7.86 (m, 1H)7.78 (d, J = 8.0 Hz, 1H)8.31 (d, J = 7.5 Hz, 1H) 
(HOBNHNCHCH3C6H4), 8.19 (s, 1H, HOBNHNCHCH3C6H4),  
13C NMR (100 MHz, DMSO, 25 °C): δ = 21.45 (HOBNHNCHCH3C6H4),129.14 131.85, 
132.31, 135.22, 142.23 (HOBNC6H5NCHCH3C6H4) 
11B NMR (300 MHz, DMSO, 25°C): δ = 27.05 
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Compound 44  procedure A 
 
 
 
Isolated yield = 80% 
1H NMR (400 MHz, DMSO, 25 °C, TMS): δ = 7.59(s,1H), 7.63 – 7.54 (m, 1H),8.14 (d, J = 
7.5 Hz, 1H) (HOBNC6H5NCHC6H4F), 8.14 (s, 1H, HOBNC6H5NCHC6H4F),8.62 (s, 1H, 
HOBNC6H5NCHC6H4F), 
13C NMR (100 MHz, DMSO, 25 °C): δ = 117.23, 117.45(HOBNC6H5NCHC6F),128.30, 
131.29 (HOBNC6H5NCHC6F), 131.42 (HOBNC6H5NCHC6F), 160, 146.43 
(HOBNC6H5NCHC6F), 
11B NMR (300 MHz, DMSO, 25°C):  δ = 27.2 
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Compound 45 procedure A 
 
 
 
Isolated yield = 83% 
1H NMR (400 MHz, DMSO, 25 °C, TMS): δ = 7. 9 (d, J = 4.7 Hz, 1H) 7.50 (d, J = 4.8 Hz, 
1H) (HOBNC6H5NCHC4SH2), 8.13(s, 1H, HOBNHNCHC4SH2), 8.32 (s, 1H, 
HOBNHNCHC4SH2), 10.18 (s, 1H, HOBNHNCHC4SH2) 
13C NMR (    MHz, DMSO, 2  °C): δ =  4 .   (HOBNHNCHC4SH2), 125.74, 134.25 (1H, 
HOBNC6H5NCHC4SH2) 
11B NMR (3   MHz, DMSO, 2 °C): δ =  27.  
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Compound 46 procedure A 
 
 
 
Isolated yield = 28% 
1H NMR (400 MHz, DMSO, 25 °C, TMS): δ = 7.   (d, J = 4.8 Hz, 1H) 8.02 (d, J = 4.8 Hz, 
1H) (HOBNC6H5NCHC4SH2),8.12 (s, 1H, HOBNHNCHC4SH2),8.32 (s, 1H, 
HOBNHNCHC4SH2),10.18 (s, 1H, HOBNHNCHC4SH2) 
13C NMR (    MHz, DMSO, 2  °C): δ =  44. 7 (HOBNHNCHC4SH2), 125.72, 134.28 
(HOBNC6H5NCHC4SH2) 
11B NMR (3   MHz, DMSO, 2 °C): δ = 27.2  
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Compound 47 procedure B 
 
 
 
Isolated yield = 80% 
1H NMR (400 MHz, DMSO, 25 °C, TMS):δ = 7.24 (t, J = 7.3 Hz, 1H) 7.41 (t, J = 7.8 Hz, 
2H) 7.53 (d, J = 7.7 Hz, 2H) (HOBNC6H5NCHC4SH2), 7.80 (d, J = 4.9 Hz, 1H) 7.89 (d, J = 
4.9 Hz, 1H) (HOBNC6H5NCHC4SH2), 8.38 (s, 1H, HOBNC6H5NCHC4SH2), 8.95 (s, 1H, 
HOBNC6H5NCHC4SH2). 
13C NMR (    MHz, DMSO, 2  °C): δ = 2 .3  (s, HOBNC6H5NCHC4SH2), 125.38, 128.58 
(s, HOBNC6H5NCHC4SH2), 130.32, 130.05, 133.05 (HOBNC6H5NCHC4SH2),  
11B NMR (3   MHz, DMSO, 2 °C):δ = 3 .3  
Experimetnal  Chapter  7 
 
160 
 
Compound 48 procedure B 
 
 
 
Isolated yield = 81% 
1H NMR (400 MHz, DMSO, 25 °C, TMS): δ = 7.24 (t, J = 7.3 Hz, 1H) 7.41 (t, J = 7.8 Hz, 
2H)7.54 (d, J = 7.7 Hz, 2H)(HOBNC6H5NCHC4SH2), 7.81 (d, J = 5.0 Hz, 1H)7.89 (d, J = 
4.9 Hz, 1H) (HOBNC6H5NCHC4SH2), 8.39 (s, 1H, HOBNC6H5NCHC4SH2), 8.93 (s, 1H, 
HOBNC6H5NCHC4SH2),  
13C NMR (    MHz, DMSO, 2  °C): δ =  2 .3 ,  2 .  ,  2 .   (HOBNC6H5NCHC4SH2), 
130.05, 130.34, 133.06 (HOBNC6H5NCHC4SH2) 145.3 (HOBNC6H5NCHC4SH2), 
11B NMR (3   MHz, DMSO, 2 °C): δ = 2 .  
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Compound 49 procedure A 
 
 
 
Isolated yield = 53% 
1H NMR (400 MHz, DMSO, 25 °C, TMS): δ = 3.39 (s, 3H, HOBNSO2C6H4CH3NCHC6H4), 
7.41 (dd, J = 16.0, 8.2 Hz, 2H, HOBNSO2C6H4CH3NCHC6H4), 7.63–7.85 (m, 3H, 
HOBNSO2C6H4CH3NCHC6H4), 7.90 (d, J = 8.1 Hz, 2H, HOBNSO2C6H4CH3NCHC6H4), 
8.13 (s, 1H, HOBNSO2C6H4CH3NCHC6H4), 8.21 (d, J = 6.2 Hz, 1H, 
HOBNSO2C6H4CH3NCHC6H4), 9.02 (s, 1H, HOBNSO2C6H4C6H3NCHC6H4). 
13C NMR (    MHz, DMSO, 2  °C): δ = 2 . 3 (HOBNSO2C6H4CH3NCHC6H4), 128.21 
(HOBNSO2C6H4CH3NCHC6H4), 128.35 (HOBNSO2C6H4CH3NCHC6H4), 130.20 
(HOBNSO2C6H4CH3NCHC6H4), 131.07, 132.26, 133.13 (HOBNSO2C6H4CH3NCHC6H4), 
134.41, 136.34 (HOBNSO2C6H4CH3NCHC6H4), 142.81(HOBNSO2C6H4CH3NCHC6H4), 
144.90 (HOBNSO2C6H4CH3NCHC6H4), 
11B NMR (3   MHz, DMSO, 2 °C): δ = 3 .3  
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Compound 50 procedure A 
 
 
 
Isolated yield = 60% 
1H NMR (400 MHz, DMSO, 25 °C, TMS): δ = 7.43 (t, J = 6.8 Hz, 2H), 7.49 (d, J = 7.5 Hz, 
1H) 7.62 (d, J = 6.7 Hz, 1H) (HOBNCONH2NCHC6H4), 7.79 (s, 1H, 
HOBNCONH2NCHC6H4), 7.83 (s, 1H, HOBNCONH2NCHC6H4) 
13C NMR (    MHz, DMSO, 2  °C): δ =  27.7,  2 .  ,  3 .4 ,  3 ,72 
(HOBNCONH2NCHC6H4), 131.60 (HOBNCONH2NCHC6H4), 145.94 
(HOBNCONH2NCHC6H4) 
11B NMR (3   MHz, DMSO, 2 °C): δ = 3 .37  
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Compound 51 procedure A 
 
 
 
Isolated yield = 68% 
1H NMR (400 MHz, DMSO, 25 °C, TMS): δ =7.25 (t, J = 7.3 Hz, 1H)7.43 (t, J = 7.7 Hz, 
2H)7.63 – 7.53 (m, 3H) (HOBNC6H5NCHC6F), 7.61(s,1H), 7.77 – 7.64 (m, 1H),8.23 (d, J = 
7.5 Hz, 1H) (HOBNC6H5NCHC6H4F), 8.34 (s, 1H, HOBNC6H5NCHC6H4F),9.19 (s, 1H, 
HOBNC6H5NCHC6H4F), 
13C NMR (100 MHz, DMSO, 25 °C): δ =117.34, 117.54 (HOBNC6H5NCHC6F), 125.16, 
125.7, 128.68 (HOBNC6H5NCHC6F), 128.30, 131.29 (HOBNC6H5NCHC6F), 131.42 
(HOBNC6H5NCHC6F), 160, 146.43 (HOBNC6H5NCHC6F), 
11B NMR (300 MHz, DMSO, 25°C):  δ = 27.9 
  
Experimetnal  Chapter  7 
 
164 
 
Compound 52 procedure A 
 
 
 
Isolated yield = 60% 
1H NMR (400 MHz, DMSO, 25 °C, TMS):, δ = 7.23 (t, J = 7.3 Hz, 1H) 7.41 (t, J = 7.9 Hz, 
2H) 7.58 (d, J = 7.5 Hz, 2H) (HOBNC6H5NCHC6H4), 7.63 – 7.72 (m, 1H) 7.74–7.87 (m, 
2H) (HOBNC6H5NCHC6H4), 8.21 (s, 1H, HOBNC6H5NCHC6H4), 8.40 (d, J = 7.6 Hz, 1H, 
HOBNHNCHC6H4), 8.99 (s, 1H, HOBNHNCHC6H4). 
13C NMR (100 MHz, DMSO, 2  °C): δ =  2 .2,  2 .33 (HOBNC6H5NCHC6H4), 127.45 
(HOBNC6H5NCHC6H4), 128.61 (HOBNC6H5NCHC6H4), 129.48 131.91, 132.10 
(HOBNC6H5NCHC6H4), 135.43 (HOBNC6H5NCHC6H4), 139.61 (HOBNC6H5NCHC6H4) 
11B NMR (3   MHz, DMSO, 2 °C): δ = 2 .9    
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Compound 53 procedure A 
 
 
 
Isolated yield = 68% 
1H NMR (400 MHz, DMSO, 25 °C, TMS): δ =6.17 (s, 2H, HOBNC6H5NCHC6H2OCH2O), 
7.21 (t, J = 7.3 Hz, 1H)(HOBNC6H5NCHC6H2OCH2O), 7.33 (s, 1H, 
HOBNC6H5NCHC6H2OCH2O), 7.40 (t, J = 7.9 Hz, 2H)7.54 (d, J = 8.1 Hz, 2H) 
(HOBNC6H5NCHC6H2OCH2O), 7.81 (s, 1H, HOBNC6H5NCHC6H2OCH2O), 8.04 (s, 1H, 
HOBNC6H5NCHC6H2OCH2O), 8.69 (s, 1H, HOBNC6H5NCHC6H2OCH2O) 
13C NMR (100 MHz, DMSO, 25 °C): δ =101.95(HOBNC6H5NCHC6H2OCH2O), 106.26 
109.43 (HOBNC6H5NCHC6H2OCH2O), 124.98, 125.27, 128.57 
(HOBNC6H5NCHC6H2OCH2O), 132.12 (HOBNC6H5NCHC6H2OCH2O), 
138.74(HOBNC6H5NCHC6H2OCH2O), 149.24, 150.96 (HOBNC6H5NCHC6H2OCH2O) 
11B NMR (300 MHz, DMSO, 25°C): δ = 33.5 
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Compound 54 procedure B 
 
 
 
Isolated yield = 77% 
1H NMR (400 MHz, DMSO, 25 °C, TMS): δ =2.51 (s, 3H, HOBNC6H5NCHCH3C6H4), 7.27 
– 7.16 (m, 1H)7.40 (t, J = 7.6 Hz, 2H)7.57 (t, J = 9.0 Hz, 2H)(HOBNC6H5NCHCH3C6H4), 
7.62–7.75 (m, 1H)7.72–7.87 (m, 1H)7.89 (d, J = 8.0 Hz, 1H)8.42 (d, J = 7.5 Hz, 1H) 
(HOBNC6H5NCHCH3C6H4), 8.81(s, 1H, HOBNC6H5NCHCH3C6H4),  
13C NMR (100 MHz, DMSO, 25 °C): δ = 20.48 (HOBNC6H5NCHCH3C6H4), 124.99, 125.81, 
128.56 (HOBNC6H5NCHCH3C6H4), 129.17 131.87, 132.32, 135.24, 143.23 
(HOBNC6H5NCHCH3C6H4) 
11B NMR (300 MHz, DMSO, 25°C): δ = 30.9 
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Compound 55 procedure B 
 
 
 
Isolated yield = 65% 
IR (film):νmax (cm
-1):   
1H NMR (400 MHz, DMSO, 25 °C, TMS): δ =  2.53 (s, 3H, HOBNHNCHCH3C6H4), (s, 1H, 
HOBNHNCHCH3C6H4), (s, 1H, HOBNHNCHCH3C6H4) 
13C NMR (100 MHz, DMSO, 25 °C): δ = (s, 1H, HOBNHNCHCH3C6H4), (s,1H, 
HOBNHNCHCH3C6H4), (s,1H, HOBNHNCHCH3C6H4) 
11B NMR (300 MHz, DMSO, 25°C): δ = 29.2 
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7.3 Mass confirmation and X-ray Crystallography 
analysis of compound 1 
 
Mass Spectrum By Direct Infusion; Full Scan m/z 60-800; ESI+, Positive and negative 
electrospray ionization mode was tested for sample ionization. 
Positive ionization mode (ESI+) analysis presents higher ion signals intensity. 
m/z 298 is attributed to sodium adducts of the molecular ion of the original compound 
([M+Na]+). 
 
 
Figure 92 -  Mass Spectrum of sample nr 226/10 (Full Scan m/z 60-800; ESI+; 
Capillary Potential 3,0kV; Source Potential 40V). 
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Figure 93 -Mass Spectrum of reaction products at T0, T10 and T120 (Full Scan m/z 
60-600; ESI+; Capillary Potential 3,0kV; Source Potential 40V). 
 
 
Figure 94 - List of signal intensities of m/z ions on full scan at T0 (m/z 60-600) mass 
spectrum. 
ESTUDO CINETICO 18FEV2011_T0_1 1 (0.018) Scan ES+ 
No Mass Inten %BPI %TIC No Mass Inten %BPI %TIC No Mass Inten %BPI %TIC No Mass Inten %BPI %TIC No Mass Inten %BPI %TIC No Mass Inten %BPI %TIC
1: 69.65 2.40e7 90.71 5.50
2: 70.85 3.34e6 12.63 0.77
3: 72.49 3.90e6 14.75 0.89
4: 98.67 7.46e6 28.24 1.71
5: 113.77 2.75e6 10.40 0.63
6: 115.78 3.31e6 12.52 0.76
7: 137.87 4.42e6 16.74 1.02
8: 142.84 4.39e6 16.61 1.01
9: 158.95 4.70e6 17.81 1.08
10: 174.93 7.63e6 28.89 1.75
11: 222.94 4.83e6 18.30 1.11
12: 224.01 2.11e7 80.05 4.86
13: 255.03 3.91e6 14.78 0.90
14: 256.04 1.82e7 68.73 4.17
15: 298.01 5.34e6 20.21 1.23
16: 413.20 4.45e6 16.85 1.02
17: 509.26 2.64e7 100.00 6.07
18: 510.33 5.89e6 22.29 1.35
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Figure 95 - List of signal intensities of m/z ions on full scan at T10 (m/z 60-600) mass 
spectrum. 
 
Figure 96 - List of signal intensities of m/z ions on full scan at T120 (m/z 60-600) mass 
spectrum-ray Crystallography. 
ESTUDO CINETICO 18FEV2011_T10_2 1 (0.018) Scan ES+ 
No Mass Inten %BPI %TIC No Mass Inten %BPI %TIC No Mass Inten %BPI %TIC No Mass Inten %BPI %TIC No Mass Inten %BPI %TIC No Mass Inten %BPI %TIC
1: 69.65 2.31e7 97.63 5.51
2: 71.61 3.28e6 13.86 0.78
3: 95.77 2.90e6 12.24 0.69
4: 113.83 9.77e6 41.27 2.33
5: 115.84 2.37e7 100.00 5.64
6: 137.87 1.06e7 44.59 2.52
7: 144.92 3.89e6 16.45 0.93
8: 157.94 3.04e6 12.85 0.72
9: 158.89 8.14e6 34.39 1.94
10: 174.93 5.13e6 21.67 1.22
11: 179.90 1.13e7 47.54 2.68
12: 212.00 3.16e6 13.35 0.75
13: 240.00 2.63e6 11.12 0.63
14: 265.92 2.45e6 10.35 0.58
15: 282.97 4.44e6 18.76 1.06
16: 283.98 2.09e7 88.25 4.98
17: 285.05 3.00e6 12.69 0.72
18: 297.00 2.56e6 10.83 0.61
19: 298.01 1.29e7 54.47 3.07
20: 299.96 3.57e6 15.10 0.85
21: 313.99 7.73e6 32.65 1.84
22: 344.00 1.02e7 43.22 2.44
23: 358.03 6.59e6 27.84 1.57
24: 418.05 2.94e6 12.40 0.70
25: 423.02 2.84e6 12.00 0.68
26: 545.05 4.84e6 20.46 1.15
27: 550.59 2.51e6 10.59 0.60
28: 559.08 3.19e6 13.48 0.76
ESTUDO CINETICO 18FEV2011_T120_2 1 (0.018) Scan ES+ 
No Mass Inten %BPI %TIC No Mass Inten %BPI %TIC No Mass Inten %BPI %TIC No Mass Inten %BPI %TIC No Mass Inten %BPI %TIC No Mass Inten %BPI %TIC
1: 69.65 5.76e6 20.79 1.00
2: 71.61 4.81e6 17.35 0.84
3: 83.69 1.08e7 38.99 1.88
4: 111.82 1.48e7 53.34 2.57
5: 113.83 9.16e6 33.05 1.59
6: 125.85 1.07e7 38.78 1.87
7: 127.93 1.64e7 59.27 2.85
8: 145.99 3.20e6 11.54 0.56
9: 153.92 2.86e6 10.32 0.50
10: 155.93 2.77e7 100.00 4.81
11: 157.94 3.54e6 12.78 0.62
12: 171.91 4.92e6 17.75 0.85
13: 173.99 8.72e6 31.46 1.51
14: 179.97 4.32e6 15.59 0.75
15: 185.94 6.53e6 23.55 1.13
16: 197.96 1.13e7 40.74 1.96
17: 204.00 4.49e6 16.19 0.78
18: 216.02 1.52e7 54.85 2.64
19: 230.05 5.18e6 18.69 0.90
20: 231.00 5.41e6 19.51 0.94
21: 244.02 2.96e6 10.68 0.51
22: 248.05 3.59e6 12.94 0.62
23: 249.06 3.56e6 12.83 0.62
24: 251.07 4.21e6 15.18 0.73
25: 269.06 3.00e6 10.84 0.52
26: 293.10 3.69e6 13.32 0.64
27: 296.94 3.86e6 13.92 0.67
28: 298.01 1.93e7 69.61 3.35
29: 311.03 3.56e6 12.84 0.62
30: 312.98 2.83e6 10.19 0.49
31: 313.99 3.76e6 13.58 0.65
32: 357.15 9.82e6 35.41 1.70
33: 387.09 3.96e6 14.27 0.69
34: 417.10 2.99e6 10.78 0.52
35: 447.11 2.87e6 10.35 0.50
36: 459.13 3.68e6 13.27 0.64
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Crystals of compound 1suitable for X-ray diffraction study were mounted on a loop with 
protective oil. X-ray data were collected at 150K on a Bruker AXS-KAPPA APEX II 
diffractometer using graphite monochromated Mo-Kα radiation (λ= .7   9  ) and 
operating at 50kV and 30 mA. Cell parameters were retrieved using Bruker SMART1  
software and refined using Bruker SAINT2  on all observed reflections. Absorption 
corrections were applied using SADABS3. Structure solution and refinement were 
performed using direct methods with program SIR974  and SHELXL975, both included in 
the package of programs WINGX-Version 1.70.016.  Non-hydrogen atoms were refined 
anisotropically. A full-matrix least-squares refinement was used for the non-hydrogen 
atoms with anisotropic thermal parameters. All hydrogen atoms were inserted in idealized 
positions and allowed to refine riding in the parent carbon atom. 
Crystallographic data for the compound 1: C42H54B3N3O12, fw=825.31, orthorhombic, 
space group P212121, a=9.9490(6) Å, b=19.6140(12) Å, c=21.5700(12) Å, V = 4209.2(4) 
Å3, Z=4, T=150K, ρ calc = 1.302 mg.m-3, μ=  . 94 mm-1, F(000) = 1752, colorless crystal 
(0.18 x 0.12 x 0.10 mm). Of 18706 reflections collected, 7938 were independent (Rint= 
0.0587); 543 variables refined with 7938 reflections to final R indices R (I > 2σ(I))= 
 .  9 , wR2(I > 2σ(I))=  .  77, R (all data)=  . 4 4, wR2(all data)=  . 2  , GOF= .93 . 
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Figure 97 – Molecular diagram for compound 1. Ellipsoids are set at 50% probability. 
 
 
Bond 
Bond distances / Å 
Mol 1 Mol 2 Mol 3 CSD8 range CSD8 average 
B1-O1 1.487(5) 1.480(5) 1.494(4) 1.381 - 1.678 1.477 
B1-O3 1.451(5) 1.421(5) 1.464(4) 1.289 - 1.548 1.460 
B1-N1 1.683(5) 1.686(5) 1.679(5) 1.559 - 1.898 1.644 
O4-C12 1.417(4) 1.435(9) 1.406(5) 1.404 - 1.503 1.439 
O4-C13 1.427(4) 1.402(10) 1.416(5) 1.360 - 1.511 1.432 
Figure 98 – Selected bond distances for compound 1.  
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7.4 DFT calculations 
 
Compound 1 
All calculations were performed using the Gaussian 03 software package,[126] and the 
PBE1PBE functional, without symmetry constraints. That functional uses a hybrid 
generalized gradient approximation (GGA), including 25 % mixture of Hartree-Fock [127] 
exchange with DFT [128] exchange-correlation, given by Perdew, Burke and Ernzerhof 
functional (PBE). [129] The optimized geometries were obtained with a standard 6-31G(d,p)  
basis set. Transition state optimizations were performed with the Synchronous Transit-
Guided Quasi-Newton Method (STQN) developed by Schlegel et al, [130] after a thorough 
search of the Potential Energy Surfaces (PES). Frequency calculations were performed to 
confirm the nature of the stationary points, yielding one imaginary frequency for the 
transition states and none for the minima. Each transition state was further confirmed by 
following its vibrational mode downhill on both sides, and obtaining the minima presented 
on the energy profiles. The energy values reported result from single point calculations 
using a standard 6-311++G(d,p)[131] basis set and the geometries optimized at the 
PBE1PBE/6-31G(d,p) level.   
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Energy profile for the entire mechanism for the formation of compound 
1 
 
 
 
 
 
 
 
Figure 99 - Energy profile for MeOH decoordination, from A to B. The energy values 
(kcal/mol) are referred to A1 and the value in italics correspond to the energy barrier. 
The main transformation is highlighted in red, in the transition state.
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Figure 100 – Energy profile for the formation of intermediate C: the complex between 
proline, boronic acid and glycolaldehyde. The energy values (kcal/mol) are referred to 
B2 and values in italics correspond to energy barriers. The main transformations in 
each step are highlighted in red in the corresponding transition state. 
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Figure 101 - Energy profile for the formation of the iminium ion F. The energy values 
(kcal/mol) are referred to D1 and values in italics correspond to energy barriers. The 
main transformations in each step are highlighted in red in the corresponding 
transition state. 
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Figure 102 - Energy profile for the formation of the enol G. The energy values 
(kcal/mol) are referred to D1 and values in italics correspond to energy barriers. The 
main transformations in each step are highlighted in red in the corresponding 
transition state. 
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Figure 103 – Energy profile for the coordination of enol G. The energy values 
(kcal/mol) are referred to D1 and values in italics correspond to energy barriers. The 
main transformations in each step are highlighted in red in the corresponding 
transition state. 
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Figure 104 - Energy profile for the formation of coordinated adehylde, I, with 
elimination of one water molecule. The energy values (kcal/mol) are referred to D1 
and values in italics correspond to energy barriers. The main transformations in each 
step are highlighted in red in the corresponding transition state. 
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Figure 105– Energy profile for the formation of the two epimers of the product, J and 
J’, by means of nucleophilic attack from methanol. The energy values (kcal/mol) are 
referred to D1 and values in italics correspond to energy barriers. The main 
transformations in each step are highlighted in red in the corresponding transition 
state.
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Atomic coordinates for the optimized species 
 
H2O 
 H    -0.543970    -0.163342    -0.198984 
 O     0.140786     0.430544     0.119861 
 H     0.868184    -0.155002     0.346423 
 
MeOH 
 C    -0.476279    -0.051405     0.070908 
 O     0.555682     0.779749     0.545500 
 H     1.299299     0.217987     0.780535 
 H    -1.314871     0.597757    -0.193321 
 H    -0.831645    -0.767510     0.827108 
 H    -0.191986    -0.615678    -0.830031 
 
B 
 O     1.603782    -0.028904     1.970849 
 N     1.718195     0.060532    -0.332843 
 O     3.511208     1.053340     2.520039 
 C     2.953430     0.639603     0.174958 
 H     3.826503     0.011264    -0.050954 
 C     2.770863     0.616020     1.686588 
 C    -2.623207    -1.169594     2.011230 
 H    -3.203753    -1.068831     2.923838 
 C     1.369063     0.706248    -1.583887 
 H     0.299244     0.612954    -1.784194 
 H     1.916111     0.252553    -2.422117 
 C    -0.543652    -0.827719     0.797351 
 C    -1.132608    -1.434923    -0.322430 
 H    -0.549919    -1.564792    -1.231140 
 C    -1.310794    -0.712891     1.966984 
 H    -0.864811    -0.259812     2.848272 
 C    -3.191409    -1.761051     0.885108 
 H    -4.215936    -2.121286     0.918665 
 B     0.907991    -0.288994     0.771035 
 C    -2.443080    -1.898551    -0.281739 
 H    -2.880924    -2.371299    -1.156357 
 C     3.096439     2.020663    -0.507210 
 H     3.990154     2.031503    -1.136702 
 H     3.207751     2.821688     0.227821 
 C     1.820423     2.156296    -1.357307 
 H     1.043717     2.686282    -0.795818 
 H     1.991119     2.702701    -2.288939 
 
J 
 O     1.257013    -1.905747     0.300396 
 O     1.291281     0.033174     1.805769 
 N     1.417530     0.349918    -0.633080 
 O     3.552423    -1.460020     0.207878 
 O     2.692185     1.670666     2.438458 
 C     2.386920    -1.812264    -0.491533 
 H     2.536290    -2.776837    -1.002565 
 C     2.352386     1.271044     0.096601 
 H     3.387953     1.012878    -0.131784 
 C     2.142132     1.016290     1.587726 
 C    -2.997261     0.333431     1.435292 
 H    -3.531408     1.021117     2.085717 
 C     0.490252     1.213684    -1.425322 
 H    -0.485698     0.728915    -1.488121 
 H     0.906409     1.328879    -2.433546 
 C    -0.886145    -0.586271     0.636244 
 C    -1.622005    -1.444398    -0.193437 
 H    -1.087181    -2.163668    -0.809905 
 C     2.094602    -0.674763    -1.459576 
 H     2.983734    -0.269367    -1.949775 
 H     1.383174    -1.021945    -2.213084 
 C    -1.605038     0.295021     1.455139 
 H    -1.060783     0.942022     2.139522 
 C    -3.704952    -0.517759     0.590660 
 H    -4.791188    -0.491946     0.574122 
 B     0.706243    -0.612591     0.621875 
 C    -3.013492    -1.412741    -0.222684 
 H    -3.560734    -2.091662    -0.871613 
 C     1.965082     2.691870    -0.309350 
 H     2.555411     3.018420    -1.172502 
 H     2.150165     3.385326     0.513761 
 C     3.863985    -2.361939     1.253251 
 H     4.795571    -2.013469     1.701822 
 H     4.009865    -3.379992     0.863697 
 H     3.073786    -2.377891     2.009791 
 C     0.494872     2.544669    -0.696389 
 H    -0.142595     2.486533     0.192573 
 H     0.125314     3.357512    -1.325930 
 
J’ 
 O     1.086307     0.605002     0.313207 
 O    -0.420424    -0.436913     1.939790 
 N    -1.120615     1.592154     0.724585 
 O     2.253732     2.582216     0.126233 
 H     1.442642     1.898059     1.874992 
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 O    -1.503603    -0.064132     3.872927 
 C     1.243354     1.904462     0.784172 
 C    -1.609988     1.591432     2.138620 
 H    -1.134775     2.395820     2.708062 
 C    -1.173739     0.264188     2.759937 
 C    -2.180866    -2.742994    -1.262583 
 H    -2.876288    -3.539817    -1.012270 
 C    -2.320946     1.740269    -0.151319 
 H    -2.147748     1.206771    -1.087844 
 H    -2.465991     2.807070    -0.360401 
 C    -0.774479    -0.884900    -0.549777 
 C    -0.374428    -0.727387    -1.884674 
 H     0.355232     0.042865    -2.124771 
 C    -0.073005     2.595260     0.447435 
 H    -0.254427     3.527365     0.990278 
 H    -0.056047     2.797142    -0.626768 
 C    -1.679417    -1.915263    -0.260773 
 H    -1.973317    -2.085777     0.772588 
 C    -1.781381    -2.556621    -2.583353 
 H    -2.169213    -3.201629    -3.367208 
 B    -0.219735     0.091950     0.575984 
 C    -0.871361    -1.548262    -2.893251 
 H    -0.543698    -1.409004    -3.920221 
 C    -3.130685     1.738678     2.075185 
 H    -3.414981     2.793431     2.154198 
 H    -3.599336     1.195432     2.898494 
 C     3.536986     2.049289     0.389030 
 H     3.771268     2.088869     1.462756 
 H     4.252905     2.667649    -0.155003 
 H     3.611291     1.011852     0.047312 
 C    -3.466287     1.200715     0.685483 
 H    -3.454690     0.105651     0.672592 
 H    -4.438146     1.534207     0.314252 
 
A1 
 O     1.798860     0.324042     2.231839 
 N     1.786530     0.662895    -0.151347 
 C     3.414697    -1.629447    -2.323282 
 C     1.632375    -2.707810     1.617142 
 O     3.513691     1.666611     2.802335 
 O     2.173123    -1.433355    -1.676226 
 C     2.938737     1.364966     0.454925 
 O     1.976612    -1.601551     0.783398 
 H     2.108328    -0.486811    -1.295495 
 H     3.901323     0.941572     0.141695 
 H     3.467084    -2.668965    -2.657111 
 C     2.814040     1.154383     1.966839 
 C    -2.483490    -0.244818     2.227909 
 H     4.267875    -1.435056    -1.658835 
 H    -3.047752     0.089869     3.094412 
 C     0.926702     1.689550    -0.781912 
 H    -0.127519     1.430184    -0.665047 
 H     3.504313    -0.983143    -3.204214 
 H     2.353014    -3.509686     1.444589 
 H     1.140592     1.736532    -1.859181 
 C    -0.354028    -0.441551     1.062005 
 C    -1.030580    -1.098751     0.021253 
 H     0.614906    -3.050261     1.411509 
 H    -0.474793    -1.435493    -0.853615 
 H     1.704650    -2.364122     2.649298 
 C    -1.109390    -0.023389     2.164498 
 H    -0.603970     0.480714     2.984379 
 C    -3.133344    -0.896825     1.183956 
 H    -4.204783    -1.071613     1.231045 
 B     1.213298    -0.176554     0.996256 
 C    -2.402824    -1.324931     0.077323 
 H    -2.904160    -1.834239    -0.741581 
 C     2.816656     2.843539     0.073300 
 H     3.345442     3.035326    -0.866993 
 H     2.055157    -1.804967    -0.218459 
 H     3.249501     3.482991     0.846502 
 C     1.310928     3.009552    -0.119767 
 H     0.810719     3.102415     0.851666 
 H     1.044078     3.882794    -0.721408 
 
TSA1B1 
 O     1.480137     0.559898     2.327123 
 N     1.605510     0.835776     0.007583 
 C     2.895996    -1.489839    -2.498699 
 C     2.270325    -2.825984     1.979318 
 O     3.439499     1.491860     2.955039 
 O     1.851591    -1.535374    -1.552302 
 C     2.868098     1.316858     0.586719 
 O     2.685701    -1.861278     1.042389 
 H     1.820031    -0.682050    -1.068761 
 H     3.713287     0.676088     0.310304 
 H     2.913815    -2.449970    -3.020772 
 C     2.682038     1.159417     2.090306 
 C    -2.740635    -0.611371     2.213717 
 H     3.879984    -1.338390    -2.032705 
 H    -3.345776    -0.572309     3.115004 
 C     1.125440     1.817015    -0.972571 
 H     0.035720     1.781839    -1.044804 
 H     2.741897    -0.701519    -3.249051 
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 H     2.759178    -3.798873     1.822660 
 H     1.537179     1.599358    -1.967919 
 C    -0.635782    -0.178327     1.076318 
 C    -1.187059    -0.720007    -0.096244 
 H     1.181981    -2.980729     1.971470 
 H    -0.575371    -0.802606    -0.991636 
 H     2.549729    -2.462124     2.971355 
 C    -1.432086    -0.143047     2.231928 
 H    -1.011875     0.257422     3.150673 
 C    -3.272713    -1.136734     1.037878 
 H    -4.294104    -1.507209     1.022466 
 B     0.810971     0.367600     1.117238 
 C    -2.493265    -1.197378    -0.115065 
 H    -2.902931    -1.622790    -1.026775 
 C     3.052371     2.763763     0.092415 
 H     3.794546     2.786265    -0.711572 
 H     2.382980    -2.118339     0.155141 
 H     3.411962     3.416304     0.891851 
 C     1.669487     3.146984    -0.447020 
 H     1.026945     3.508831     0.364174 
 H     1.711803     3.925568    -1.213571 
 
B1 
 O     1.335467     0.324655     2.301337 
 N     1.496732     0.782473     0.025764 
 C     2.698630    -1.657274    -2.455684 
 C     3.170434    -2.687295     2.014760 
 O     3.324573     1.117792     3.023710 
 O     1.797721    -1.721721    -1.370489 
 C     2.766743     1.188938     0.645775 
 O     3.354878    -1.823606     0.918804 
 H     1.713284    -0.829722    -0.976889 
 H     3.598527     0.552594     0.326368 
 H     2.756529    -2.655412    -2.896906 
 C     2.567214     0.899271     2.124919 
 C    -3.003514    -0.385133     2.057079 
 H     3.710541    -1.363965    -2.143198 
 H    -3.633129    -0.307479     2.938843 
 C     1.105775     1.793544    -0.958485 
 H     0.022825     1.787544    -1.103029 
 H     2.357439    -0.962754    -3.235904 
 H     3.502363    -3.714019     1.800735 
 H     1.581288     1.590181    -1.927803 
 C    -0.833961    -0.113872     0.995263 
 C    -1.388530    -0.593365    -0.202089 
 H     2.124996    -2.724932     2.352504 
 H    -0.753741    -0.717730    -1.076184 
 H     3.772333    -2.301491     2.841691 
 C    -1.661920    -0.028265     2.125441 
 H    -1.241553     0.322345     3.064299 
 C    -3.537679    -0.849870     0.856943 
 H    -4.584976    -1.134276     0.803143 
 B     0.649428     0.314105     1.087396 
 C    -2.727781    -0.961630    -0.270873 
 H    -3.139858    -1.342181    -1.201090 
 C     2.980412     2.668300     0.263350 
 H     3.785992     2.742786    -0.473072 
 H     2.782414    -2.106684     0.185408 
 H     3.272019     3.268647     1.128703 
 C     1.643683     3.094957    -0.358111 
 H     0.953156     3.446741     0.417055 
 H     1.753850     3.894402    -1.095882 
 
B2 
 O     0.394292     1.252945    -2.024581 
 C    -4.922287     1.777676     1.094416 
 H    -0.937872     0.269830     3.316543 
 O    -4.019892     2.276183     0.123149 
 N     0.113139    -0.560183    -0.615362 
 H    -4.046068     1.678368    -0.637137 
 C    -1.406145     0.522625     2.336438 
 H    -4.893210     2.465356     1.943018 
 O     2.645627     1.442950    -2.003800 
 H    -4.640567     0.778015     1.444854 
 C    -0.844643     1.764834     1.698072 
 H    -5.950446     1.754476     0.711975 
 C     1.534033    -0.248164    -0.632856 
 O    -1.306019     2.055317     0.428878 
 H     1.893225     0.133252     0.334380 
 O    -2.300843    -0.153013     1.884756 
 C     1.644322     0.901880    -1.627126 
 H    -2.283496     2.145545     0.435950 
 C    -3.526566     0.839137    -3.872333 
 H     0.246958     1.637986     1.655937 
 H    -3.712958     1.314685    -4.831073 
 H    -1.008578     2.583057     2.428629 
 C    -0.061333    -1.992957    -0.473680 
 H    -1.030521    -2.306637    -0.867699 
 H    -0.015166    -2.290056     0.583454 
 C    -1.986191     0.283665    -2.069772 
 C    -3.042678    -0.362954    -1.406742 
 H    -2.873129    -0.795174    -0.424375 
 C    -2.255444     0.886957    -3.306872 
 H    -1.453103     1.405430    -3.824651 
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 C    -4.560336     0.187262    -3.205175 
 H    -5.553646     0.148066    -3.643740 
 B    -0.543558     0.343354    -1.488646 
 C    -4.317688    -0.412795    -1.968990 
 H    -5.122576    -0.920162    -1.443294 
 C     2.264215    -1.565088    -0.988016 
 H     2.876372    -1.889118    -0.141711 
 H     2.934355    -1.433864    -1.841294 
 C     1.127007    -2.565038    -1.258737 
 H     0.876531    -2.576349    -2.325078 
 H     1.385182    -3.586500    -0.965411 
 
TSB2B3 
 O     0.296533     1.422741    -1.726736 
 C    -4.813659     1.935342     1.104527 
 H    -0.848292     0.225112     3.285053 
 O    -3.895637     2.271475     0.075256 
 N     0.079953    -0.460032    -0.351661 
 H    -4.039951     1.664808    -0.666223 
 C    -1.378350     0.467670     2.337004 
 H    -4.638430     2.628884     1.929893 
 O     2.539558     1.520458    -1.931274 
 H    -4.666142     0.912465     1.467463 
 C    -0.778360     1.618799     1.574724 
 H    -5.848242     2.061988     0.765629 
 C     1.503595    -0.194089    -0.536734 
 O    -1.289174     1.795711     0.288518 
 H     2.014629     0.106141     0.391022 
 O    -2.371861    -0.133907     2.005678 
 C     1.552760     1.005046    -1.478019 
 H    -2.270327     1.957867     0.302568 
 C    -3.332475     0.603563    -3.898774 
 H     0.302034     1.454918     1.501700 
 H    -3.415125     0.986797    -4.912154 
 H    -0.912999     2.527535     2.186155 
 C    -0.141016    -1.895716    -0.453490 
 H    -1.160049    -2.109406    -0.782988 
 H     0.003511    -2.383761     0.521813 
 C    -2.015039     0.315254    -1.868027 
 C    -3.109586    -0.361684    -1.301094 
 H    -3.041150    -0.720850    -0.276767 
 C    -2.155417     0.793813    -3.177972 
 H    -1.325704     1.330202    -3.630226 
 C    -4.404114    -0.070471    -3.320590 
 H    -5.323237    -0.219959    -3.880365 
 B    -0.651976     0.546902    -1.103844 
 C    -4.291283    -0.553389    -2.016921 
 H    -5.122356    -1.084272    -1.559349 
 C     2.134693    -1.493848    -1.086110 
 H     2.729539    -1.974867    -0.303378 
 H     2.802439    -1.287725    -1.926486 
 C     0.925174    -2.361608    -1.449124 
 H     0.585642    -2.140134    -2.467495 
 H     1.138190    -3.432975    -1.389904 
 
B3 
 O     0.241259     1.454496    -1.741408 
 C    -4.443191     1.813058     1.409639 
 H     0.019810    -0.302782     2.196162 
 O    -3.842727     2.228088     0.178114 
 N    -0.135734    -0.304326    -0.173529 
 H    -4.117680     1.613397    -0.520904 
 C    -0.877421     0.125735     1.699198 
 H    -4.264379     2.613191     2.130862 
 O     2.482229     1.335461    -1.917788 
 H    -3.990898     0.884571     1.773482 
 C    -0.764949     1.610939     1.369942 
 H    -5.524038     1.696747     1.286235 
 C     1.311423    -0.083739    -0.328427 
 O    -1.332533     1.842451     0.074969 
 H     1.762962     0.328484     0.586078 
 O    -1.985041    -0.403861     1.810029 
 C     1.446660     0.976535    -1.420544 
 H    -2.342449     1.996730     0.127699 
 C    -3.248918     0.514074    -4.063220 
 H     0.270469     1.960464     1.345183 
 H    -3.256399     0.819189    -5.106126 
 H    -1.322613     2.208874     2.096712 
 C    -0.398967    -1.736346    -0.394678 
 H    -1.370307    -1.884211    -0.865772 
 H    -0.422014    -2.250856     0.575197 
 C    -2.095796     0.412441    -1.920291 
 C    -3.215738    -0.260592    -1.395827 
 H    -3.200869    -0.583080    -0.353796 
 C    -2.137711     0.788804    -3.267457 
 H    -1.283562     1.310169    -3.690934 
 C    -4.350163    -0.143838    -3.524475 
 H    -5.216959    -0.357944    -4.143458 
 B    -0.829419     0.777843    -1.019787 
 C    -4.331934    -0.534687    -2.186018 
 H    -5.180907    -1.065276    -1.762115 
 C     1.945292    -1.432626    -0.689643 
 H     2.331954    -1.917601     0.212748 
 H     2.777115    -1.298106    -1.385425 
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185 
 
 C     0.765241    -2.220996    -1.253593 
 H     0.590781    -1.951900    -2.302113 
 H     0.906421    -3.304174    -1.203627 
 
TSB3C1 
 O     0.211383     1.433611    -1.779191 
 C    -4.199298     1.991936     1.854353 
 H    -0.106564    -0.296650     2.055806 
 O    -3.893861     1.847802     0.465359 
 N    -0.253559    -0.270268    -0.146069 
 H    -4.021311     0.915634     0.237963 
 C    -0.917790     0.118976     1.407334 
 H    -3.913310     3.005725     2.142485 
 O     2.455545     1.290594    -1.844495 
 H    -3.645378     1.252286     2.440239 
 C    -0.796285     1.638842     1.226644 
 H    -5.276148     1.877819     2.015910 
 C     1.211918    -0.050452    -0.256047 
 O    -1.418942     1.896439    -0.050676 
 H     1.607610     0.390742     0.667058 
 O    -2.096336    -0.336192     1.504109 
 C     1.393821     0.964565    -1.382247 
 H    -2.439452     1.906460     0.100055 
 C    -3.170766     0.531375    -4.243432 
 H     0.222783     2.031440     1.176681 
 H    -3.149152     0.880911    -5.272101 
 H    -1.349238     2.176384     1.998413 
 C    -0.494154    -1.714871    -0.412235 
 H    -1.435167    -1.857081    -0.937401 
 H    -0.569016    -2.223655     0.554819 
 C    -2.118580     0.410348    -2.051061 
 C    -3.212501    -0.357942    -1.614585 
 H    -3.214843    -0.732665    -0.588313 
 C    -2.120478     0.842928    -3.382935 
 H    -1.282957     1.433086    -3.744710 
 C    -4.246340    -0.225843    -3.789004 
 H    -5.064768    -0.470797    -4.460260 
 B    -0.915661     0.819701    -1.092867 
 C    -4.264938    -0.673357    -2.470078 
 H    -5.095820    -1.274993    -2.110908 
 C     1.858782    -1.403940    -0.551473 
 H     2.160988    -1.887210     0.383352 
 H     2.745483    -1.278417    -1.177210 
 C     0.718766    -2.176995    -1.206300 
 H     0.613481    -1.890042    -2.259318 
 H     0.850354    -3.261435    -1.166367 
 
C1 
 O     0.173438     1.653747    -1.616384 
 C    -4.508908     2.015879     2.208331 
 H     0.295176     0.002032     1.979453 
 O    -3.818546     1.157038     1.325313 
 N    -0.277605    -0.188206    -0.061796 
 H    -2.494405     0.103853     1.715449 
 C    -0.580078     0.254781     1.367871 
 H    -5.187784     2.686033     1.667564 
 O     2.370039     1.308853    -1.945769 
 H    -3.828637     2.625937     2.818509 
 C    -0.784626     1.755694     1.182756 
 H    -5.103887     1.391524     2.878595 
 C     1.178278    -0.085813    -0.392751 
 O    -1.593574     1.866719     0.034371 
 H     1.752814     0.207360     0.492328 
 O    -1.665529    -0.404077     1.880383 
 C     1.321287     1.037423    -1.416096 
 H    -3.265402     1.671664     0.703666 
 C    -2.551574     0.059890    -4.455142 
 H     0.175434     2.275004     1.048095 
 H    -2.239091     0.069473    -5.496004 
 H    -1.290696     2.190876     2.049924 
 C    -0.685238    -1.600121    -0.338134 
 H    -1.730219    -1.626033    -0.644167 
 H    -0.575642    -2.176962     0.584827 
 C    -2.052351     0.523513    -2.111578 
 C    -3.341259     0.067032    -1.792947 
 H    -3.682662     0.073982    -0.760306 
 C    -1.683494     0.513528    -3.465002 
 H    -0.703097     0.889543    -3.745783 
 C    -3.820644    -0.396863    -4.112283 
 H    -4.501706    -0.750947    -4.881470 
 B    -1.021784     1.036539    -1.007957 
 C    -4.214851    -0.388819    -2.776896 
 H    -5.207393    -0.734778    -2.500478 
 C     1.608414    -1.452891    -0.928324 
 H     2.037315    -2.057769    -0.122625 
 H     2.366063    -1.334818    -1.706127 
 C     0.291819    -2.059629    -1.405560 
 H     0.001137    -1.651654    -2.379867 
 H     0.321769    -3.148741    -1.488690 
 
D1 
 O     1.516107     1.327275    -1.921637 
 C     1.365368    -1.529982     4.154185 
 H     2.918271    -2.339259    -0.680462 
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 O     1.346128    -0.784139     2.932398 
 N     1.387175    -1.024747    -1.344386 
 C     2.250344    -1.603143    -0.215780 
 H     0.402228    -2.012383     4.347222 
 O     2.723061     1.193003    -3.819657 
 H     1.630904    -0.885143     4.996700 
 C     3.017330    -0.393651     0.296082 
 H     2.129982    -2.299353     4.042009 
 C     2.177871    -0.828181    -2.620740 
 O     1.961043     0.596490     0.379036 
 H     3.210724    -1.164645    -2.486754 
 O     1.470516    -2.206910     0.719639 
 C     2.193780     0.672219    -2.885390 
 H     0.655142    -0.114180     2.982441 
 C    -2.458808     2.260078    -0.668640 
 H     3.797263    -0.056880    -0.392769 
 H    -2.962857     3.085044    -1.162699 
 H     3.422083    -0.557909     1.295297 
 C     0.241988    -1.947109    -1.698702 
 H    -0.611349    -1.726135    -1.061547 
 H     0.572685    -2.971416    -1.506467 
 C    -0.502129     0.829689    -0.448362 
 C    -1.160077     0.150200     0.592049 
 H    -0.677172    -0.692473     1.083340 
 C    -1.177312     1.890584    -1.069219 
 H    -0.689041     2.436674    -1.871623 
 C    -3.091172     1.573541     0.362632 
 H    -4.091336     1.858918     0.674346 
 B     0.952959     0.484660    -0.922169 
 C    -2.440198     0.514177     0.993434 
 H    -2.936564    -0.029797     1.791778 
 C     1.448410    -1.616192    -3.713284 
 H     1.883865    -2.615269    -3.808469 
 H     1.544881    -1.111310    -4.676746 
 C     0.022518    -1.700213    -3.178512 
 H    -0.519124    -0.760547    -3.336839 
 H    -0.560606    -2.502095    -3.635940 
 H     1.364077    -1.653023     1.537086 
 H     2.285741     1.501235     0.508016 
 
TSD1E1 
 O     1.346334     1.138780    -0.832214 
 C     1.049098     0.788757     3.334745 
 H     1.626670    -3.101193    -0.440935 
 O     1.970174     0.023452     2.558919 
 N     1.275520    -1.190258    -1.301122 
 C     1.820301    -2.071950    -0.118375 
 H     0.404460     1.411344     2.704862 
 O     3.203106     1.709220    -1.991709 
 H     1.581330     1.417943     4.053882 
 C     3.314127    -1.911185     0.100037 
 H     0.431217     0.076733     3.882702 
 C     2.280649    -0.525160    -2.216662 
 O     3.595408    -0.546547     0.313936 
 H     3.254385    -1.005104    -2.160024 
 O     1.059521    -1.793003     0.974761 
 C     2.399221     0.890455    -1.687751 
 H     2.562669     0.604889     2.070217 
 C    -2.787760     1.718392     0.096863 
 H     3.874798    -2.323540    -0.750354 
 H    -3.205314     2.716728     0.012825 
 H     3.551061    -2.526801     0.978355 
 C     0.351308    -1.961333    -2.208106 
 H    -0.587144    -2.159276    -1.690219 
 H     0.842162    -2.909098    -2.452693 
 C    -0.906728     0.193184    -0.169253 
 C    -1.715829    -0.849812     0.323485 
 H    -1.291600    -1.837576     0.470399 
 C    -1.467834     1.484542    -0.266005 
 H    -0.859821     2.306300    -0.633721 
 C    -3.571454     0.668544     0.569826 
 H    -4.603548     0.849448     0.855258 
 B     0.535109     0.052152    -0.654658 
 C    -3.033133    -0.613268     0.687512 
 H    -3.642323    -1.424250     1.074089 
 C     1.684592    -0.608884    -3.639327 
 H     2.243411    -1.349421    -4.217377 
 H     1.768277     0.345288    -4.163941 
 C     0.241088    -1.069984    -3.428802 
 H    -0.427928    -0.225585    -3.225205 
 H    -0.161640    -1.606756    -4.290093 
 H     1.467997    -1.108616     1.591271 
 H     4.542769    -0.429853     0.445504 
 
E1 
 O     1.210949     1.031491    -0.150982 
 C     2.113244     1.174248     3.028095 
 H     1.052295    -2.938920    -0.097349 
 O     2.466546    -0.162110     2.579638 
 N     1.163559    -1.150695    -1.205518 
 C     1.584647    -1.982288    -0.041218 
 H     1.946018     1.828196     2.170797 
 O     2.944291     1.925410    -1.273669 
 H     2.922096     1.539531     3.659734 
Experimetnal  Chapter  7 
 
187 
 
 C     3.057282    -2.277309     0.162913 
 H     1.204167     1.067078     3.617485 
 C     2.154646    -0.269302    -1.894785 
 O     3.767036    -1.080465     0.437367 
 H     3.158446    -0.692508    -1.868186 
 O     1.003918    -1.164778     0.965280 
 C     2.176605     1.027069    -1.088977 
 H     3.277160    -0.167490     2.032640 
 C    -3.124410     1.276263    -0.574258 
 H     3.438134    -2.779214    -0.736030 
 H    -3.578116     2.182125    -0.964945 
 H     3.137060    -2.985749     0.998612 
 C     0.326932    -1.804506    -2.248204 
 H    -0.631041    -2.093752    -1.810293 
 H     0.851942    -2.693720    -2.616843 
 C    -1.131717    -0.015691    -0.048415 
 C    -1.959971    -1.031928     0.453074 
 H    -1.514935    -1.926366     0.884865 
 C    -1.739834     1.143134    -0.555763 
 H    -1.118492     1.957195    -0.921427 
 C    -3.927703     0.250523    -0.081327 
 H    -5.008585     0.354477    -0.092458 
 B     0.422905    -0.165647    -0.070828 
 C    -3.345011    -0.903918     0.436818 
 H    -3.970622    -1.697386     0.834507 
 C     1.636878    -0.127462    -3.339941 
 H     2.283106    -0.698101    -4.012210 
 H     1.662408     0.913554    -3.668259 
 C     0.226812    -0.724404    -3.310033 
 H    -0.514784     0.019732    -3.002829 
 H    -0.080866    -1.128149    -4.276409 
 H     1.716520    -0.649790     1.851995 
 H     4.710191    -1.229686     0.305238 
 
E2 
 O     1.096370     1.103774    -0.097132 
 C     2.607813     0.136025     3.641897 
 H     1.323621    -2.829791    -0.540219 
 O     2.679405     0.151713     2.201205 
 N     1.156824    -0.918759    -1.416854 
 C     1.776813    -1.841011    -0.424123 
 H     1.603978     0.400198     3.982934 
 O     2.557203     2.350159    -1.272000 
 H     3.343250     0.830308     4.052188 
 C     3.289018    -1.958662    -0.366342 
 H     2.850485    -0.877823     3.958429 
 C     1.993003     0.141779    -2.078433 
 O     3.932271    -0.735930    -0.161289 
 H     3.035878    -0.160695    -2.162418 
 O     1.196794    -1.226574     0.746851 
 C     1.945826     1.335884    -1.134043 
 H     2.473958     1.039799     1.869773 
 C    -3.276793     0.942873    -0.101043 
 H     3.629437    -2.376190    -1.321659 
 H    -3.852215     1.841419    -0.301725 
 H     3.528250    -2.705881     0.402926 
 C     0.296807    -1.536139    -2.468674 
 H    -0.585826    -1.974288    -1.997788 
 H     0.875013    -2.315807    -2.977656 
 C    -1.128166    -0.187145     0.034848 
 C    -1.799448    -1.352710     0.438120 
 H    -1.232855    -2.250098     0.680005 
 C    -1.891521     0.961492    -0.226352 
 H    -1.391918     1.883586    -0.513162 
 C    -3.923388    -0.226446     0.291899 
 H    -5.004398    -0.241033     0.393332 
 B     0.417392    -0.147469    -0.151051 
 C    -3.183852    -1.375174     0.565743 
 H    -3.686913    -2.282725     0.885394 
 C     1.343540     0.371313    -3.455777 
 H     1.980716    -0.064690    -4.229581 
 H     1.247540     1.436961    -3.673681 
 C     0.002002    -0.362591    -3.384398 
 H    -0.775049     0.265250    -2.936263 
 H    -0.353355    -0.689695    -4.363326 
 H     1.849166    -0.733622     1.398130 
 H     4.005028    -0.549887     0.784218 
 
TSE2F1 
 O     0.771004     1.155222    -0.285584 
 C     2.817954     0.463507     3.368551 
 H     0.932409    -2.696414    -0.587710 
 O     2.903336     0.242522     1.948840 
 N     1.387353    -1.040626    -1.686182 
 C     1.617375    -1.846787    -0.589643 
 H     1.987860     1.132442     3.609532 
 O     2.874545     1.901694    -0.451361 
 H     3.756910     0.883642     3.734319 
 C     3.025735    -2.293950    -0.229709 
 H     2.653100    -0.508937     3.832152 
 C     2.183398     0.149199    -1.982334 
 O     3.956333    -1.254610    -0.167275 
 H     3.252318    -0.057666    -2.051349 
 O     1.090725    -1.015895     0.695582 
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188 
 
 C     2.024064     1.156343    -0.848875 
 H     3.056289     1.084190     1.484933 
 C    -3.579035     0.574689    -0.259906 
 H     3.325259    -2.976381    -1.035200 
 H    -4.247239     1.327100    -0.666625 
 H     2.979077    -2.886872     0.693415 
 C     0.399374    -1.341721    -2.736661 
 H    -0.521756    -1.732584    -2.294565 
 H     0.799155    -2.086436    -3.436403 
 C    -1.329657    -0.211136     0.212539 
 C    -1.876862    -1.362559     0.809298 
 H    -1.217533    -2.110011     1.243269 
 C    -2.204950     0.756485    -0.317904 
 H    -1.796988     1.659459    -0.764455 
 C    -4.100217    -0.577501     0.329260 
 H    -5.175970    -0.719087     0.375815 
 B     0.175970    -0.002520     0.136497 
 C    -3.251687    -1.545674     0.865516 
 H    -3.666519    -2.434838     1.329601 
 C     1.598718     0.651983    -3.321126 
 H     2.242330     0.290108    -4.127909 
 H     1.578939     1.742342    -3.384757 
 C     0.211241     0.011399    -3.407414 
 H    -0.526924     0.601210    -2.855217 
 H    -0.136536    -0.082559    -4.438138 
 H     1.844186    -0.552178     1.236390 
 H     4.024618    -0.931895     0.740696 
F1 
 O     0.511643    -0.187255    -0.448949 
 C     3.498537     0.568708     3.443622 
 H     1.660010    -3.515699    -1.562454 
 O     2.925389     0.344955     2.148041 
 N     1.969056    -1.605325    -2.124163 
 C     2.101701    -2.560040    -1.278548 
 H     3.034354     1.432661     3.926264 
 O     2.066066     1.437564    -0.221063 
 H     4.578936     0.719426     3.369254 
 C     2.787257    -2.519510     0.043437 
 H     3.298230    -0.322709     4.038027 
 C     2.383063    -0.189636    -1.927941 
 O     3.604135    -1.420447     0.224388 
 H     3.442694    -0.152714    -1.682683 
 O     0.187192     0.289701     1.907216 
 C     1.636875     0.439460    -0.750818 
 H     3.040451     1.129784     1.589944 
 C    -3.795525    -0.194046    -0.999220 
 H     3.356707    -3.463505     0.106618 
 H    -4.215419    -0.406331    -1.977952 
 H     1.981822    -2.620943     0.793118 
 C     1.250886    -1.767678    -3.416825 
 H     0.414363    -2.456344    -3.285787 
 H     1.961645    -2.192995    -4.133252 
 C    -1.858599     0.085832     0.444522 
 C    -2.727739     0.353083     1.515129 
 H    -2.308829     0.566921     2.494213 
 C    -2.418970    -0.187357    -0.812450 
 H    -1.766396    -0.401837    -1.655616 
 C    -4.639095     0.076258     0.076667 
 H    -5.715750     0.074251    -0.066343 
 B    -0.335580     0.108353     0.692942 
 C    -4.105036     0.350029     1.334300 
 H    -4.764760     0.561271     2.170304 
 C     2.034383     0.476851    -3.266373 
 H     2.894128     0.406028    -3.939741 
 H     1.803750     1.535384    -3.132842 
 C     0.861943    -0.347146    -3.794274 
 H    -0.070650    -0.061231    -3.299628 
 H     0.722206    -0.243839    -4.871769 
 H     1.158891     0.309366     1.999663 
 H     3.393739    -0.934601     1.050928 
 
F2 
 O    -0.200433     0.592466     0.268083 
 C    -1.102597     4.505923    -0.360952 
 C     2.991498     0.758042     3.939594 
 H     0.798072    -2.423596    -1.568854 
 O    -1.259174     3.171733    -0.812967 
 O     2.256634     0.731477     2.709748 
 N     1.088370    -0.441512    -1.777603 
 C     1.261370    -1.536801    -1.134956 
 H     2.630165     1.559990     4.588940 
 H    -1.243838     4.594381     0.723050 
 O     1.332444     2.217495     0.626509 
 H     4.061065     0.886940     3.751425 
 H    -1.790469     5.195410    -0.866076 
 C     2.021238    -1.749522     0.129718 
 H    -0.079147     4.809388    -0.592468 
 H     2.825329    -0.200627     4.431234 
 C     1.529431     0.913017    -1.348190 
 O     2.851178    -0.704509     0.486896 
 H     2.601055     0.895308    -1.158171 
 O    -0.496514     0.875223     2.657577 
 C     0.866826     1.316238    -0.031379 
 H     2.338982     1.581825     2.247824 
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 H    -2.126975     2.858529    -0.533142 
 C    -4.525923     0.686732    -0.215266 
 H     2.595474    -2.678861    -0.029982 
 H    -4.967253     0.499312    -1.189722 
 H     1.260736    -2.010505     0.886830 
 C     0.302491    -0.361524    -3.039100 
 H    -0.540669    -1.052935    -2.985631 
 H     0.967493    -0.666071    -3.854232 
 C    -2.557043     0.861120     1.207488 
 C    -3.400810     1.151204     2.291659 
 H    -2.961011     1.327904     3.268988 
 C    -3.146621     0.627109    -0.046288 
 H    -2.513727     0.382297    -0.896446 
 C    -5.342720     0.983659     0.874306 
 H    -6.420041     1.032359     0.745951 
 B    -1.024412     0.811802     1.434121 
 C    -4.779642     1.214487     2.127833 
 H    -5.418293     1.443180     2.975612 
 C     1.129946     1.816582    -2.522137 
 H     1.963278     1.879181    -3.228576 
 H     0.885935     2.821379    -2.176835 
 C    -0.070910     1.108103    -3.141272 
 H    -0.968826     1.334397    -2.560973 
 H    -0.247313     1.402232    -4.177516 
 H     0.475912     0.817317     2.729976 
 H     2.647237    -0.360082     1.382571 
 
TSF2F3 
 O    -0.151464     0.722699     0.179527 
 C    -0.876650     4.543425     0.299569 
 C     2.949180     0.880395     3.877472 
 H     0.558557    -2.449097    -1.462701 
 O    -1.191087     3.286751    -0.282273 
 O     2.250536     0.904987     2.628128 
 N     1.011608    -0.516978    -1.809480 
 C     1.094897    -1.575323    -1.091229 
 H     2.751857     1.789994     4.451453 
 H    -1.263989     4.629421     1.321832 
 O     1.501408     2.259675     0.414027 
 H     4.026506     0.767773     3.723690 
 H    -1.261864     5.376906    -0.300154 
 C     1.828565    -1.759172     0.192631 
 H     0.211688     4.608909     0.338309 
 H     2.573992     0.021852     4.434869 
 C     1.561386     0.822810    -1.469011 
 O     2.708930    -0.742675     0.509021 
 H     2.636243     0.745045    -1.315748 
 O    -0.505855     1.482655     2.460316 
 C     0.961244     1.347019    -0.166648 
 H     2.514544     1.681426     2.111381 
 H    -2.148034     3.175780    -0.263392 
 C    -4.466730     0.384858    -0.309760 
 H     2.352170    -2.726326     0.094132 
 H    -4.881543     0.070342    -1.263058 
 H     1.042589    -1.934969     0.948003 
 C     0.206042    -0.447549    -3.057516 
 H    -0.666902    -1.096171    -2.964397 
 H     0.838524    -0.807134    -3.876285 
 C    -2.535963     0.945687     1.064219 
 C    -3.407529     1.186307     2.138233 
 H    -2.992668     1.494856     3.093657 
 C    -3.093089     0.540479    -0.158823 
 H    -2.437156     0.338186    -1.002692 
 C    -5.312637     0.632903     0.769493 
 H    -6.386013     0.512505     0.655897 
 B    -1.007649     1.139110     1.269198 
 C    -4.781860     1.032799     1.994057 
 H    -5.441648     1.223308     2.835183 
 C     1.168467     1.695764    -2.669481 
 H     1.968251     1.672423    -3.415937 
 H     1.015076     2.731923    -2.363686 
 C    -0.100072     1.034687    -3.201625 
 H    -0.959215     1.317743    -2.586785 
 H    -0.315152     1.298908    -4.238567 
 H     0.460906     1.418087     2.549471 
 H     2.507401    -0.332804     1.377681 
 
F3 
 O    -0.285501     1.210406    -0.290841 
 C    -0.531252     4.201348     1.587876 
 C     3.098813     1.630740     3.529607 
 H    -0.054938    -2.310501    -0.973114 
 O    -1.234742     3.305169     0.702415 
 O     2.307469     1.391553     2.364580 
 N     0.832720    -0.659553    -1.711940 
 C     0.629359    -1.490504    -0.755919 
 H     2.930107     2.640046     3.916579 
 H    -0.701274     3.915486     2.627654 
 O     1.605319     2.425048    -0.053093 
 H     4.163522     1.491760     3.319103 
 H    -0.877744     5.217440     1.395670 
 C     1.210545    -1.450659     0.614076 
 H     0.521339     4.111295     1.328103 
 H     2.785654     0.906935     4.282372 
Experimetnal  Chapter  7 
 
190 
 
 C     1.585726     0.620831    -1.614223 
 O     2.380083    -0.714005     0.691778 
 H     2.606738     0.416772    -1.297561 
 O    -0.499304     1.346265     2.145692 
 C     0.952139     1.522299    -0.546153 
 H     2.519722     2.028191     1.664030 
 H    -2.189807     3.453074     0.765017 
 C    -4.614062     0.888300    -0.589267 
 H     1.369129    -2.502247     0.906502 
 H    -5.135436     1.022225    -1.532963 
 H     0.398221    -1.075017     1.264652 
 C     0.171734    -0.778792    -3.035918 
 H    -0.813513    -1.231902    -2.913697 
 H     0.796179    -1.428769    -3.658237 
 C    -2.589805     1.124053     0.748692 
 C    -3.277995     0.555938     1.829291 
 H    -2.755883     0.429695     2.774080 
 C    -3.284500     1.281464    -0.461118 
 H    -2.777074     1.719017    -1.320343 
 C    -5.275401     0.321221     0.497506 
 H    -6.312249     0.012243     0.402024 
 B    -1.085263     1.600771     0.921145 
 C    -4.605107     0.154187     1.707143 
 H    -5.120320    -0.286238     2.555996 
 C     1.476405     1.212021    -3.025655 
 H     2.319329     0.867022    -3.632523 
 H     1.510142     2.302848    -3.000406 
 C     0.159501     0.648801    -3.557782 
H    -0.693847     1.192341    -3.142207 
 H     0.091758     0.679139    -4.646675 
 H     0.455340     1.494282     2.238022 
 H     2.353825    -0.081837     1.442230 
 
TSF3G1 
 O    -0.219548     1.728819    -0.537888 
 C    -0.159738     4.016603     1.751692 
 C     2.815711     1.981947     3.666811 
 H    -0.465308    -1.964337    -0.630594 
 O    -1.159219     3.065985     1.305911 
 O     2.225421     1.478353     2.466486 
 N     0.618752    -0.561512    -1.651716 
 C     0.395780    -1.303231    -0.562651 
 H     2.591231     3.044399     3.806926 
 H     0.094736     3.827896     2.796660 
 O     1.892982     2.336392    -0.084974 
 H     3.899201     1.838565     3.650758 
 H    -0.568673     5.018549     1.624014 
 C     1.056939    -1.277734     0.651624 
 H     0.700983     3.865180     1.101001 
 H     2.394326     1.412820     4.495838 
 C     1.529470     0.581111    -1.700955 
 O     2.330661    -0.731864     0.708405 
 H     2.546523     0.295549    -1.432856 
 O    -0.172603     0.835642     1.726749 
 C     1.099463     1.639983    -0.689216 
 H     2.568299     1.940652     1.682992 
 H    -2.009085     3.134579     1.763358 
 C    -4.426031     0.762023    -0.812115 
 H     0.855259    -2.118741     1.318641 
 H    -4.960871     0.923396    -1.743458 
 H     0.140497    -0.144153     1.272760 
 C    -0.252108    -0.632218    -2.835560 
 H    -1.293138    -0.778377    -2.532480 
 H     0.052172    -1.480363    -3.460049 
 C    -2.412612     1.028219     0.527429 
 C    -3.058252     0.354705     1.575575 
 H    -2.528239     0.178383     2.509098 
 C    -3.123209     1.225974    -0.666669 
 H    -2.647154     1.751922    -1.490801 
 C    -5.047073     0.091381     0.240242 
 H    -6.064114    -0.272209     0.127620 
 B    -0.948674     1.596730     0.701588 
 C    -4.362877    -0.112004     1.435161 
 H    -4.844155    -0.636485     2.255261 
 C     1.408368     1.068841    -3.153886 
 H     2.134226     0.519547    -3.761232 
 H     1.629488     2.133747    -3.257216 
 C    -0.021445     0.696788    -3.546908 
 H    -0.725001     1.448602    -3.179182 
 H    -0.149052     0.612113    -4.627999 
 H     0.681381     1.225599     2.086909 
 H     2.472107    -0.317566     1.571094 
 
G1 
 O    -0.132779     1.419724    -0.352234 
 C    -0.588604     3.960438     0.923942 
 C     2.136560     2.208483     3.711455 
 H    -0.175608    -2.237604    -1.216640 
 O    -0.663371     2.743089     1.723130 
 O     2.107539     1.229242     2.666096 
 N     0.829876    -0.569497    -1.884960 
 C     0.616879    -1.541317    -0.955148 
 H     1.560579     3.097917     3.440894 
 H    -0.685516     4.805043     1.605522 
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 O     1.932365     2.147999     0.140821 
 H     3.172136     2.482677     3.919902 
 H    -1.385607     3.961726     0.178428 
 C     1.218186    -1.756237     0.237403 
 H     0.394045     3.949308     0.459088 
 H     1.705625     1.742151     4.597426 
 C     1.675627     0.588126    -1.685864 
 O     2.225536    -0.938983     0.737032 
 H     2.701331     0.314229    -1.429786 
 O    -0.034566     0.442555     1.878319 
 C     1.189138     1.461678    -0.537748 
 H     2.464633     1.600131     1.836008 
 H    -1.473454     2.771949     2.258763 
 C    -4.426909     0.977532    -0.390170 
 H     0.957046    -2.634568     0.822406 
 H    -4.974421     1.136859    -1.314416 
 H     0.084367    -0.448199     1.474334 
 C    -0.014771    -0.454262    -3.076874 
 H    -1.062700    -0.658734    -2.832085 
 H     0.303801    -1.176968    -3.839254 
 C    -2.324654     0.984311     0.832226 
 C    -3.023362     0.555912     1.972965 
 H    -2.480503     0.357186     2.895977 
 C    -3.052667     1.190050    -0.348418 
 H    -2.531445     1.509210    -1.247752 
 C    -5.101410     0.556730     0.754015 
 H    -6.173699     0.388725     0.721661 
 B    -0.782879     1.305576     0.918805 
 C    -4.398778     0.344016     1.937132 
 H    -4.920857     0.004496     2.826705 
 C     1.602512     1.317294    -3.038814 
 H     2.365087     0.890781    -3.697386 
 H     1.800027     2.388513    -2.952396 
 C     0.200657     0.982539    -3.546617 
 H    -0.538171     1.645783    -3.086354 
 H     0.112333     1.082652    -4.630445 
 H     0.958651     0.803509     2.280511 
 H     3.009988    -1.472574     0.906594 
 
G2 
 O    -0.151015     1.207258    -0.262520 
 C    -0.619002     3.887609     0.688387 
 C     2.124421     2.693684     3.835321 
 H    -0.341083    -2.304316    -2.055952 
 O    -0.693038     2.785273     1.637483 
 O     2.100891     1.703477     2.806454 
 N     0.694638    -0.528638    -2.141072 
 C     0.293932    -1.645886    -1.469305 
 H     1.439433     3.519257     3.615671 
 H    -0.743918     4.813013     1.250112 
 O     1.915278     1.992068     0.144544 
 H     3.139285     3.078602     3.957730 
 H    -1.397806     3.778624    -0.068384 
 C     0.525046    -2.062269    -0.214417 
 H     0.373478     3.836307     0.247576 
 H     1.818448     2.203890     4.760081 
 C     1.648635     0.441278    -1.663876 
 O     1.241287    -1.299274     0.726095 
 H     2.562997    -0.031869    -1.286078 
 O     0.076854     0.542097     2.065731 
 C     1.154924     1.289872    -0.500809 
 H     2.372016     2.077384     1.948598 
 H    -1.525546     2.857467     2.134018 
 C    -4.424174     0.638554    -0.067650 
 H     0.094652    -2.983005     0.159063 
 H    -5.010339     0.664486    -0.981530 
 H     0.449283    -0.310204     1.664501 
 C     0.243227    -0.254045    -3.504184 
 H    -0.839212    -0.392717    -3.591015 
 H     0.731495    -0.926675    -4.224066 
 C    -2.280339     0.851339     1.057729 
 C    -2.921528     0.552621     2.271043 
 H    -2.337257     0.483594     3.187316 
 C    -3.056391     0.887907    -0.109502 
 H    -2.575012     1.098062    -1.061302 
 C    -5.042820     0.350342     1.147168 
 H    -6.110272     0.153792     1.179813 
 B    -0.753289     1.236009     1.039357 
 C    -4.290629     0.304937     2.318045 
 H    -4.768924     0.066785     3.263406 
 C     1.955588     1.296198    -2.909391 
 H     2.790248     0.839630    -3.449519 
 H     2.244868     2.317369    -2.651775 
 C     0.669613     1.191806    -3.726982 
 H    -0.092096     1.873055    -3.332044 
 H     0.818108     1.427015    -4.782901 
 H     0.914050     1.086255     2.449728 
 H     1.958788    -1.828815     1.093505 
 
TSG2G3 
 O    -0.093731     0.902255    -0.193780 
 C    -0.698456     3.864402     0.815536 
 C     1.920908     2.805845     3.636702 
 H     0.068296    -2.557274    -2.093971 
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 O    -0.600062     2.847763     1.816474 
 O     1.886576     1.665701     2.745876 
 N     0.864141    -0.655936    -2.165822 
 C     0.632623    -1.833876    -1.512335 
 H     1.081735     3.466928     3.422922 
 H    -0.893494     4.838757     1.273102 
 O     1.952540     1.730707     0.281696 
 H     2.875283     3.305009     3.476471 
 H    -1.490959     3.632945     0.096391 
 C     0.965031    -2.227875    -0.272930 
 H     0.262607     3.896983     0.301684 
 H     1.872728     2.418411     4.653379 
 C     1.713964     0.401541    -1.685667 
 O     1.601232    -1.383094     0.649494 
 H     2.713387     0.042345    -1.413221 
 O    -0.007814     0.179859     2.098497 
 C     1.195325     1.066651    -0.424149 
 H     1.959351     1.879798     1.731912 
 H    -1.456742     2.794149     2.261184 
 C    -4.430854     1.204211    -0.025492 
 H     0.685030    -3.207056     0.096339 
 H    -4.992576     1.505967    -0.904429 
 H     0.588287    -0.519500     1.723480 
 C     0.294001    -0.374477    -3.481540 
 H    -0.759601    -0.668363    -3.518538 
 H     0.829408    -0.923525    -4.269519 
 C    -2.299995     0.770632     1.061888 
 C    -2.997839     0.403405     2.224786 
 H    -2.440367     0.067456     3.095756 
 C    -3.041859     1.167393    -0.062987 
 H    -2.521787     1.430561    -0.980947 
 C    -5.103498     0.845541     1.141532 
 H    -6.188764     0.872025     1.170802 
 B    -0.750702     0.744469     1.053681 
 C    -4.387324     0.443176     2.266926 
 H    -4.913806     0.151989     3.170806 
 C     1.793681     1.381873    -2.874626 
 H     2.653009     1.104100    -3.491825 
 H     1.935649     2.417712    -2.557745 
 C     0.488466     1.129671    -3.628214 
 H    -0.339727     1.664178    -3.150753 
 H     0.538050     1.446728    -4.672014 
 H     1.012068     1.127614     2.735655 
 H     2.404376    -1.808581     0.971733 
 
G3 
 O    -0.147465     0.701167    -0.223225 
 C    -0.685224     3.986751     0.874811 
 C     1.869730     2.786740     3.589967 
 H     0.501584    -2.730678    -2.178350 
 O    -0.646470     2.989039     1.887308 
 O     1.718857     1.601035     2.767139 
 N     1.005425    -0.728891    -2.204404 
 C     0.939390    -1.941393    -1.573918 
 H     1.016220     3.445594     3.435605 
 H    -1.064642     4.939116     1.261086 
 O     1.829849     1.631023     0.346802 
 H     2.803004     3.256183     3.283499 
 H    -1.304547     3.674138     0.025839 
 C     1.303275    -2.298497    -0.332434 
 H     0.339337     4.133450     0.527385 
 H     1.944982     2.454210     4.624493 
 C     1.710580     0.422118    -1.705303 
 O     1.779408    -1.377147     0.611014 
 H     2.757031     0.200400    -1.464818 
 O    -0.121708    -0.098763     2.029671 
 C     1.126689     0.961316    -0.415206 
 H     1.732882     1.746521     1.696761 
 H    -1.556094     2.805635     2.152774 
 C    -4.421494     1.487496     0.045829 
 H     1.172094    -3.314522     0.019803 
 H    -4.954372     1.907073    -0.802037 
 H     0.618675    -0.651515     1.678414 
 C     0.389095    -0.498310    -3.509058 
 H    -0.609226    -0.944410    -3.549460 
 H     0.993431    -0.938664    -4.315248 
 C    -2.348489     0.717548     1.056417 
 C    -3.066677     0.386389     2.218645 
 H    -2.541778    -0.062143     3.058049 
 C    -3.051278     1.268398    -0.028918 
 H    -2.517561     1.511378    -0.944432 
 C    -5.112976     1.161557     1.211667 
 H    -6.183979     1.331545     1.270576 
 B    -0.826716     0.471694     1.000280 
 C    -4.436474     0.610264     2.298349 
 H    -4.980147     0.347640     3.200682 
 C     1.618759     1.443289    -2.861021 
 H     2.501642     1.321712    -3.495218 
 H     1.605321     2.478320    -2.510858 
 C     0.355789     1.021267    -3.610119 
 H    -0.536332     1.409991    -3.108216 
 H     0.344299     1.373878    -4.643605 
 H     0.863388     1.120462     2.893246 
 H     2.635710    -1.670211     0.943937 
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G4 
 O     1.519880     0.538547     0.243104 
 C     4.279173     2.970239     2.274275 
 H     0.356381    -3.213584    -1.822483 
 O     3.905827     1.594325     2.455836 
 N     1.396001    -1.384316    -1.700710 
 C     0.919262    -2.570099    -1.153347 
 H     3.541668     3.508165     1.671710 
 O     3.725298     0.165518     0.542907 
 H     5.244614     2.970803     1.769634 
 C     1.073330    -2.959975     0.116101 
 H     4.384667     3.442018     3.252129 
 C     2.689703    -0.884446    -1.302965 
 O     1.664272    -2.132589     1.052821 
 H     3.406339    -1.686279    -1.077067 
 O     1.435823     0.620303     2.617076 
 C     2.647675    -0.040211    -0.054297 
 H     3.795251     0.875735     1.436451 
 C    -2.778053     0.578839    -0.058296 
 H     0.687695    -3.908994     0.470666 
 H    -3.262055     0.309112    -0.991860 
 H     0.832539     0.537052     3.364546 
 C     1.112394    -1.066095    -3.097231 
 H     0.036602    -0.935715    -3.248507 
 H     1.457514    -1.863133    -3.775297 
 C    -0.764423     0.791945     1.281459 
 C    -1.552362     1.265550     2.344819 
 H    -1.091802     1.563605     3.286291 
 C    -1.401184     0.454163     0.075410 
 H    -0.801602     0.078768    -0.749137 
 C    -3.539952     1.050427     1.008866 
 H    -4.616077     1.150782     0.902986 
 B     0.755331     0.629729     1.426984 
 C    -2.927717     1.397427     2.212334 
 H    -3.523275     1.772515     3.038564 
 C     3.179583    -0.047003    -2.516869 
 H     3.874121    -0.664896    -3.092574 
 H     3.715956     0.859822    -2.226369 
 C     1.902948     0.213956    -3.314487 
 H     1.355636     1.068318    -2.903385 
 H     2.105061     0.412419    -4.369096 
 H     3.030252     1.499631     2.875887 
 H     2.088811    -2.670174     1.729021 
 
TSG4G5 
 O     1.678514     0.642470     0.267004 
 C     3.682188     3.233788     2.056477 
 H    -0.183854    -2.572430    -1.826713 
 O     3.834373     1.805658     2.211705 
 N     1.380834    -1.191065    -1.765649 
 C     0.524228    -2.086674    -1.161639 
 H     2.807865     3.466712     1.443994 
 O     3.903490     0.477084     0.212049 
 H     4.590749     3.598374     1.579787 
 C     0.436472    -2.397045     0.137097 
 H     3.587660     3.675087     3.048212 
 C     2.712954    -0.952126    -1.263002 
 O     1.206551    -1.736168     1.092943 
 H     3.138010    -1.846527    -0.781665 
 O     1.687536     0.396199     2.621848 
 C     2.788139     0.110359    -0.183482 
 H     3.923492     1.243387     1.236323 
 C    -2.635969     0.874030     0.116542 
 H    -0.296932    -3.099659     0.510106 
 H    -3.129813     0.995331    -0.842792 
 H     1.138890     0.359442     3.412466 
 C     1.301819    -0.970504    -3.210496 
 H     0.340833    -0.521346    -3.478586 
 H     1.403734    -1.917315    -3.762523 
 C    -0.600524     0.539595     1.403557 
 C    -1.374545     0.573489     2.574235 
 H    -0.913098     0.461210     3.556124 
 C    -1.259188     0.690951     0.173480 
 H    -0.677059     0.668051    -0.743230 
 C    -3.382613     0.902720     1.291640 
 H    -4.458230     1.045528     1.248859 
 B     0.933487     0.343367     1.444268 
 C    -2.751199     0.751485     2.524665 
 H    -3.331904     0.776285     3.441462 
 C     3.539511    -0.575734    -2.512038 
 H     4.001905    -1.484761    -2.906730 
 H     4.338060     0.132722    -2.284994 
 C     2.483599    -0.052528    -3.483282 
 H     2.219527     0.984673    -3.249262 
 H     2.811847    -0.090982    -4.523788 
 H     3.022828     1.385259     2.607501 
 H     1.289934    -2.280188     1.883428 
 
G5 
 O     1.703351     0.616599     0.207243 
 C     3.140385     3.269363     1.982349 
 H    -0.235294    -2.442364    -1.834427 
 O     3.602724     1.899806     2.046690 
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 N     1.488269    -1.300073    -1.828079 
 C     0.521112    -2.008262    -1.185523 
 H     2.239215     3.339393     1.369420 
 O     3.895229     0.745851    -0.089561 
 H     3.947648     3.859869     1.552100 
 C     0.342501    -2.230709     0.124124 
 H     2.945806     3.601856     3.001203 
 C     2.792184    -1.009744    -1.268465 
 O     1.169063    -1.569443     1.073242 
 H     3.151516    -1.846275    -0.649179 
 O     1.755826     0.224795     2.563717 
 C     2.820002     0.189836    -0.331665 
 H     3.812214     1.500375     1.074126 
 C    -2.508521     1.520183     0.474410 
 H    -0.510576    -2.745534     0.539076 
 H    -2.973958     2.082049    -0.330002 
 H     1.171025     0.431067     3.302209 
 C     1.473333    -1.162280    -3.288778 
 H     0.553880    -0.669721    -3.618037 
 H     1.530381    -2.148337    -3.771075 
 C    -0.542059     0.444753     1.415111 
 C    -1.315435     0.087292     2.530562 
 H    -0.876547    -0.489444     3.346960 
 C    -1.166384     1.162914     0.388043 
 H    -0.590006     1.446782    -0.488553 
 C    -3.255996     1.157843     1.591987 
 H    -4.303454     1.435695     1.659977 
 B     0.980378     0.057034     1.347531 
 C    -2.658776     0.436655     2.622911 
 H    -3.239219     0.147929     3.493970 
 C     3.695919    -0.824004    -2.498618 
 H     4.116264    -1.795133    -2.775181 
 H     4.522063    -0.140605    -2.298297 
 C     2.722768    -0.340309    -3.571687 
 H     2.511573     0.727494    -3.447048 
 H     3.099350    -0.492127    -4.584911 
 H     2.871160     1.273497     2.391407 
 H     1.315186    -2.086363     1.876613 
 
TSG5H1 
 O     1.999795     0.907238     0.137131 
 C     4.360355     2.981134     2.927049 
 H     1.019966    -3.478462    -0.793599 
 O     3.689439     1.921119     2.255776 
 N     1.383450    -1.349281    -1.054200 
 C     1.232990    -2.529296    -0.305676 
 H     4.063103     3.961729     2.538792 
 O     4.123122     0.935762    -0.500055 
 H     5.445228     2.870281     2.839067 
 C     1.320636    -2.433193     1.013365 
 H     4.089970     2.920398     3.982494 
 C     2.751752    -0.872586    -1.330508 
 O     1.553892    -1.127448     1.490175 
 H     3.505973    -1.614857    -1.050353 
 O     1.365080     0.913416     2.613422 
 C     3.052519     0.388378    -0.527738 
 H     3.947535     1.896299     1.320108 
 C    -2.333284     1.633186    -0.383231 
 H     1.282900    -3.200384     1.772535 
 H    -2.676055     2.426509    -1.040394 
 H     0.667970     1.530705     2.860910 
 C     0.556207    -1.240220    -2.272894 
 H    -0.453236    -0.916764    -2.005451 
 H     0.489424    -2.220438    -2.766484 
 C    -0.506670     0.371803     0.610661 
 C    -1.452999    -0.392142     1.311721 
 H    -1.132867    -1.188669     1.980191 
 C    -0.971847     1.390742    -0.237367 
 H    -0.256458     2.003267    -0.780366 
 C    -3.255531     0.860710     0.318983 
 H    -4.318899     1.049666     0.207493 
 B     1.016063     0.147738     0.739399 
 C    -2.814627    -0.152494     1.167792 
 H    -3.533184    -0.753070     1.716931 
 C     2.771989    -0.572629    -2.839703 
 H     3.081648    -1.474307    -3.376830 
 H     3.475070     0.225252    -3.087188 
 C     1.311406    -0.243325    -3.140199 
 H     1.073171     0.782118    -2.837732 
 H     1.061235    -0.345575    -4.197992 
 H     2.244792     1.415809     2.535347 
 H     1.471078    -0.940915     2.448517 
 
H1 
 O     1.984689     0.572022     0.559275 
 C     3.346035     3.137290     2.278128 
 H     1.945159    -3.545677    -0.547833 
 O     3.998971     1.848926     2.219423 
 N     1.428235    -1.410419    -0.747760 
 C     1.616413    -2.658660    -0.024235 
 H     2.346179     3.076084     1.843807 
 O     4.076930     0.888083    -0.105635 
 H     3.967040     3.843120     1.728604 
 C     1.342596    -2.507341     1.271284 
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 H     3.297282     3.431205     3.325705 
 C     2.726355    -0.793054    -1.209034 
 O     0.924540    -1.285789     1.656656 
 H     3.534234    -1.525291    -1.144622 
 O     2.702398     0.072475     3.369880 
 C     3.002423     0.303956    -0.208908 
 H     4.105586     1.531021     1.236772 
 C    -1.912549     2.181876    -0.440901 
 H     1.410175    -3.270596     2.038096 
 H    -1.981583     3.192523    -0.832449 
 H     2.476570     0.092074     4.304325 
 C     0.557404    -1.525213    -1.965589 
 H    -0.487581    -1.515018    -1.653635 
 H     0.784296    -2.479833    -2.451649 
 C    -0.548303     0.291051     0.264015 
 C    -1.728319    -0.395567     0.587635 
 H    -1.668318    -1.394500     1.013775 
 C    -0.666925     1.591813    -0.247253 
 H     0.230200     2.160883    -0.483761 
 C    -3.070378     1.475613    -0.125613 
 H    -4.043984     1.932689    -0.275082 
 B     0.853608    -0.393852     0.477090 
 C    -2.977246     0.185690     0.391696 
 H    -3.878363    -0.362610     0.649810 
 C     2.495808    -0.304865    -2.651934 
 H     2.985175    -0.997150    -3.341826 
 H     2.928218     0.684014    -2.821002 
 C     0.975361    -0.347523    -2.825128 
 H     0.504359     0.568648    -2.456418 
 H     0.678930    -0.480285    -3.867680 
 H     3.447864     1.120544     2.733502 
 H     1.980615    -0.372153     2.882367 
 
H2 
 O     1.595875    -0.966552     0.567599 
 C     1.041506     0.468371     3.549273 
 H     2.875014    -2.911146    -2.841601 
 O     0.331938    -0.287274     2.522188 
 N     1.839384    -1.248462    -1.823665 
 C     2.129563    -2.651600    -2.103301 
 H     1.707955    -0.241680     4.034430 
 O     3.240247     0.508084     0.959679 
 H     0.298930     0.832384     4.256832 
 C     1.347049    -3.445178    -1.369888 
 H     1.609445     1.279774     3.093632 
 C     3.012802    -0.491134    -1.247167 
 O     0.473741    -2.828276    -0.559164 
 H     3.898377    -1.133541    -1.256601 
 C     2.672950    -0.229561     0.204577 
 H    -0.388970     0.221503     2.103395 
 C    -1.824131     1.547269    -0.150534 
 H     1.333847    -4.528872    -1.376088 
 H    -1.816217     2.583656     0.175300 
 C     1.393571    -0.480874    -3.042524 
 H     0.317286    -0.610814    -3.165152 
 H     1.906887    -0.911526    -3.907436 
 C    -0.610616    -0.525035    -0.623715 
 C    -1.827799    -1.100471    -1.011587 
 H    -1.843079    -2.140965    -1.323669 
 C    -0.637096     0.816229    -0.191069 
 H     0.287679     1.320663     0.094502 
 C    -3.018790     0.947902    -0.545421 
 H    -3.946000     1.511844    -0.515862 
 B     0.708895    -1.411550    -0.603020 
 C    -3.016575    -0.374418    -0.979242 
 H    -3.945994    -0.846077    -1.283909 
 C     3.195292     0.768999    -2.097012 
 H     3.983873     0.598886    -2.834898 
 H     3.496397     1.617352    -1.478284 
 C     1.841972     0.947093    -2.787095 
 H     1.127005     1.461754    -2.138495 
 H     1.916219     1.517294    -3.715457 
 H     0.967065    -0.625643     1.698352 
 
TSH2I1 
 O     0.861119     0.380392     0.954296 
 C     2.604055    -2.367319     3.319719 
 H     2.121928    -3.075055    -0.653414 
 O     2.400521    -1.512174     2.163959 
 N     1.373912    -1.018134    -0.915879 
 C     1.486398    -2.306768    -0.219678 
 H     3.029024    -1.753674     4.113165 
 O     2.693715     1.699176     0.960708 
 H     3.320062    -3.129671     3.017567 
 C     0.260878    -2.573466     0.374757 
 H     1.661791    -2.817402     3.637646 
 C     2.505798    -0.057668    -0.689263 
 O    -0.536066    -1.579341     0.518223 
 H     3.394934    -0.599891    -0.353685 
 C     2.054126     0.814660     0.475021 
 H     2.031046    -1.992782     1.163584 
 C    -1.787953     2.708656    -1.589851 
 H    -0.027727    -3.528062     0.815440 
 H    -1.722746     3.792055    -1.559083 
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 C     1.211599    -1.148465    -2.402186 
 H     0.183549    -1.439782    -2.626050 
 H     1.895599    -1.931050    -2.748282 
 C    -0.956798     0.535917    -0.876622 
 C    -1.976298    -0.065053    -1.631472 
 H    -2.087623    -1.147896    -1.630054 
 C    -0.888643     1.937528    -0.859538 
 H    -0.138078     2.436577    -0.251129 
 C    -2.779524     2.090369    -2.347110 
 H    -3.484513     2.690996    -2.913936 
 B     0.078404    -0.323548    -0.070978 
 C    -2.877555     0.700825    -2.363039 
 H    -3.662885     0.217323    -2.936191 
 C     2.762964     0.651660    -2.028493 
 H     3.721642     0.319836    -2.434012 
 H     2.821439     1.733675    -1.893632 
 C     1.603609     0.219004    -2.934212 
 H     0.760490     0.907993    -2.848784 
 H     1.895286     0.166637    -3.985185 
 H     1.790022    -0.764674     2.331575 
 
I1 
 O     0.304904     1.615757     0.577052 
 C     4.088542    -3.240782     1.847301 
 H     0.268178    -2.592376    -0.425112 
 O     2.938718    -2.455435     2.155169 
 N     0.936571    -0.559124    -0.344103 
 C     0.540954    -1.827321     0.314185 
 H     5.012637    -2.739185     2.153003 
 O     2.286005     2.234987     1.450807 
 H     4.107232    -3.373625     0.763882 
 C    -0.647818    -1.496174     1.126482 
 H     4.039735    -4.228937     2.317059 
 C     2.129280     0.127301     0.304541 
 O    -1.085116    -0.346389     1.035826 
 H     2.525367    -0.490704     1.116106 
 C     1.608485     1.445404     0.865347 
 H     1.344193    -2.246542     0.949482 
 C    -2.189842     2.434071    -2.846900 
 H    -1.145842    -2.209579     1.789413 
 H    -2.213616     3.444491    -3.243265 
 C     1.294614    -0.745031    -1.801156 
 H     0.380808    -0.717891    -2.396513 
 H     1.778757    -1.722164    -1.901673 
 C    -1.299923     0.827570    -1.254560 
 C    -2.145846    -0.145206    -1.811798 
 H    -2.165023    -1.158855    -1.410714 
 C    -1.343223     2.124513    -1.786754 
 H    -0.717813     2.899666    -1.352367 
 C    -3.012234     1.451739    -3.390959 
 H    -3.676794     1.693774    -4.214758 
 B    -0.310346     0.528803    -0.078769 
 C    -2.992558     0.158621    -2.871114 
 H    -3.643702    -0.604899    -3.285503 
 C     3.146787     0.351880    -0.818519 
 H     3.858761    -0.478764    -0.850537 
 H     3.708633     1.272085    -0.645895 
 C     2.282931     0.368321    -2.077672 
 H     1.759800     1.323938    -2.194113 
 H     2.850631     0.183871    -2.991937 
 H     2.916673    -2.323408     3.108938 
 
I2 
 O    -1.050858    -2.102362     0.767539 
 O    -1.040377    -0.034801     2.035611 
 N    -0.329582    -0.016414    -0.302158 
 O     3.158283    -0.998369    -0.118492 
 O     2.034787    -1.818766     2.211697 
 O     0.832379     0.785300     2.970905 
 C    -0.192314    -2.352368    -0.084548 
 H     0.150319    -3.382111    -0.212598 
 C     0.618588     0.784816     0.572341 
 H     1.645778     0.435394     0.431308 
 C     0.177186     0.517931     1.999637 
 C    -5.162525     0.564168     0.873360 
 H    -5.784223     1.219979     1.475119 
 C    -0.867960     0.941919    -1.332482 
 H    -1.839903     0.585719    -1.677783 
 H    -0.158583     0.968386    -2.166487 
 C    -2.992068    -0.432124     0.419393 
 C    -3.573607    -1.134889    -0.648140 
 H    -2.977298    -1.824513    -1.245628 
 C     0.300924    -1.223575    -0.892912 
 H     1.410138    -1.187335    -0.865075 
 H    -0.007322    -1.365080    -1.937650 
 C    -3.812976     0.414312     1.178486 
 H    -3.391089     0.946821     2.026780 
 C    -5.715982    -0.133999    -0.196056 
 H    -6.769673    -0.020880    -0.432304 
 B    -1.476916    -0.560963     0.790234 
 C    -4.920673    -0.988001    -0.957874 
 H    -5.354140    -1.543660    -1.783745 
 C     0.434518     2.254985     0.155766 
 H     1.256152     2.547741    -0.504068 
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 H     0.454545     2.918365     1.023083 
 C     4.532874    -0.909518    -0.458628 
 C     2.232856    -2.973357     3.025751 
 H     5.086273    -0.284826     0.251807 
 H     1.363421    -3.161847     3.664005 
 H     4.600368    -0.449634    -1.446444 
 H     3.125499    -2.876188     3.652238 
 H     5.004415    -1.898240    -0.505190 
 H     2.371562    -3.824347     2.356096 
 C    -0.893371     2.267501    -0.600866 
 H    -1.748379     2.305449     0.082308 
 H    -0.979630     3.108069    -1.292462 
 H     3.048901    -1.379067     0.774135 
 H     1.938083    -1.050217     2.792589 
 
TSI2J1 
 O    -0.876561    -2.060176     0.563794 
 O    -0.971783    -0.061628     1.957100 
 N    -0.352710     0.126940    -0.398030 
 O     2.977944    -1.321746    -0.109150 
 O     2.087156    -1.675373     2.412540 
 O     0.829419     0.906639     2.890126 
 C    -0.104434    -2.208703    -0.388035 
 H     0.282306    -3.203991    -0.619417 
 C     0.648033     0.845675     0.492449 
 H     1.648670     0.427859     0.342126 
 C     0.204739     0.571537     1.920665 
 C    -5.158037     0.305149     0.959449 
 H    -5.802309     0.877878     1.619437 
 C    -0.966927     1.181608    -1.287570 
 H    -1.983918     0.880805    -1.543767 
 H    -0.356543     1.247172    -2.194238 
 C    -2.942529    -0.512675     0.384160 
 C    -3.509170    -1.180346    -0.713509 
 H    -2.888533    -1.787133    -1.373002 
 C     0.243578    -0.997704    -1.158383 
 H     1.342180    -0.933643    -1.222949 
 H    -0.179262    -1.068173    -2.168733 
 C    -3.793106     0.226111     1.219196 
 H    -3.381107     0.730170     2.089294 
 C    -5.697244    -0.357158    -0.139566 
 H    -6.762770    -0.299753    -0.340108 
 B    -1.410456    -0.552492     0.700577 
 C    -4.871407    -1.103794    -0.978031 
 H    -5.292463    -1.631386    -1.828336 
 C     0.544441     2.331827     0.128941 
 H     1.307943     2.585424    -0.612622 
 H     0.709346     2.958808     1.007669 
 C     4.365756    -1.343290    -0.401772 
 C     2.234554    -2.804235     3.267800 
 H     4.919331    -0.595536     0.178622 
 H     1.369724    -2.914836     3.930080 
 H     4.488142    -1.113354    -1.462427 
 H     3.146210    -2.738447     3.871156 
 H     4.804565    -2.330413    -0.212999 
 H     2.303795    -3.687446     2.630022 
 C    -0.853446     2.454510    -0.474084 
 H    -1.626064     2.483352     0.302089 
 H    -0.973870     3.342035    -1.098577 
 H     2.844557    -1.501477     0.844948 
 H     2.019658    -0.877188     2.953662 
 
J1 
 O    -0.192580    -1.966513    -0.156039 
 O    -0.152355    -0.350689     1.632479 
 N    -0.015105     0.414095    -0.688646 
 O     2.055856    -1.646889     0.125467 
 O     2.055033    -1.778631     2.730432 
 O     1.683171     0.625030     2.404493 
 C     0.974871    -1.760649    -0.827700 
 H     1.200943    -2.605809    -1.490815 
 C     0.823278     1.256089     0.231065 
 H     1.856103     1.304513    -0.120170 
 C     0.814217     0.505410     1.537668 
 C    -4.470792    -0.052271     1.368715 
 H    -5.007820     0.470208     2.154900 
 C    -0.930069     1.355124    -1.410224 
 H    -1.821206     0.808964    -1.725478 
 H    -0.401319     1.740211    -2.289536 
 C    -2.360847    -0.732344     0.361260 
 C    -3.090809    -1.418493    -0.621033 
 H    -2.559761    -1.983336    -1.384073 
 C     0.778373    -0.453382    -1.597265 
 H     1.698617     0.041582    -1.918574 
 H     0.166500    -0.664550    -2.477894 
 C    -3.078933    -0.057330     1.359222 
 H    -2.541425     0.454875     2.154674 
 C    -5.173909    -0.726608     0.373698 
 H    -6.259827    -0.725211     0.379172 
 B    -0.788081    -0.742027     0.322915 
 C    -4.482261    -1.414088    -0.620817 
 H    -5.028518    -1.954257    -1.388429 
 C     0.166642     2.651604     0.272603 
 H     0.784570     3.348670    -0.299168 
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 H     0.095792     3.040186     1.291079 
 C     3.350438    -1.893305    -0.421496 
 C     1.155989    -2.578092     3.547858 
 H     4.064209    -1.824022     0.400156 
 H     0.121360    -2.348054     3.293550 
 H     3.611735    -1.146328    -1.178971 
 H     1.375501    -2.328403     4.584240 
 H     3.399929    -2.893926    -0.865353 
 H     1.391419    -3.623679     3.357091 
 C    -1.194829     2.451497    -0.397850 
 H    -1.949933     2.119666     0.320300 
 H    -1.560966     3.363380    -0.874017 
 H     1.938718    -1.946089     1.744162 
 H     1.894477    -0.732727     2.818944 
 
I3 
 O    -0.932913    -1.157731    -2.036645 
 O    -1.496633     1.117921    -2.717021 
 N    -2.015715     0.345579    -0.462593 
 O     0.756091    -2.785458    -0.111572 
 O    -0.181589    -1.602619     2.181044 
 H    -1.544947    -2.914724    -1.259404 
 O    -3.523767     1.895512    -3.318521 
 C    -1.487922    -1.831469    -1.158013 
 C    -3.269755     0.819437    -1.179237 
 H    -3.951178    -0.019861    -1.344104 
 C    -2.807201     1.342594    -2.539869 
 C     2.661784     1.847347    -2.127563 
 H     3.180731     2.423574    -2.887465 
 C    -1.810201     1.300708     0.699391 
 H    -0.743317     1.475388     0.830732 
 H    -2.209720     0.817092     1.595072 
 C     0.617953     0.788361    -1.334285 
 C     1.318071     0.379897    -0.183272 
 H     0.816574    -0.159567     0.620651 
 C    -2.082127    -1.074467    -0.037152 
 H    -3.103666    -1.398439     0.190174 
 H    -1.469059    -1.254446     0.876068 
 C     1.317117     1.529963    -2.298280 
 H     0.798206     1.861557    -3.192913 
 C     3.338491     1.428980    -0.986184 
 H     4.386534     1.678506    -0.850990 
 B    -0.874408     0.410153    -1.658649 
 C     2.663002     0.698334    -0.010657 
 H     3.180845     0.389456     0.892960 
 C    -3.863347     1.927907    -0.317740 
 H    -4.540159     1.510771     0.434698 
 H    -4.427591     2.625518    -0.940196 
 C    -0.080257    -1.887652     3.567710 
 C     1.286136    -4.050471    -0.512197 
 H    -0.641298    -1.119184     4.102773 
 H     0.610237    -4.818272    -0.131967 
 H     0.960044    -1.853907     3.910329 
 H     2.280208    -4.218170    -0.085914 
 H    -0.506412    -2.866499     3.817818 
 H     1.343475    -4.131811    -1.602741 
 C    -2.623542     2.529731     0.337684 
 H    -2.076690     3.166616    -0.366293 
 H    -2.851173     3.129931     1.220953 
 H     1.350647    -2.088400    -0.424023 
 H     0.320444    -2.251880     1.660498 
 
TSI3J’1 
 O    -1.056725    -1.257067    -1.624251 
 O    -1.576074     0.856795    -2.742478 
 N    -2.134686     0.548031    -0.386065 
 O     1.064641    -3.024351    -0.227680 
 O    -0.301031    -2.138806     1.952030 
 H    -1.691967    -2.820243    -0.523915 
 O    -3.571843     1.571905    -3.504392 
 C    -1.667432    -1.738850    -0.663959 
 C    -3.357907     0.964183    -1.184329 
 H    -4.109521     0.170007    -1.173129 
 C    -2.877899     1.164900    -2.622816 
 C     2.486049     1.985074    -1.973654 
 H     2.976401     2.635337    -2.691589 
 C    -1.868973     1.670004     0.597061 
 H    -0.792164     1.765447     0.739414 
 H    -2.342142     1.395037     1.544641 
 C     0.505179     0.765531    -1.263622 
 C     1.223768     0.313717    -0.141241 
 H     0.753792    -0.331655     0.601856 
 C    -2.263079    -0.767870     0.277324 
 H    -3.290536    -1.013473     0.564547 
 H    -1.630206    -0.844200     1.181834 
 C     1.161410     1.605570    -2.174070 
 H     0.627820     1.957457    -3.052366 
 C     3.180464     1.529418    -0.857562 
 H     4.213234     1.825451    -0.700266 
 B    -0.979212     0.350435    -1.564749 
 C     2.547309     0.693398     0.061367 
 H     3.084601     0.344956     0.938774 
 C    -3.844318     2.272516    -0.565920 
 H    -4.557385     2.073266     0.240256 
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 H    -4.342172     2.884565    -1.320804 
 C     0.048866    -2.484655     3.281675 
 C     1.724211    -4.271243    -0.437600 
 H    -0.666404    -2.002355     3.951395 
 H     1.099363    -5.043870     0.013242 
 H     1.054583    -2.136291     3.546509 
 H     2.709698    -4.294442     0.039889 
 H    -0.004370    -3.567348     3.448073 
 H     1.833736    -4.486965    -1.505327 
 C    -2.555884     2.876536    -0.012652 
 H    -1.944674     3.308839    -0.812661 
 H    -2.731046     3.655915     0.731611 
 H     1.600822    -2.319539    -0.610550 
 H     0.330705    -2.550261     1.330246 
J’1 
 O    -0.894265    -1.431764    -0.118092 
 O    -1.151130    -0.103274    -2.132693 
 N    -1.878342     0.735708     0.018543 
 O     1.120151    -2.764368    -0.379033 
 O    -0.968302    -1.863814     2.190717 
 H    -2.549548    -2.067332     0.912306 
 O    -3.106108    -0.009060    -3.250357 
 C    -1.676543    -1.432021     1.111232 
 C    -3.061086     0.573911    -0.910125 
 H    -3.742075    -0.194099    -0.532333 
 C    -2.469558     0.108566    -2.244986 
 C     2.737988     1.634266    -1.506485 
 H     3.206153     2.172434    -2.325258 
 C    -1.685980     2.227421     0.201922 
 H    -0.617453     2.446856     0.203860 
 H    -2.110090     2.493083     1.174858 
 C     0.802319     0.467967    -0.599487 
 C     1.537529     0.242159     0.579784 
 H     1.086109    -0.300324     1.411138 
 C    -2.007385     0.042404     1.317948 
 H    -2.998043     0.195863     1.753061 
 H    -1.254489     0.450874     1.997446 
 C     1.431406     1.169780    -1.637973 
 H     0.891693     1.340096    -2.565889 
 C     3.446611     1.401495    -0.331064 
 H     4.465968     1.761184    -0.228798 
 B    -0.681870    -0.048183    -0.779087 
 C     2.845392     0.703123     0.714686 
 H     3.393947     0.522555     1.634639 
 C    -3.694650     1.953818    -1.037801 
 H    -4.403851     2.130769    -0.222562 
 H    -4.230474     2.038113    -1.985516 
 C    -0.914776    -3.279685     2.382888 
 C     1.279720    -3.300412    -1.709000 
 H    -1.919982    -3.714070     2.347694 
 H     2.228864    -3.834841    -1.770841 
 H    -0.489574    -3.434635     3.373747 
 H     1.236776    -2.504939    -2.457521 
 H    -0.273116    -3.755048     1.634501 
 H     0.459794    -4.000681    -1.864330 
 C    -2.482371     2.874174    -0.918267 
 H    -1.908812     2.888054    -1.851333 
 H    -2.745965     3.905473    -0.675206 
 H    -0.024981    -2.078984    -0.187556 
H     1.836400    -2.136804    -0.194280 
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Fran_OM 
C       -5.604574000     -0.013974000      1.963233000 
C       -5.514288000    -1.40407 000        2.139029000 
C       -4.533631000     -2.152672000      1.513721000 
C       -3.579445000     -1.524324000      0.698582000 
C       -3.678613000     -0.117603000      0.503600000 
C       -4.699108000      0.615875000      1.135315000 
O       -2.655943000     -2.256234000      0.103315000 
B       -1.427758000     -1.640418000     -0.425402000 
N       -1.816966000     -0.195647000     -0.934691000 
C       -2.821374000      0.472032000     -0.477577000 
O       -1.020408000     -2.247137000     -1.710757000 
C       -0.724437000     -1.340023000     -2.631561000 
C       -1.065267000      0.080455000     -2.139160000 
C        0.212104000      0.903695000     -1.892791000 
C       -0.104172000      2.286712000     -1.392302000 
C       -0.222608000     -1.611871000      0.637025000 
C        0.981334000     -2.280870000      0.379768000 
C        2.035769000     -2.259923000      1.290646000 
C        1.909502000     -1.561149000      2.487231000 
C        0.721640000     -0.889092000      2.768668000 
C       -0.326817000     -0.918590000      1.853560000 
C       -0.085119000      2.569754000     -0.023283000 
C       -0.424199000      3.837622000      0.443475000 
C       -0.790259000      4.838544000     -0.451642000 
C       -0.813544000      4.566911000     -1.817949000 
C       -0.473514000      3.300514000     -2.282675000 
O       -0.231762000     -1.560281000     -3.707766000 
H       -6.383735000      0.551947000      2.462064000 
H       -6.231643000     -1.907780000      2.781025000 
H       -4.464530000     -3.226946000      1.645733000 
H       -4.759251000      1.687443000      0.960894000 
H       -3.048255000      1.452914000     -0.897064000 
H       -1.688594000      0.586149000     -2.883706000 
H        0.744198000      0.935666000     -2.849171000 
H        0.845335000      0.369100000     -1.177986000 
H        1.087642000     -2.831762000     -0.551411000 
H        2.957078000     -2.790678000      1.065546000 
H        2.730461000     -1.540364000      3.198755000 
H        0.612848000     -0.345348000      3.703594000 
H       -1.247202000     -0.391023000      2.098584000 
H        0.202188000      1.788459000      0.676818000 
H       -0.397192000      4.043788000      1.509733000 
H       -1.050266000      5.828446000     -0.088119000 
H       -1.089371000      5.345389000     -2.523609000 
H       -0.483360000      3.096619000     -3.351488000 
Fran_AM_WI 
C       -4.373399000     -0.239318000      0.541012000 
C       -3.200058000     -2.343879000      0.337274000 
C       -1.963324000     -1.685996000      0.412138000 
C       -1.943092000     -0.282090000      0.564297000 
C       -3.143935000      0.416358000      0.612578000 
O       -0.841922000     -2.399196000      0.367517000 
B        0.479584000     -1.774083000      0.010557000 
N        0.392461000     -0.261453000     -0.197990000 
C       -0.584638000      0.366440000      0.672229000 
O        0.846444000     -2.274261000     -1.363617000 
C        0.694183000     -1.333056000     -2.268118000 
C        0.229665000     -0.028025000     -1.611981000 
C        1.052816000      1.139149000     -2.188454000 
C        0.596397000      2.500778000     -1.749559000 
C        1.572357000     -2.251045000      1.105499000 
C        1.429063000     -3.436022000      1.839803000 
C        2.388214000     -3.850093000      2.761502000 
C        3.525909000     -3.075806000      2.980692000  
C        3.688356000     -1.887712000      2.271358000 
C        2.721586000     -1.489152000      1.350295000 
C        1.226121000      3.170328000     -0.695203000 
C        0.785042000      4.420539000     -0.270722000 
C       -0.298851000      5.031184000     -0.895932000 
C       -0.936363000      4.377520000     -1.948052000 
C       -0.490831000      3.128528000     -2.368492000 
O        0.904245000     -1.463703000     -3.458877000 
C       -4.388855000     -1.626130000      0.408027000 
H       -5.302085000      0.323727000      0.583100000 
H       -3.196131000     -3.424155000      0.222877000 
H       -3.110252000      1.500785000      0.713485000 
H       -0.216542000      0.259427000      1.704297000 
H       -0.661780000      1.443593000      0.481085000 
H       -0.827357000      0.119156000     -1.908782000 
H        1.002874000      1.050594000     -3.279980000 
H        2.096252000      0.983667000     -1.893002000 
H        0.534793000     -4.035061000      1.684501000 
H        2.248182000     -4.776586000      3.315848000 
H        4.276341000     -3.392786000      3.702211000 
H        4.569411000     -1.270862000      2.440686000 
H        2.836407000     -0.554179000      0.804905000 
H        2.062262000      2.688472000     -0.195147000 
H        1.289114000      4.918523000      0.553919000 
H       -0.644443000      6.007628000     -0.566630000 
H       -1.783945000      4.843400000     -2.444783000 
H       -0.993934000      2.622840000     -3.189774000 
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H       -5.336966000     -2.156791000      0.348030000 
 
Fran_WE 
C       -4.459186000     -0.444114000      1.838294000 
C       -3.251061000     -2.518561000      1.444731000 
C       -2.307191000     -1.837383000      0.661340000 
C       -2.480178000     -0.442794000      0.446341000 
C       -3.563327000      0.233093000      1.038085000 
O       -1.310204000     -2.515762000      0.120209000 
B       -0.138193000     -1.841992000     -0.438727000 
N       -0.576145000     -0.425728000     -0.952428000 
C       -1.627296000      0.185312000     -0.513131000 
O        0.251719000     -2.429869000     -1.775178000 
C        0.428423000     -1.602856000     -2.750731000 
C        0.102167000     -0.181716000     -2.210033000 
C        1.423038000      0.595638000     -2.054774000 
C        1.189849000      1.996154000     -1.556107000 
C        1.109374000     -1.814917000      0.566706000 
C        2.343196000     -2.392638000      0.240681000 
C        3.420304000     -2.353823000      1.123839000 
C        3.286829000     -1.727854000      2.359425000 
C        2.069150000     -1.147268000      2.708254000 
C        0.997420000     -1.196231000      1.821589000 
C        1.257221000      2.287274000     -0.190116000 
C        0.998718000      3.574582000      0.274289000 
C        0.666711000      4.588763000     -0.619354000 
C        0.595895000      4.309442000     -1.982278000 
C        0.854888000      3.023172000     -2.444608000 
C       -4.295525000     -1.825728000      2.029322000 
H       -5.287769000      0.078441000      2.303884000 
H       -3.122165000     -3.585825000      1.588736000 
H       -3.681351000      1.297759000      0.851527000 
H       -1.894819000      1.153314000     -0.939040000 
H       -0.552404000      0.351854000     -2.908807000 
H        1.902420000      0.597437000     -3.039264000 
H        2.080556000      0.048304000     -1.372046000 
H        2.458993000     -2.885086000     -0.721634000 
H        4.365137000     -2.813829000      0.846689000 
H        4.125715000     -1.693308000      3.049138000 
H        1.955192000     -0.660677000      3.673492000 
H        0.052440000     -0.743430000      2.117580000 
H        1.519433000      1.497169000      0.509877000 
H        1.062328000      3.785691000      1.338112000 
H        0.469723000      5.593670000     -0.257265000 
H        0.345912000      5.097021000     -2.687602000 
H        0.807129000      2.812623000     -3.511084000 
H       -5.004250000     -2.366356000      2.650436000 
 
Fran_Am_WoutI 
C       -4.242741000     -0.562512000      1.855195000 
C       -2.854891000     -2.541574000      1.681464000 
C       -2.207311000     -1.988912000      0.575344000 
C       -2.591981000     -0.724020000      0.102595000 
C       -3.597801000     -0.013477000      0.751135000 
O       -1.242231000     -2.667455000     -0.066316000 
B       -0.045175000     -1.998070000     -0.528497000 
N       -0.424284000     -0.431945000     -0.960853000 
C       -1.893530000     -0.253705000     -1.130595000 
O        0.352916000     -2.538783000     -1.837797000 
C        0.626843000     -1.620289000     -2.747457000 
C        0.345234000     -0.214325000     -2.208592000 
C        1.658123000      0.542154000     -1.962485000 
C        1.426850000      1.896733000     -1.346103000 
C        1.154422000     -1.950531000      0.537471000 
C        2.411201000     -2.498239000      0.250162000 
C        3.455980000     -2.443740000      1.170885000 
C        3.265073000     -1.834046000      2.407437000 
C        2.021437000     -1.289261000      2.720921000 
C        0.982598000     -1.351898000      1.795518000 
C        1.621257000      2.094935000      0.024925000 
C        1.358158000      3.333947000      0.607405000 
C        0.901443000      4.389803000     -0.173701000 
C        0.709234000      4.204052000     -1.541795000 
C        0.967122000      2.967071000     -2.121465000 
O        1.072152000     -1.821580000     -3.848632000 
C       -3.870409000     -1.828000000      2.307959000 
H       -5.030507000     -0.010149000      2.357232000 
H       -2.548288000     -3.522821000      2.028230000 
H       -3.884337000      0.968239000      0.380287000 
H       -0.107060000      0.218806000     -0.239021000 
H       -2.107285000      0.794196000     -1.363934000 
H       -2.176513000     -0.867899000     -1.994499000 
H       -0.265710000      0.339064000     -2.928745000 
H        2.152605000      0.622887000     -2.935575000 
H        2.305632000     -0.061963000     -1.318319000 
H        2.567091000     -2.983547000     -0.710448000 
H        4.420169000     -2.879826000      0.923341000 
H        4.078257000     -1.788262000      3.126566000 
H        1.860013000     -0.822835000      3.689355000 
H        0.012553000     -0.937129000      2.068768000 
H        1.995440000      1.276321000      0.637452000 
H        1.518844000      3.472501000      1.672575000 
Experimetnal  Chapter  7 
 
203 
 
H        0.701479000      5.356902000      0.277975000 
H        0.362586000      5.027842000     -2.159132000 
H        0.823475000      2.830826000     -3.191312000 
H       -4.372726000     -2.262251000      3.167788000 
Water 
O       -0.484569000      0.162495000      0.000000000 
H       -0.438146000      1.122212000      0.000000000 
H        0.435715000     -0.113707000      0.000000000 
 
HydroniumIon 
O        0.022975000      0.036527000     -0.053275000 
H       -0.161136000      0.991580000      0.052168000 
H        0.570910000     -0.168924000     -0.837340000 
H       -0.778869000     -0.519357000      0.013612000 
 
Fran_OM1 
C       -4.108728000      0.359383000      1.864953000 
C       -4.225344000     -0.973081000      2.293688000 
C       -3.172857000     -1.863950000      2.190582000 
C       -1.955662000     -1.454465000      1.623396000 
C       -1.828703000     -0.100481000      1.202241000 
C       -2.909246000      0.790278000      1.339394000 
O       -0.958171000     -2.312937000      1.544232000 
B        0.184698000     -2.081841000      0.642053000 
N        0.400194000     -0.516982000      0.556842000 
C       -0.529447000      0.341711000      0.805405000 
O        1.460423000     -2.458500000      1.282665000 
C        2.389599000     -1.515303000      1.189011000 
C        1.825411000     -0.256031000      0.494862000 
C       -0.004485000     -2.763412000     -0.797117000 
O        3.528035000     -1.620905000      1.565319000 
C        3.717567000      0.473874000     -1.051546000 
C        0.861917000     -3.772745000     -1.237350000 
C        0.699922000     -4.379685000     -2.480958000 
C       -0.338642000     -3.984353000     -3.318786000 
C       -1.213560000     -2.982598000     -2.904199000 
C       -1.044326000     -2.384532000     -1.659501000 
C        3.885472000      1.851396000     -1.215223000 
C        4.853438000     -0.335273000     -0.971417000 
C        6.125041000      0.222174000     -1.053789000 
C        6.280897000      1.595970000     -1.217216000 
C        2.330757000     -0.108232000     -0.960203000 
C        5.156320000      2.411832000     -1.297598000 
H       -4.947412000      1.040480000      1.958860000 
H       -5.164676000     -1.315197000      2.719204000 
H       -3.259886000     -2.891724000      2.525646000 
H       -2.782792000      1.822610000      1.021957000 
H       -0.295238000      1.407784000      0.780587000 
H        2.090187000      0.636317000      1.070557000 
H        1.672835000     -4.089323000     -0.585834000 
H        1.384458000     -5.163011000     -2.795683000 
H       -0.466995000     -4.453846000     -4.290314000 
H       -2.027630000     -2.669153000     -3.552611000 
H       -1.743208000     -1.606388000     -1.356436000 
H        3.008948000      2.492140000     -1.290471000 
H        4.740027000     -1.405003000     -0.827670000 
H        6.997913000     -0.420700000     -0.988222000 
H        7.274926000      2.028599000     -1.283867000 
H        1.624204000      0.550462000     -1.478151000 
H        2.272904000     -1.080990000     -1.458960000 
H        5.267425000      3.484171000     -1.431009000 
 
Fran_OM2 
C       -5.917158000      0.394394000      1.889835000 
C       -5.927267000     -0.971400000      2.214987000 
C       -4.823759000     -1.777107000      1.999438000 
C       -3.662874000     -1.240732000      1.421511000 
C       -3.642417000      0.145607000      1.106104000 
C       -4.772400000      0.945882000      1.353453000 
O       -2.615831000     -2.021236000      1.231359000 
B       -1.528244000     -1.636393000      0.319853000 
N       -1.422808000     -0.058303000      0.344003000 
C       -2.399061000      0.713382000      0.684101000 
O       -0.205984000     -1.976665000      0.897233000 
C        0.653328000     -0.976745000      0.812655000 
C       -0.018958000      0.278324000      0.206316000 
C       -1.704035000     -2.206018000     -1.168954000 
C        0.468694000      1.565002000      0.854373000 
O        1.812375000     -1.006204000      1.139764000 
C        0.065787000      2.844336000      0.160531000 
C       -0.787754000     -3.117533000     -1.708828000 
C       -0.941553000     -3.627719000     -2.996041000 
C       -2.021364000     -3.229876000     -3.778462000 
C       -2.945450000     -2.322178000     -3.265290000 
C       -2.783904000     -1.820882000     -1.977638000 
C       -0.559202000      3.870134000      0.875647000 
C       -0.919957000      5.062819000      0.253099000 
C       -0.659699000      5.248458000     -1.100476000 
C       -0.031415000      4.236912000     -1.823252000 
C        0.328642000      3.048049000     -1.198114000 
H       -6.793924000      1.006944000      2.069475000 
H       -6.822427000     -1.409589000      2.647651000 
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H       -4.828523000     -2.831621000      2.252880000 
H       -4.727193000      2.005365000      1.112868000 
H       -2.251860000      1.793434000      0.698735000 
H        0.227520000      0.263126000     -0.865136000 
H        1.561014000      1.471353000      0.886361000 
H        0.138296000      1.582900000      1.899681000 
H        0.056857000     -3.436098000     -1.102875000 
H       -0.217636000     -4.337147000     -3.388443000 
H       -2.143742000     -3.624127000     -4.783698000 
H       -3.791557000     -2.006518000     -3.870207000 
H       -3.519918000     -1.114276000     -1.597068000 
H       -0.756379000      3.735313000      1.937223000 
H       -1.402231000      5.847259000      0.829282000 
H       -0.940248000      6.176324000     -1.589797000 
H        0.182926000      4.375312000     -2.878990000 
H        0.829290000      2.274163000     -1.775157000 
 
Fran_OM3 
C       -4.148091000     -1.287526000      2.542322000 
C       -4.246911000      0.032025000      2.072926000 
C       -3.230321000     -2.178534000      2.015846000 
C       -2.352428000     -1.766961000      1.001471000 
C       -2.459648000     -0.436467000      0.512398000 
C       -3.414397000      0.443301000      1.053178000 
O       -1.489079000     -2.630939000      0.502666000 
B       -0.325884000     -2.190491000     -0.279469000 
N       -0.732159000     -0.858179000     -1.035922000 
C       -1.679212000     -0.083994000     -0.633429000 
O       -0.111338000     -3.069760000     -1.450957000 
C        0.064632000     -2.389201000     -2.568648000 
C       -0.015447000     -0.865076000     -2.304064000 
C        0.452096000      0.545373000     -4.368947000 
C        1.004364000     -1.995907000      0.594347000 
C        2.162988000     -2.736059000      0.326834000 
C        3.320747000     -2.574264000      1.084592000 
C        3.345130000     -1.658370000      2.131765000 
C        2.205429000     -0.909718000      2.418123000 
C        1.053744000     -1.081022000      1.657041000 
C        1.235782000     -0.264200000     -5.197401000 
C        0.660858000      1.926156000     -4.384077000 
C        1.629659000      2.492911000     -5.207521000 
C        2.204892000      0.302356000     -6.019227000 
C        2.405445000      1.680525000     -6.028190000 
O        0.263121000     -2.871781000     -3.655806000 
C       -0.600696000     -0.051626000     -3.462977000 
H       -4.808181000     -1.620656000      3.338380000 
H       -4.975791000      0.712347000      2.499543000 
H       -3.154542000     -3.199143000      2.374708000 
H       -3.484632000      1.452580000      0.654416000 
H       -1.927443000      0.815930000     -1.196392000 
H        1.012967000     -0.537247000     -2.093415000 
H        2.151347000     -3.458265000     -0.485720000 
H        4.204611000     -3.164491000      0.857495000 
H        4.246966000     -1.527695000      2.723712000 
H        2.216222000     -0.193562000      3.235642000 
H        0.173993000     -0.487833000      1.901823000 
H        1.080568000     -1.339172000     -5.181202000 
H        0.055652000      2.568418000     -3.747419000 
H        1.775994000      3.569301000     -5.207730000 
H        2.806023000     -0.338504000     -6.658010000 
H        3.161903000      2.119073000     -6.672536000 
H       -1.206666000      0.770278000     -3.068267000 
H       -1.273859000     -0.697861000     -4.036326000 
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  Reagents (kcal/mol) Products (kcal/mol) 
(kcal/mol) UnprotonatedA
mine 
Hydronium 
Ion 
ProtonatedAmine Water 
ElectronicEnergy - 724.122,76    - 48.082,31    - 724.460,38    - 47.902,17    
ThermalEnthalpies - 723.878,02    - 48.057,99    - 724.205,66    - 47.886,17    
SUM -771.936,02 - 772.091,83 
Thermal Free 
Energies 
- 723.925,95    - 48.072,42    - 724.252,29    - 47.900,02    
SUM - 771.998,37 - 772.152,31 
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7.5 Biological assays 
 
Human neutrophil elastase activity assay of bicycle-boronate 
heterocycle collection with fluorogenic peptide substrate 
 
Fluorometric assays for the Human neutrophil elastase (HNE) (Merck, Germany) inhibition 
activity were carried out in 200 µL assay buffer (0.1 M HEPES pH 7.5 at 25 ºC) containing 
2  µL of  . 7 μM HNE in assay buffer (stock solution  .7 μM in  .   M acetate buffer, pH 
5.5), and 5 µL of each concentration of tested inhibitors. Reaction was initiated by the 
addition of 175 µL of fluorogenic substrate to final concentration of 200 µM (MeO-Suc-Ala-
Ala-Pro-Val-AMC, Merck, Germany), and activity was monitored (excitation 380 nm; 
emission 460 nm) for 30 min, at 25ºC on a Fluorescence Microplate Reader Tecan infinite 
M200 (Tecan, Switzerland). The Km of this substrate of HNE was previously determined to 
be 185 µM (data not shown). For all assays, saturated substrate concentration was used, 
throughout, in order to obtain linear fluorescence curves. Inhibitors stock solutions were 
prepared in DMSO, and serial dilutions were made in DMSO. Controls were performed 
using enzyme alone, substrate alone, enzyme with DMSO and a positive control 
(MeOSuc-Ala-Ala-Pro-Ala-CMK, Calbiochem, Germany). By computing the log of inhibitors 
concentrations versus the percentage of activity and using the GrafPad program the IC50 
values were determined by non-linear regression analysis. Assays were performed in 
triplicate and data presented as the mean and the standard deviation.  
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Human neutrophil elastase activity assay of diazaborine collection with 
fluorogenic peptide substrate 
 
Fluorometric assays for the Human neutrophil elastase (HNE) (Merck, Germany) inhibition 
activity were carried out in 200 µL assay buffer (0.1 M HEPES pH 7.5 at 25 ºC) containing 
2  µL of  . 7 μM HNE in assay buffer (stock solution  .7 μM in  .   M acetate buffer, pH 
5.5), and 5 µL of each concentration of tested inhibitors. The diazaborines were 
preincubated for 3 ’ minute with the enzyme before the substrate was added. Reaction 
was initiated by the addition of 175 µL of fluorogenic substrate to final concentration of 200 
µM (MeO-Suc-Ala-Ala-Pro-Val-AMC, Merck, Germany), and activity was monitored 
(excitation 380 nm; emission 460 nm) for 30 min, at 25ºC on a Fluorescence Microplate 
Reader Tecan infinite M200 (Tecan, Switzerland). The Km of this substrate of HNE was 
previously determined to be 185 µM (data not shown). For all assays, saturated substrate 
concentration was used, throughout, in order to obtain linear fluorescence curves. 
Inhibitors stock solutions were prepared in DMSO, and serial dilutions were made in 
DMSO. Controls were performed using enzyme alone, substrate alone, enzyme with 
DMSO and a positive control (MeOSuc-Ala-Ala-Pro-Ala-CMK, Calbiochem, Germany). By 
computing the log of inhibitors concentrations versus the percentage of activity and using 
the GrafPad program the IC50 values were determined by non-linear regression analysis. 
Assays were performed in triplicate and data presented as the mean and the standard 
deviation.  
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Phenylalanine hydroxylase activity 
 
Escherichia coli TOP 10 and the prokaryotic expression vector pTrcHis were obtained from 
Invitrogen (Carlsbad, CA). The cofactor (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4), L-
Phe, Hepes, were from Sigma (St. Louis, MO, USA). Ascorbic acid was obtained from 
Merck (Darmstadt, Germany). Unless stated otherwise, all reagents were of analytical 
grade. The hPAH protein was expressed in E. coli as a fusion protein with the hexa-histidyl 
tag (6xHis-(pep)EK-hPAH) as described [132]. Cells were grown at 37 °C, and the induction 
of protein expression by 1 mM isopropyl--D-thiogalactoside (IPTG) was performed during 
3 h, at 37 °C. The recombinant tetramers were isolated by size exclusion chromatography 
(SEC), using a HiLoad Superdex 200 HR column (1.6 cm  60 cm, GE-Healthcare) and a 
mobile phase containing 20 mM Na-Hepes, 200 mM NaCl, pH 7 pumped at a flow rate of 
0.7 mLmin-1. The hPAH activity was measured essentially as previously described [132] in a 
200 L final volume reaction mixture, containing 100 M L-Phe, 0.1 M Na-Hepes, pH 7, 0.1 
mgmL catalase, 5 g of recombinant hPAH tetramers, 100 M of each compound or 1% 
DMSO (vehicle control). After 4 minutes preincubation, 100 M (NH4)2Fe(II)SO4 was 
added and unless otherwise stated the reaction was started by addition of 75 M BH4 
(together with 5 mM ascorbic acid) after 1 minute incubation with the iron. To study the 
specific activity of the non-activated hPAH, 100 M L-Phe and 100 M of each compound 
were added together with 75 µM BH4 at the start of the hydroxylation reaction. To evaluate 
activation of the enzyme by the compound, hPAH was incubated 4 minutes with each 
compound and the L-Phe substrate was added together with 75 µM BH4 at the start of the 
reaction. Blank reactions where the substrate L-Phe was omitted, were also made for each 
compound. The amount of L-Tyr produced after 1 min was quantified by a HPLC method 
[133] using a LiChroCART® 250-4 LiChrospher® 60 RP-select B (  μm) column (Merck 
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KGaA, Darmstadt, Germany), a 5% ethanol mobile phase pumped at 0.7 mLmin and 
fluorimetric detection (λexc= 274 nm and λem= 304 nm). Specific activities are presented as 
mean ± SEM obtained from three independent experiments. Differential scanning 
fluorimetry (DSF) was performed in a C1000 Touch thermal cycler equipped with a CFX96 
optical reaction module (Bio Rad). For all fluorescence measurements, samples containing 
purified recombinant hPAH tetramers at 100 g/mL in 20 mM NaHepes, 200 mM NaCl, pH 
7, 2.5-fold Sypro Orange (Invitrogen; 5000-fold stock solution), 1% DMSO (unless 
otherwise stated) and     μM of each compound were incubated at 2  ºC for    minutes. 
The PCR plate was sealed with Optical-Quality Sealing Tape (Bio-Rad) and centrifuged at 
500xg for 5 min. The DSF was carried out by increasing the temperature from 20 to 90 °C, 
with a 1 s hold time every 0.2 °C and fluorescence acquisition using the FRET channel. 
Control experiments in the absence of DMSO and/or compounds were routinely performed 
in each microplate. Data were processed using CFX Manager Software V3.0 (Bio-Rad) 
and the GraphPad Prism 6. Temperature scan curves were fitted to a biphasic dose-
response function and the Tm values were obtained from the midpoint of the first and 
second transitions. To monitor the binding properties of the regulatory and catalytic 
domain towards each compound, DSF assays were run in the presence of increased 
compound concentrations (02.56 mM) or 1% DMSO (vehicle control). 
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